<SEC-DOCUMENT>0001193125-23-030281.txt : 20230209
<SEC-HEADER>0001193125-23-030281.hdr.sgml : 20230209
<ACCEPTANCE-DATETIME>20230209170107
ACCESSION NUMBER:		0001193125-23-030281
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230203
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230209
DATE AS OF CHANGE:		20230209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33277
		FILM NUMBER:		23607150

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d457771d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdgl="http://www.madrigalpharma.com/20230203" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-02-03_to_2023-02-03">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-02-03_to_2023-02-03">0001157601</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mdgl-20230203.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-02-03_to_2023-02-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157601</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-03</xbrli:startDate> <xbrli:endDate>2023-02-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-02-03_to_2023-02-03">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt:datemonthdayyearen">February&#160;3, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-02-03_to_2023-02-03">MADRIGAL PHARMACEUTICALS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-02-03_to_2023-02-03">001-33277</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-02-03_to_2023-02-03">04-3508648</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-02-03_to_2023-02-03">Four Tower Bridge</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-02-03_to_2023-02-03">200 Barr Harbor Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-02-03_to_2023-02-03">Suite 200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-02-03_to_2023-02-03">West Conshohocken</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:stateprovnameen">Pennsylvania</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-02-03_to_2023-02-03">19428</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive office)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-02-03_to_2023-02-03">(267)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-02-03_to_2023-02-03">824-2827</ix:nonNumeric></span></p> <p style="margin-top:20pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-02-03_to_2023-02-03">Common Stock, $0.0001 Par Value Per Share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-02-03_to_2023-02-03">MDGL</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-02-03_to_2023-02-03" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">First Amendment to Loan And Security Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;3, 2023, Madrigal Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;) and its subsidiary, Canticle Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;Canticle&#8221; and, together with the Company, the &#8220;Borrowers&#8221;), entered into a First Amendment (the &#8220;Amendment&#8221;) to the Loan and Security Agreement, dated May&#160;9, 2022 (the &#8220;Loan Agreement&#8221; and as amended by the Amendment, the &#8220;Amended Loan Agreement&#8221;), with the several banks and other financial institutions or entities party thereto (each, a &#8220;Lender&#8221; and collectively referred to as the &#8220;Lenders&#8221;), and Hercules Capital, Inc., a Maryland corporation (&#8220;Hercules&#8221;), as Lender and in its capacity as administrative agent and collateral agent for the Lenders (in such capacity, &#8220;Agent&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amendment amended certain terms of the Loan Agreement as described below. The original terms of the Loan Agreement were previously disclosed in the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the Securities and Exchange Commission on May&#160;9, 2022, which Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Interest Rate.</span> The interest rate formula for the Company under the Amended Loan Agreement was adjusted by the Amendment such that the borrowings bear interest at a variable per annum rate determined based on the greater of (i)&#160;the prime rate as reported in The Wall Street Journal plus 2.45% and (ii) 8.25%. This has resulted in a reduction of the Company&#8217;s borrowing costs by 150 basis points after giving effect to the Amendment to 10.2% as of February&#160;3, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Amount.</span> The Amended Loan Agreement continues to provide for an aggregate of $250.0&#160;million in term loans (collectively, the &#8220;Term Loans&#8221;), but the terms of certain tranches of Term Loans were revised as part of the Amendment. The second tranche of Loan Agreement (&#8220;Tranche 2&#8221;) was amended to increase the committed amount available by $15.0&#160;million, to $65.0&#160;million. As previously announced, the Company achieved the Phase 3 clinical development milestone under Tranche 2 (the &#8220;Clinical Milestone&#8221;). In connection with the Amendment, on February&#160;3, 2023, the Borrowers drew $35.0&#160;million under Tranche 2 and have the ability to draw an additional $15.0&#160;million under Tranche 2 by June&#160;19, 2023 and an additional $15.0&#160;million under Tranche 2 by September&#160;30, 2023 (for a total of $30.0&#160;million in additional committed Tranche 2 capacity). The third tranche (&#8220;Tranche 3&#8221;) of $75.0&#160;million remains unchanged by the Amendment, and such borrowings are available subject to the Company obtaining certain FDA approval for resmetirom (the &#8220;Approval Milestone&#8221;) until the earlier of June&#160;30, 2024 and 90 days following achievement of the Approval Milestone. Coincident with the expansion of Tranche 2 borrowing capacity by $15&#160;million, the Amendment reduced the fourth tranche (&#8220;Tranche 4&#8221;) by $15.0&#160;million to $60.0&#160;million , which amount is available subject to Hercules&#8217; sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Borrowings.</span> The Borrowers have $85.0&#160;million in outstanding borrowings under the Amended Loan Agreement, consisting of $35.0&#160;million drawn under Tranche 2 Term Loans on February&#160;3, 2023 and $50.0&#160;million drawn under Tranche 1 Term Loans on May&#160;9, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Term and Repayment.</span> As previously disclosed, the Term Loans have a scheduled maturity date of May&#160;1, 2026, which may be extended for an additional year upon the Company achieving the Approval Milestone (the &#8220;Scheduled Maturity Date&#8221;). Due to the Company&#8217;s satisfaction of the Clinical Milestone, the interest-only period of the Term Loans extends through May&#160;1, 2025. This interest-only period may be extended to (i)&#160;May 1, 2026 if the Company achieves the Approval Milestone and (ii)&#160;May 3, 2027 if the Company achieves a certain revenue milestone as set forth in the Amended Loan Agreement and maintains compliance with the financial covenants previously disclosed. The terms of the Approval Milestone and such financial covenants are as set forth in the Amended Loan Agreement. After the conclusion of the interest-only period, monthly installments of principal and interest will be paid through the Scheduled Maturity Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Termination of Warrant Rights; Amendment of Warrant Terms For Advances Under Tranches 2, 3 and 4 of the Amended Loan Agreement.</span> In connection with the Amendment, the rights and obligations under all previously unvested warrants (to purchase 59,545 shares of Common Stock at an exercise price of $67.12 per share) were terminated, and the Company agreed to issue warrants in connection with borrowings made under Tranche 2, 3 and 4 (&#8220;Warrants&#8221;) on and after the date of the Amendment under the terms described below </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amendment, the number of shares of the Company&#8217;s common stock subject to exercisable Warrants associated with Tranche 2 Term Loans funded (&#8220;Tranche 2 Warrants&#8221;) equals 2.0% times the principal amount of such advances that are funded, divided by $285.31 (the &#8220;Tranche 2 Coverage Ratio&#8221;). On February&#160;3, 2023, in connection with the $35.0&#160;million Tranche 2 Term Loan funding, the Company issued Tranche 2 Warrants to purchase 2,543 shares of Common Stock at an exercise price of $285.31 per share. In the event future Tranche 2 Term Loan borrowings are made, the Company will issue additional Tranche 2 Warrants in accordance with the Tranche 2 Coverage Ratio at an exercise price of $285.31 per share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amendment, the number of shares of the Company&#8217;s common stock subject to exercisable Warrants associated with (i)&#160;Tranche 3 Term Loans funded in the future will equal (1) 2.0% times the principal amount of such advances that are funded, divided by (2)&#160;the volume-weighted average price for Company Common Stock for the three full trading days immediately before written confirmation from the Agent of satisfaction of the Approval Milestone under Tranche 3 of the Loan Agreement (or the Tranche 3 Warrant Exercise Price); and (ii)&#160;Tranche 4 Term Loans funded funded in the future will equal 2.0% times the principal amount of advances that are funded, divided by volume-weighted average price for Company Common Stock for the three full trading days immediately before execution and delivery of written agreement concerning the commitments made available under Tranche 4 of the Loan Agreement (or the Tranche 4 Warrant Exercise Price). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants described above will terminate at the earlier of (i)&#160;the seventh anniversary of the date of the Amendment and (ii)&#160;the consummation of certain acquisition transactions involving the Company, as set forth in the Warrants. The number of shares for which each Warrant is exercisable and the associated exercise price are subject to certain customary proportional adjustments for fundamental events, including stock splits and reverse stock splits, as set forth in the Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued warrants to the Lenders to acquire to purchase 14,899 shares of the Company&#8217;s common stock at an exercise price of $67.12 per share, which vested based on Tranche 1 Term Loan advances on May&#160;9, 2022; the exercise price and number of shares that may be purchased via these warrants were not affected by the Amendment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Amendment, the Amended Loan Agreement and the Tranche 2 Warrants contained herein do not purport to be complete and are qualified in their entirety by reference to the complete text of the Amendment (which includes the Amended Loan Agreement as Annex A thereto) and the form of Tranche 2 Warrant Agreement, copies which are attached hereto as exhibits and are incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Creation of a Direct Financial Obligation or an Obligation under an <span style="white-space:nowrap">Off-Balance</span> Sheet Arrangement of a Registrant. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in Item 1.01 above relating to the Amended Loan Agreement is incorporated by reference into this Item 2.03. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in Item 1.01 above relating to the Warrants is incorporated by reference into this Item 3.02. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Company nor Hercules engaged any investment advisors with respect to the Amended Loan Agreement and the Warrants. The issuance of the Tranche 2 Warrants was made in reliance on the exemption from registration contained in Section&#160;4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:98%;border:0;margin-left:auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d457771dex41.htm">Form of Tranche 2 Warrant&#160;Agreement,&#160;dated&#160;February&#160;3,&#160;2023,&#160;by&#160;and&#160;among&#160;Madrigal&#160;Pharmaceuticals,&#160;Inc.&#160;and Hercules&#160;Capital,&#160;Inc.&#160;and&#160;affiliates. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d457771dex101.htm">Loan and Security Agreement, dated May&#160;9, 2022, as amended by the First Amendment to Loan and Security Agreement, dated February&#160;3, 2023, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL file)</td></tr>
</table></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation <span style="white-space:nowrap">S-K.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Madrigal&#160;Pharmaceuticals,&#160;Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;9, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian J. Lynch</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brian J. Lynch</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President and General Counsel</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d457771dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT&nbsp;HAS BEEN OMITTED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND REPLACED WITH &#147;[***]&#148; BECAUSE IT IS NOT MATERIAL AND WOULD BE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS.
THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED WARRANT AGREEMENT </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">To Purchase Up to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares of the Common Stock of </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MADRIGAL PHARMACEUTICALS, INC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of February&nbsp;3, 2023 (the &#147;<U>Effective Date</U>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Madrigal Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), has entered into a Loan and Security
Agreement dated May&nbsp;9, 2022, as amended as of February&nbsp;3, 2023 (collectively, and as may be further amended and in effect from time to time, the &#147;<U>Loan Agreement</U>&#148;) with Hercules Capital, Inc., a Maryland corporation (the
&#147;<U>Warrantholder</U>&#148;) and the other Lender parties thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to grant to Warrantholder, in
consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of its Common Stock (as defined below) pursuant to this Warrant Agreement (this &#147;<U>Warrant</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Company and Warrantholder agree
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 1.</B> GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For value received, the Company hereby grants to the Warrantholder the right, and the Warrantholder is entitled, upon the terms and
subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common
Stock, at a purchase price per share equal to the Exercise Price (as defined below). The number of shares of Common Stock and the Exercise Price of such shares is subject to adjustment as provided in <U>Section</U><U></U><U>&nbsp;8</U>. As used
herein, the following terms shall have the following meanings: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>1934 Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acknowledgment of Exercise</U>&#148; has the meaning given to it in <U>Section</U><U></U><U>&nbsp;3(a)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Act</U>&#148; means the Securities Act of 1933, as amended, and as the same may be in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Charter</U>&#148; means the Company&#146;s Certificate of Incorporation or other constitutional document, as the same may be amended
from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Claims</U>&#148; has the meaning given to it in <U>Section</U><U></U><U>&nbsp;12(p)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the Company&#146;s common stock, $0.0001 par value per share, together with any securities of the Company
into or for which such common stock may be converted, exchanged or substituted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning given to it in
the preamble to this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; has the meaning given to it in the preamble to this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exercise Price</U>&#148; means $285.31 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lender</U>&#148; has the meaning given to it in the Loan Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Loan Agreement</U>&#148; has the meaning given to it in the preamble to this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Event</U>&#148; means (a)&nbsp;any merger, consolidation or other business combination involving the Company in which
(i)&nbsp;the Company is not the surviving entity or becomes a wholly owned subsidiary of another entity, or (ii)&nbsp;the outstanding shares of the Company&#146;s Common Stock (excluding, for the avoidance of doubt, any shares canceled for no
consideration) are otherwise converted into or exchanged for (A)&nbsp;shares of capital of another entity, (B)&nbsp;cash (and/or rights to receive one or more present or future payments of cash, whether such rights are absolute or contingent) or
(C)&nbsp;a combination of the foregoing; (b)&nbsp;the sale of all or substantially all of the assets of the Company; or (c)&nbsp;any other transaction or series of related transactions involving the Company or its capital stock or other securities
(including, without limitation, any other merger, consolidation or business combination involving the Company or any tender or exchange offer for, or other acquisition of, capital stock or other securities of the Company) that results in
(i)&nbsp;any person or group (in each case, as defined in Section&nbsp;13(d)(3) of the 1934 Act) being or becoming the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act), directly or
indirectly, of more than 50% of the outstanding voting securities of the Company or (ii)&nbsp;the persons who were the holders of the outstanding voting securities of the Company immediately prior to the consummation of such transaction (or series
of related transactions) holding less than 50% of the outstanding voting securities of the Company immediately following such transaction (or series of related transactions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Issuance</U>&#148; has the meaning given to it in
<U>Section</U><U></U><U>&nbsp;3(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Notice of Exercise</U>&#148; has the meaning given to it in
<U>Section</U><U></U><U>&nbsp;3(a)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Acquisition</U>&#148; means any Merger Event which is effected such that the
holders of Common Stock (excluding, for the avoidance of doubt, holders of shares canceled for no consideration) shall be entitled to receive (i)&nbsp;cash (and/or rights to receive one or more present or future payments of cash, whether such rights
are absolute or contingent), (ii) shares of stock that are of a publicly traded company listed on a national market or exchange which may be resold without restrictions (other than restrictions to which Warrantholder may separately agree in writing)
after the consummation of such Merger Event, or (iii)&nbsp;a combination of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Price</U>&#148; means, with
respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Common Stock requested to be exercised under this Warrant pursuant to such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rules</U>&#148; has the meaning given to it in <U>Section</U><U></U><U>&nbsp;12(q)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Notice</U>&#148; has the meaning given to it in <U>Section</U><U></U><U>&nbsp;11</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant</U>&#148; has the meaning given to it in the preamble to this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Term</U>&#148; has the meaning given to it in <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrantholder</U>&#148; has the meaning given to it in the preamble to this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 2.</B> TERM OF THE AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided for herein, the term of this Warrant (the &#147;<U>Warrant Term</U>&#148;) and the right to purchase Common Stock
as granted herein shall commence on the Effective Date and shall be exercisable for a period ending upon the earlier to occur of (A)&nbsp;seven (7) years from the Effective Date or (B)&nbsp;the consummation of a Public Acquisition, with the Warrant
expiring and terminating in its entirety upon the consummation of either of the foregoing events (the &#147;<U>Termination Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 3.</B> EXERCISE OF THE PURCHASE RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exercise</U>. Subject to the terms and conditions hereof, the purchase rights set forth in this Warrant may be exercised, in whole or
in part, at any time, or from time to time, during the Warrant Term, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Notice of Exercise</U>&#148;), duly completed
and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3)&nbsp;business days thereafter, the Company shall issue to the
Warrantholder a certificate or book entry shares representing the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as <U>Exhibit B</U> (the &#147;<U>Acknowledgment of
Exercise</U>&#148;) indicating the number of shares which remain subject to future purchases under this Warrant, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Price may be paid at the Warrantholder&#146;s election either (I)&nbsp;by cash
or check, or (II)&nbsp;by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Warrant and, if applicable, an amended Warrant representing the remaining number of shares purchasable hereunder, as
determined below (&#147;<U>Net Issuance</U>&#148;). If the Warrantholder elects the Net Issuance method, the Company will issue Common Stock in accordance with the following formula: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">X = <U><FONT STYLE="white-space:nowrap">Y(A-B)</FONT></U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A</TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = the number of shares
of Common Stock to be issued to the Warrantholder. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Y = the number of shares of Common Stock requested to be exercised
under this Warrant. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">A = the fair market value of one (1)&nbsp;share of Common Stock at the time of issuance of such shares
of Common Stock. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">B = the Exercise Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the above calculation, the fair market value of one (1)&nbsp;share of Common Stock shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the Common Stock is traded on any exchange operated by the NASDAQ Stock Market, LLC or any other national securities exchange , the fair
market value of one (1)&nbsp;share of Common Stock shall be deemed to be the volume-weighted average of the closing prices over the thirty (30)&nbsp;consecutive trading days ending two (2)&nbsp;trading days before the day the fair market value of
one (1)&nbsp;share of Common Stock is being determined; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if at any time the Common Stock is not listed on any securities exchange,
the fair market value of one (1)&nbsp;share of Common Stock shall be the highest price per share which the Company could obtain from a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company (based upon the
valuation by the Board of Directors of all shares of Common Stock), from authorized but unissued shares, as determined in good faith by its Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon partial exercise by either cash or Net Issuance and surrender of this Warrant, the
Company shall promptly issue an agreement substantially in the form of the Warrant representing the remaining number of shares purchasable hereunder. All other terms and conditions of such agreement shall be identical to those contained herein,
including, but not limited to the Effective Date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Prior to Expiration</U>. To the extent that the Warrantholder
has not exercised its purchase rights under this Warrant to all Common Stock subject hereto, and if the fair market value of one share of the Common Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed automatically
exercised in a Net Issuance pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(II)</U> (even if not surrendered) immediately before the expiration of the Warrant Term; <U>provided</U>, <U>however</U>, in the event that the expiration of the Warrant Term
occurs pursuant to <U>Section</U><U></U><U>&nbsp;2(B)</U>, the foregoing shall not apply, and <U>Section</U><U></U><U>&nbsp;8(a)(ii)</U> shall instead govern. For purposes of such automatic exercise, the fair market value of one share of the Common
Stock upon such expiration shall be determined pursuant to <U>Section</U><U></U><U>&nbsp;3(a)</U>. To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this <U>Section</U><U></U><U>&nbsp;3(b)</U>, the
Company agrees to promptly notify the Warrantholder of the consideration or number of shares of Common Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Legend</U>. Each certificate or book entry shares for the shares of Common Stock purchased upon exercise of this Warrant shall bear the
restrictive legend set forth on the first page of this Warrant. Such legend shall be removed and the Company shall, or shall instruct its transfer agent to, issue a certificate or book entry shares without such legend or any other legend to the
holder of such shares (i)&nbsp;if such shares are sold or transferred pursuant to an effective registration statement under the Act covering the resale of such shares by the holder thereof, (ii)&nbsp;if such shares are sold or transferred pursuant
to Rule 144 under the Act, (iii)&nbsp;if, upon advice of counsel to the Company, such shares are eligible for resale without any restrictions under Rule 144 under the Act, or (iv)&nbsp;upon the request of such holder if such request is accompanied
(at such holder&#146;s expense) by a written opinion of counsel reasonably satisfactory to the Company that registration is not required under the Act or any applicable state securities laws for the resale of the shares of Common Stock purchased
upon exercise of this Warrant. The removal of such restrictive legend from any certificates or book entry shares representing the shares of Common Stock purchased upon exercise of this Warrant is predicated upon the Company&#146;s reliance that the
holder of such shares would sell, transfer, assign, pledge, hypothecate or otherwise dispose of such shares pursuant to either the registration requirements of the Act, including any applicable prospectus delivery requirements, or an exemption
therefrom, and that if such shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 4.</B> RESERVATION OF SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Warrant Term, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock to
provide for the exercise of the rights to purchase Common Stock as provided for herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 5.</B> NO FRACTIONAL SHARES OR SCRIP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such
fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 6.</B>
NO RIGHTS AS STOCKHOLDER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the
Company prior to the exercise of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 7.</B> WARRANTHOLDER REGISTRY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall maintain a registry showing the name and address of the registered holder of this Warrant. Warrantholder&#146;s initial
address, for purposes of such registry, is set forth in <U>Section</U><U></U><U>&nbsp;12(g)</U>. Warrantholder may change such address by giving written notice of such changed address to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 8.</B> ADJUSTMENT RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Merger Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If at any time there shall be a Merger Event that is not a Public Acquisition, then, as a part of such Merger Event, lawful
provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Warrant, the kind, amount and value of shares of Common Stock or other securities or property of the successor, surviving or purchasing
corporation resulting from, or participating in, such Merger Event that would have been issuable if the Warrantholder had exercised this Warrant immediately prior to such Merger Event. In any such case, appropriate adjustment (as determined in good
faith by the Company&#146;s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Warrantholder after such Merger Event to the end that the provisions of this Warrant
(including adjustments of the Exercise Price) shall be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event other than a Public Acquisition, upon the closing thereof,
the successor, surviving or purchasing entity shall assume the obligations of this Warrant. The provisions of this <U>Section</U><U></U><U>&nbsp;8(a)(i)</U> shall similarly apply to successive Merger Events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In connection with a Merger Event that is a Public Acquisition, if the
fair market value of one (1)&nbsp;share of Common Stock, as determined immediately prior to the consummation of such Public Acquisition in the manner provided below in this <U>Section</U><U></U><U>&nbsp;8(a)(ii)</U>, is greater than the Exercise
Price in effect as of immediately prior to the consummation of such Public Acquisition, then this Warrant shall, as of immediately prior to such consummation (but subject to the occurrence thereof), automatically cease to represent the right to
purchase shares of Common Stock and shall, from and after such consummation, represent solely the right to receive the aggregate consideration that would have been payable in such Public Acquisition in respect of all shares of Common Stock for which
this Warrant was exercisable as of immediately prior to such consummation (as if such shares of Common Stock had been issued to the Warrantholder and were outstanding as of immediately prior to such consummation), solely net of the cash Purchase
Price therefor (which Purchase Price shall be calculated as if this Warrant were exercised for cash for such shares of Common Stock immediately prior to such consummation); <U>provided</U> that, for the avoidance of doubt, such right of the
Warrantholder to receive such aggregate consideration (net of such cash Purchase Price) shall survive the termination or expiration of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;2(B)</U> until such consideration has been paid. The
consideration payable to the Warrantholder pursuant to the foregoing sentence shall be paid as and when the consideration payable in such Public Acquisition in respect of shares of Common Stock is paid to the holders of the outstanding shares of
Common Stock.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Public Acquisition where the fair market value of one (1)&nbsp;share of Common Stock, as determined immediately prior to the consummation of such Public Acquisition in the manner provided below
in this <U>Section</U><U></U><U>&nbsp;8(a)(ii),</U> is equal to or less than the Exercise Price in effect as of immediately prior to such consummation, this Warrant will automatically and without further action of any party terminate and be of no
further force or effect as of immediately prior to such consummation. Solely for purposes of determining the fair market value of one (1)&nbsp;share of Common Stock immediately prior to the consummation of a Public Acquisition under this
<U>Section</U><U></U><U>&nbsp;8(a)(ii)</U>, the fair market value of one (1)&nbsp;share of Common Stock as of immediately prior to the consummation of a Public Acquisition shall be deemed to be equal to the full value of the consideration
(including, as the case may be, cash, rights to receive one or more present or future payments of cash and/or shares of stock) payable per share of Common Stock to the holders of the Common Stock pursuant to such Public Acquisition in accordance
with the definitive agreements executed in connection therewith, with the value of such per share consideration determined as follows: (A)&nbsp;if such per share consideration includes any cash, such cash shall be deemed to have a value equal to its
face value, (B)&nbsp;if such per share consideration includes any right to receive one or more present or future payments of cash (whether such right is absolute or contingent), such right shall be deemed to have a value equal to the maximum amount
of cash payable pursuant to such right, as determined in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
accordance with the definitive agreements executed in connection with such Public Acquisition, and (C)&nbsp;if such per share consideration includes any share of stock (or fraction thereof), such
share of stock (or fraction thereof) shall be deemed to have a value equal to the closing price (or, in the case of a fractional share, a pro rata portion of the closing price) of such stock on the final trading day to occur prior to the date of the
consummation of such Public Acquisition. <B>[***]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Reclassification of Shares</U>. Except as set forth in
<U>Section</U><U></U><U>&nbsp;8(a)</U>, if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Warrant exist into
the same or a different number of securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the
securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, subdivision or other change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Subdivision or Combination of Shares</U>. If the Company at any time shall combine or subdivide its Common Stock, (i)&nbsp;in the case
of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Common Stock issuable upon exercise of this Warrant shall be proportionately increased, or (ii)&nbsp;in the case of a combination, the Exercise
Price shall be proportionately increased, and the number of shares of Common Stock issuable upon the exercise of this Warrant shall be proportionately decreased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Stock Dividends</U>. If the Company at any time while this Warrant is outstanding and unexpired shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) pay a dividend with respect to the outstanding shares of Common Stock payable in additional shares of Common Stock, then
the Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of
determination by a fraction (A)&nbsp;the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B)&nbsp;the denominator of which shall be the total number of shares
of Common Stock outstanding immediately after such dividend or distribution; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) make any other distribution with
respect to the Common Stock, except any distribution specifically provided for in any other clause of this <U>Section</U><U></U><U>&nbsp;8</U>, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive
upon exercise of this Warrant a proportionate share of any such distribution as though it were the holder of the Common Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Notice of Adjustments</U>. If: (i)&nbsp;the Company shall declare any dividend or
distribution upon its Common Stock, whether in stock, cash, property or other securities (assuming Lender consents to a dividend involving cash, property or other securities under the Loan Agreement, if the consent of Lender is then required by the
terms of the Loan Agreement); (ii) the Company shall offer for subscription pro rata to the holders of Common Stock any additional shares of stock of any class or other rights; (iii)&nbsp;there shall be any Merger Event; or (iv)&nbsp;there shall be
any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice thereof at the same time and in the same manner as it notifies holders of shares of Common
Stock thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 9.</B> REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Reservation of Common Stock</U>. The shares of Common Stock issuable upon exercise of the Warrantholder&#146;s rights have been duly
and validly reserved and, when issued in accordance with the provisions of this Warrant, will upon issuance be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and will be free of any taxes, liens, charges or
encumbrances of any nature whatsoever; <U>provided</U>, that the Common Stock issuable pursuant to this Warrant may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to the
Warrantholder publicly through the SEC&#146;s EDGAR system true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock; <U>provided</U>, that the Company shall not be required to pay any tax
which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Due Authority</U>. The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company. This Warrant: (1)&nbsp;does not violate the Company&#146;s
Charter or current bylaws; (2)&nbsp;does not contravene any law or governmental rule, regulation or order applicable to it; and (3)&nbsp;does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage,
contract or other instrument to which it is a party or by which it is bound. This Warrant constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as such enforceability may be limited by
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other laws affecting the enforcement of creditors&#146; rights in general, and except that the enforceability of this Warrant is subject to general principles of equity.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Consents and Approvals</U>. No consent or approval of, giving of notice to,
registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required on the part of the Company with respect to the execution, delivery and performance by the Company of its
obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Issued Securities</U>. All issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully
paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> All outstanding shares of Common Stock and any other Company securities were issued in compliance with all applicable federal and state securities laws in all material respects. In
addition, as of the date immediately preceding the Effective Date, no stockholder of the Company has preemptive rights to purchase new issuances of the Company&#146;s capital stock pursuant to the Charter or the Company&#146;s bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exempt Transaction</U>. Subject to the accuracy of the Warrantholder&#146;s representations in <U>Section</U><U></U><U>&nbsp;10</U>,
the issuance of the Common Stock upon exercise of this Warrant will each constitute a transaction exempt from (i)&nbsp;the registration requirements of Section&nbsp;5 of the Act, in reliance upon Section&nbsp;4(a)(2) thereof, and (ii)&nbsp;the
qualification requirements of the applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Rule 144</U>. If the Warrantholder proposes to
sell Common Stock issuable upon the exercise of this Warrant in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder&#146;s written request to the Company, the Company shall furnish to the Warrantholder, within five days after
receipt of such request, a written statement confirming the Company&#146;s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time, and shall, subject to such sale being in
compliance with all of the conditions of Rule 144, issue appropriate instructions to its transfer agent to remove the restrictive legend from any certificates evidencing the Common Stock issuable upon the exercise of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Listing of Shares</U>. The Common Stock is listed for trading on the NASDAQ Stock Market LLC as of the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 10.</B> REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Investment Purpose</U>. The right to acquire Common Stock or the Common Stock issuable upon exercise of the Warrantholder&#146;s rights
contained herein has been, and such shares will be, acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the
same except pursuant to a registration under the Act or an exemption from the registration requirements of the Act. Warrantholder is not a registered broker-dealer under Section&nbsp;15 of the 1934 Act or an entity engaged in a business that would
require it to be so registered as a broker-dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Private Issue</U>. The Warrantholder understands (i)&nbsp;that the Common Stock
issuable upon exercise of this Warrant is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications
requirements thereof, and (ii)&nbsp;that the Company&#146;s reliance on such exemption is predicated on the representations set forth in this <U>Section</U><U></U><U>&nbsp;10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Financial Risk</U>. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Risk of No
Registration</U>. Without in any way limiting the Company&#146;s obligations under this Warrant, the Warrantholder understands that if the Common Stock is not registered with the SEC pursuant to Section&nbsp;12 of the 1934 Act or the Company is not
required to file reports pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the 1934 Act, or if a registration statement is not effective under the Act covering the resale of the shares of Common Stock issuable upon exercise of the Warrant when
it desires to sell (i)&nbsp;the rights to purchase Common Stock pursuant to this Warrant or (ii)&nbsp;the Common Stock issuable upon exercise of the right to purchase, as applicable, it may be required to hold such securities for an indefinite
period. The Warrantholder also understands that any sale of (A)&nbsp;its rights hereunder to purchase Common Stock or (B)&nbsp;Common Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made
only in accordance with the terms and conditions of that Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Accredited Investor</U>. Warrantholder is, and on each date on
which it exercises any portion of this Warrant, it will be, an &#147;accredited investor&#148; within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>No Short Sales</U>. Warrantholder has not engaged, and will not engage, in
&#147;short sales&#148; of the Common Stock of the Company at any time on or prior to the Effective Date and until the Termination Date. The term &#147;short sale&#148; shall mean any sale of a security which the seller does not own or any sale
which is consummated by the delivery of a security borrowed by, or for the account of, the seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 11.</B> TRANSFERS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to compliance with applicable federal and state securities laws, this Warrant and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Warrant properly endorsed. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that this Warrant, when endorsed in
blank, shall be deemed negotiable, and that the holder hereof, when this Warrant shall have been so endorsed and its transfer recorded on the Company&#146;s books, shall be treated by the Company and all other persons dealing with this Warrant as
the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Warrant. The transfer of this Warrant shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer
in the form attached hereto as <U>Exhibit C</U> (the &#147;<U>Transfer Notice</U>&#148;), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company
receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding anything herein or in any legend to the contrary, the Company shall not require an opinion of counsel in connection with
any sale, assignment or other transfer by Warrantholder of this Warrant (or any portion hereof or any interest herein) or of any shares of Common Stock issued upon any exercise hereof to an affiliate (as defined in Regulation D) of Warrantholder,
provided that such affiliate is an &#147;accredited investor&#148; as defined in Regulation D. Upon a permitted transfer of this Warrant to another entity, references to &#147;Warrantholder&#148; herein shall, unless the context otherwise requires,
refer to such permitted transferee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 12.</B> MISCELLANEOUS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Effective Date</U>. The provisions of this Warrant shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company and the Warrantholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Remedies</U>. In the event of any default hereunder, the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an
action for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the
Warrantholder or any other person entitled to the benefit of this Warrant requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Impairment of Rights</U>. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be reasonably necessary or appropriate in order to protect
the rights of the Warrantholder against impairment. Notwithstanding the foregoing, nothing in this Section&nbsp;12(c) shall negate or otherwise restrict or impair the Company&#146;s right to effect any changes to the rights, preferences, privileges
or restrictions associated with the Common Stock so long as such changes do not adversely affect the rights, preferences, privileges or restrictions associated with the shares of Common Stock issuable upon exercise of this Warrant in a manner
different from the effect that such changes have generally on the rights, preferences, privileges or restrictions associated with all other shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Documents</U>. The Company, upon execution of this Warrant, shall provide the Warrantholder with certified resolutions with
respect to the representations and warranties set forth in the first sentence of <U>Section</U><U></U><U>&nbsp;9(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U>Attorney&#146;s Fees</U>. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys&#146; fees and expenses and all reasonable
costs of proceedings incurred in enforcing this Warrant. For the purposes of this <U>Section</U><U></U><U>&nbsp;12(e)</U>, attorneys&#146; fees shall include without limitation reasonable fees incurred in connection with the following:
(i)&nbsp;contempt proceedings; (ii)&nbsp;discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv)&nbsp;garnishment, levy, and debtor and third party examinations; and
(v)&nbsp;post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability</U>. In the event any one or more of the provisions of this Warrant shall for any reason be held invalid, illegal or
unenforceable, the remaining provisions of this Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention
of the parties underlying the invalid, illegal or unenforceable provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Warrant or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly
served, given, delivered, and received upon the earlier of: (i)&nbsp;the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the recipient, or, if
transmission or delivery occurs on a <FONT STYLE="white-space:nowrap">non-business</FONT> day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery
service; or (ii)&nbsp;the third calendar day after deposit in the United States mails, with proper first class postage prepaid (<U>provided</U>, that any Advance Request shall not be deemed received until Lender&#146;s actual receipt thereof), and
shall be addressed to the party to be notified as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Warrantholder: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: <B>[***]</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: <B>[***]</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Company: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MADRIGAL PHARMACEUTICALS, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Four Tower Bridge </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">200 Barr Harbor Drive, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">West Conshohocken, PA 19428 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: <B>[***]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to
such other address as each party may designate for itself by like notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Entire Agreement; Amendments</U>. This Warrant and the
First Amendment to Loan and Security Agreement, dated February&nbsp;3, 2023, constitute the entire agreement and understanding of the parties hereto in respect of this Warrant, and supersede and replace in their entirety any prior proposals, term
sheets, letters, negotiations or other documents or agreements, whether written or oral. None of the terms of this Warrant may be amended except by an instrument executed by each of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Headings</U>. The various headings in this Warrant are inserted for convenience only and shall not affect the meaning or interpretation
of this Warrant or any provisions hereof. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Advice of Counsel</U>. Each of the parties represents to each other party hereto that
it has discussed (or had an opportunity to discuss) with its counsel this Warrant and, specifically, the provisions of <U>Sections 12(n)</U>, <U>12(o)</U> and <U>12(p)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Strict Construction</U>. The parties hereto have participated jointly in the negotiation and drafting of this Warrant. In the event
an ambiguity or question of intent or interpretation arises, this Warrant shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>No Waiver</U>. Except for the requirement that this Warrant be exercised (or be deemed
exercised), if at all, during the Warrant Term, no omission or delay by either party hereto at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the other party
hereto at any time designated, shall be a waiver of any such right or remedy to which such party is entitled, nor shall it in any way affect the right of such party to enforce such provisions thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Survival</U>. All agreements, representations and warranties contained in this Warrant or in any document delivered pursuant hereto
shall be for the benefit of Warrantholder and the Company, as the case may be, and shall survive the execution and delivery of this Warrant and the expiration or other termination of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Governing Law</U>. This Warrant has been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by Warrantholder in the State of California. Delivery of Common Stock to Warrantholder by the Company under this Warrant is due in the State of California. This Warrant shall be governed by, and construed and enforced in accordance with,
the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Consent to Jurisdiction and Venue</U>. All judicial proceedings arising in or under or related to this Warrant may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant, each party hereto generally and unconditionally: (a)&nbsp;consents to personal jurisdiction in Santa Clara County, State
of California; (b)&nbsp;waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c)&nbsp;agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d)&nbsp;irrevocably
agrees to be bound by any judgment rendered thereby in connection with this Warrant. Service of process on any party hereto in any action arising out of or relating to this Warrant shall be effective if given in accordance with the requirements for
notice set forth in <U>Section</U><U></U><U>&nbsp;12(g)</U>, and shall be deemed effective and received as set forth in <U>Section</U><U></U><U>&nbsp;12(g)</U>. Nothing herein shall affect the right to serve process in any other manner permitted by
law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Mutual Waiver of Jury Trial</U>. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes arising out
of this Warrant be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY
OTHER CLAIM (COLLECTIVELY, &#147;<U>CLAIMS</U>&#148;) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY RELATING TO THIS WARRANT. This waiver extends to all such Claims arising out
of this Warrant, including Claims that involve persons other than the Company and Warrantholder, and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Arbitration</U>. If the Mutual Waiver of Jury Trial set forth in Section&nbsp;12(p) is ineffective or unenforceable, the parties agree
that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the &#147;<U>Rules</U>&#148;), such arbitration to occur before one arbitrator, which arbitrator shall be a retired California
state judge or a retired Federal court judge. Such proceeding shall be conducted in Santa Clara County, State of California, with California rules of evidence and discovery applicable to such arbitration. The decision of the arbitrator shall be
binding on the parties, and shall be final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> to the maximum extent permitted by law. Any judgment rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by
the prevailing party as a final judgment of such court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U><FONT STYLE="white-space:nowrap">Pre-arbitration</FONT> Relief</U>. In the
event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction identified in Section&nbsp;12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced
to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
<U>Counterparts; Facsimile/Electronic Signatures </U>. This Warrant and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which
when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.. This Warrant may be executed by one or more of the parties hereto in any number of separate counterparts, all of which
together shall constitute one and the same instrument. The Company, Warrantholder and any other party hereto may execute this Warrant by electronic means and each party hereto recognizes and accepts the use of electronic signatures and the keeping
of records in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
electronic form by any other party hereto in connection with the execution and storage hereof. To the extent that this Warrant or any agreement subject to the terms hereof or any amendment hereto
is executed, recorded or delivered electronically, it shall be binding to the same extent as though it had been executed on paper with an original ink signature, as provided under applicable law, including, without limitation, any state law based on
the Uniform Electronic Transactions Act. The fact that this Warrant is executed, signed, stored or delivered electronically shall not prevent the transfer by any Holder of this Warrant pursuant to Section&nbsp;11 or the enforcement of the terms
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Specific Performance</U>. The parties hereto hereby declare that it is impossible to measure in money the damages which
will accrue to a party hereto by reason of the other party&#146;s failure to perform any of the obligations under this Warrant and agree that the terms of this Warrant shall be specifically enforceable by either party hereto. If a party hereto
institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party has an adequate remedy at law, and such person
shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Lost, Stolen, Mutilated or
Destroyed Warrant</U>. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, upon receiving an agreement from the Holder as to indemnity or otherwise as it may reasonably require (which shall, in the case of a mutilated Warrant,
include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page left blank intentionally; signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
their respective officers thereunto duly authorized as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="7">COMPANY: MADRIGAL PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Brian J. Lynch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">SVP and General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="7">WARRANTHOLDER: HERCULES CAPITAL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">CFO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Warrant &#150; Madrigal Pharmaceuticals, Inc./Hercules Capital, Inc.] </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To:&nbsp;&nbsp;&nbsp;&nbsp;[____________________________] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned Warrantholder hereby elects to purchase [_______] shares of the Common Stock of
[_________________], pursuant to the terms of the Warrant Agreement made effective the 9th day of May, 2022 (the &#147;Agreement&#148;) between Madrigal Pharmaceuticals, Inc., a Delaware corporation, and the Warrantholder, and [CASH PAYMENT: tenders
herewith payment of the cash Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section&nbsp;3(a) of the Agreement to effect a Net Issuance.] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please issue a certificate or certificates representing said shares of Common Stock in the name of the
undersigned or in such other name as is specified below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP>(Name)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP>(Address)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WARRANTHOLDER:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Maryland corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ACKNOWLEDGMENT OF EXERCISE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned, as
representative of Madrigal Pharmaceuticals, Inc. (the &#147;<U>Company</U>&#148;), hereby acknowledges receipt of the &#147;Notice of Exercise&#148; from Hercules Capital, Inc. (the &#147;<U>Warrantholder</U>&#148;), to purchase [<U></U>&nbsp;]
shares of the Common Stock of the Company, pursuant to the terms of that certain Warrant Agreement, made effective as of May&nbsp;9, 2022 between the Company and the Warrantholder (the &#147;<U>Warrant</U>&#148;), and further acknowledges that
[<U></U>&nbsp;] shares remain subject to purchase under the terms of the Warrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">COMPANY:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">MADRIGAL PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT C </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TRANSFER NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE
RECEIVED, that certain Warrant Agreement, made effective as of May&nbsp;9, 2022, between Madrigal Pharmaceuticals, Inc., as the Company, and Hercules Capital, Inc., as the Warrantholder (the &#147;<U>Warrant</U>&#148;), and all rights evidenced
thereby are hereby transferred and assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Please Print)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">whose&nbsp;address&nbsp;is</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dated:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature Guaranteed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the
Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d457771dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT&nbsp;HAS BEEN OMITTED AND REPLACED WITH &#147;[***]&#148; BECAUSE IT IS NOT MATERIAL AND
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution Version </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>F<SMALL>IRST</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> L<SMALL>OAN</SMALL> A<SMALL>ND</SMALL> S<SMALL>ECURITY</SMALL>
A<SMALL>GREEMENT</SMALL> </B>(this &#147;<B>Amendment</B>&#148;) is dated as of February 3, 2023 and is entered into by and among MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (&#147;<B>Madrigal</B>&#148;), CANTICLE PHARMACEUTICALS, INC., a
Delaware corporation (&#147;<B>Canticle</B>&#148;) (individually or collectively, as the context may require, &#147;<B>Borrower</B>&#148;), the several banks and other financial institutions or entities from time to time parties to the Loan
Agreement (collectively, referred to as &#147;<B>Lender</B>&#148;) and (c)&nbsp;HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and Lender (in such capacity,
&#147;<B>Agent</B>&#148;). <I>Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined below)</I>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> Borrower, Agent and Lender have entered into that certain Loan and Security Agreement dated as of May 9, 2022, among Borrower, Agent
and Lender (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the &#147;<B>Loan Agreement</B>&#148;), pursuant to which Lender has agreed to extend and make available to Borrower certain advances of
money. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> In accordance with Section&nbsp;11.3 of the Loan Agreement, Borrower has requested that Agent and Lender agree to amend
certain provisions of the Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> Agent and Lender have agreed to so amend the Loan Agreement upon the terms and
conditions more fully set forth herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing Recitals and other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>
<B>A<SMALL>MENDMENTS</SMALL></B><SMALL></SMALL>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> The Loan Agreement is hereby amended to reflect the changes
which are attached as Annex A hereto, such that on the First Amendment Closing Date the terms set forth in <B><U>Annex A</U> </B>hereto which appear in bold and double underlined text
(<B><FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">inserted text</U></FONT></B>) shall be added to the Loan Agreement and the terms appearing as text which is stricken (<FONT
STYLE="font-family:Times New Roman" COLOR="#ff0000"><B><STRIKE>deleted text</STRIKE></B></FONT><FONT STYLE="font-family:Times New Roman">) shall be deleted from the Loan Agreement. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> Exhibit A (Advance Request) to the Loan Agreement is hereby amended and restated in its entirety as set forth on the
annex attached as <B><U>Annex B</U> </B>hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <U>Schedule 1.1 (Commitments) </U>to the Loan Agreement is
hereby amended and restated in its entirety as set forth on the annex attached as <B><U>Annex C</U> </B>hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> With respect to the Warrants of the Company issued to each Lender
as of May 9, 2022, in connection with the Loan Agreement closing (each, a &#147;Global Warrant&#148; and collectively, the &#147;Global Warrants&#148;), the rights and obligations thereunder shall be amended and restated or terminated in connection
with the Amendment as set forth below: (a)&nbsp;to the extent each Global Warrant became vested in connection with Tranche 1 Advances made to Borrower (and evidencing the right to purchase 14,899 shares of Common Stock in the aggregate), such Global
Warrant rights shall be amended and restated to reflect the agreement terms attached as <B>Annex D- 1, <FONT STYLE="white-space:nowrap">D-2</FONT> and <FONT STYLE="white-space:nowrap">D-3</FONT> </B>hereto ; and (b)&nbsp;all other rights under each
Global Warrant that did not vest prior to this Amendment (and which evidenced the unvested right to purchase 59,545 shares of Common Stock in the aggregate) shall terminate in connection with the Amendment. As to the previous Global Warrant rights
referenced in clause (b)&nbsp;above, the Company shall be obligated to issue warrants in connection with Advances made on or after the date of the Amendment pursuant to Section&nbsp;1.5, 1.6. 1.7, 1.8 and 1.9 below. Each Lender represents and
warrants that it did not exercise, and did not make any transfer or hypothecation of, the Global Warrant issued to it, prior to the Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> Prior to or substantially concurrently with the effectiveness of this Amendment, Borrower shall have delivered duly
executed copies of Warrants to each Lender that will become vested in connection with Tranche 2a First Amendment Closing Date Advance made to Borrower, in substantially the form attached as <B>Annex <FONT STYLE="white-space:nowrap">E-1,</FONT> <FONT
STYLE="white-space:nowrap">E-2</FONT> and <FONT STYLE="white-space:nowrap">E-3</FONT> </B>hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> If Borrower
elects to draw the Tranche 2a Subsequent Advance, Borrower shall deliver duly executed copies of Warrants to each Lender that will become vested in connection with such Tranche 2a Subsequent Advance made in the future to Borrower, in substantially
the form attached as <B>Annex F</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> If Borrower elects to draw a Tranche 2b Advance, Borrower shall deliver
duly executed copies of Warrants to each Lender that will become vested in connection with such Tranche 2b Advances made in the future to Borrower, in substantially the form attached as <B>Annex G</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> If Borrower elects to draw a Tranche 3 Advance, Borrower shall deliver duly executed copies of Warrants to each
Lender that will become vested in connection with such Tranche 3 Advances made in the future to Borrower, in substantially the form attached as <B>Annex H</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> If Borrower elects to draw a Tranche 4 Advance, Borrower shall deliver duly executed copies of Warrants to each
Lender that will become vested in connection with such Tranche 4 Advances made in the future to Borrower, in substantially the form attached as <B>Annex I</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> Each reference in the Loan Agreement to &#147;this Agreement&#148; and the words &#147;hereof,&#148;
&#147;herein,&#148; &#147;hereunder,&#148; or words of like import, shall mean and be a reference to the Loan Agreement as amended by this Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>B<SMALL>ORROWER</SMALL>&#146;<SMALL>S</SMALL> R<SMALL>EPRESENTATIONS</SMALL> A<SMALL>ND</SMALL>
W<SMALL>ARRANTIES</SMALL></B><SMALL></SMALL>. Borrower represents and warrants that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> Immediately upon giving
effect to this Amendment (i)&nbsp;the representations and warranties contained in the Loan Documents are true and correct in all material respects except to the extent such representations and warranties relate to an earlier date, in which case they
are true and correct in all material respects as of such date and (ii)&nbsp;no default or Event of Default has occurred and is continuing with respect to which Borrower has not been notified in writing by Agent or Lender. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> Borrower has the corporate power and authority to execute and
deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>
The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized by all necessary corporate action on the part of Borrower.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower,
enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or
affecting creditors&#146; rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> As of the date hereof, it has no defenses against the obligations to pay any
amounts under the Obligations. Borrower acknowledges that each of Agent and Lender has, as of the date hereof, acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this
Amendment and in connection with the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower understands and acknowledges that each of Agent and Lender is entering into
this Amendment in reliance upon, and in partial consideration for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>L<SMALL>IMITATION</SMALL></B><SMALL></SMALL>. The amendments set forth in this Amendment shall be limited precisely as written
and shall not be deemed (a)&nbsp;to be a waiver or modification of any other term or condition of the Loan Agreement or of any other instrument or agreement referred to therein or to prejudice any right or remedy which Agent and/or Lender may now
have or may have in the future under or in connection with the Loan Agreement (as amended hereby) or any instrument or agreement referred to therein; or (b)&nbsp;to be a consent to any future amendment or modification or waiver to any instrument or
agreement the execution and delivery of which is consented to hereby. Except as expressly amended hereby, the Loan Agreement shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>E<SMALL>FFECTIVENESS</SMALL></B><SMALL></SMALL>. This Amendment shall become effective upon the satisfaction of all the following
conditions precedent (such date of satisfaction of all such conditions precedent, the &#147;<B>First Amendment Closing Date</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Amendment</B>. Borrower, Agent and Lender shall have duly executed and delivered this Amendment to Lender. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2 Corporate Documents</B>. Agent shall have received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> a certified copy of resolutions of the Board evidencing approval of this Amendment and other transactions evidenced
by the Loan Documents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> certified copies of the Certificate of Incorporation and the Bylaws, as amended through
the First Amendment Closing Date, of Borrower; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>a certificate of good standing for Borrower from its state
of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Payment of Lender Expenses. </B>Borrower shall have paid all
reasonable Lender expenses (including all reasonable attorneys&#146; fees and reasonable expenses) incurred through the date of this Amendment for the documentation and negotiation of this Amendment, in each case, to the extent invoiced on or prior
to the First Amendment Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Payment of Facility Charge. </B>Borrower shall have paid the Tranche 2
Facility Charge with respect to the Tranche 2a First Amendment Closing Date Advance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Warrants. </B>Borrower
shall have delivered duly executed copies of (i)&nbsp;amended and restated Warrants to each Lender with respect to Tranche 1 in substantially the form attached as <B>Annex <FONT STYLE="white-space:nowrap">D-1,</FONT>
<FONT STYLE="white-space:nowrap">D-2</FONT> and <FONT STYLE="white-space:nowrap">D-3</FONT> </B>hereto and (ii)&nbsp;Warrants to each Lender with respect to Tranche 2a in substantially the form attached as <B>Annex
<FONT STYLE="white-space:nowrap">E-1,</FONT> <FONT STYLE="white-space:nowrap">E-2</FONT> and <FONT STYLE="white-space:nowrap">E-3</FONT> </B>hereto. Borrower shall deliver duly executed original counterparts of the Warrants referred to in the
foregoing sentence within five (5)&nbsp;Business Days of the First Amendment Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>
<B>R<SMALL>ELEASE</SMALL></B><SMALL></SMALL>. In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on
behalf of itself and its successors, assigns, and other legal representatives, hereby to the extent possible under applicable law fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and
its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lender and all such other persons being
hereinafter referred to collectively as the &#147;<B>Releasees</B>&#148; and individually as a &#147;<B>Releasee</B>&#148;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums
of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of <FONT STYLE="white-space:nowrap">set-off,</FONT> demands and liabilities whatsoever of every name and nature, known or unknown, suspected
or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any
circumstance, action, cause or thing whatsoever which arises at any time prior to the execution of this Amendment, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or
transactions thereunder or related thereto. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other
proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction existing prior to the execution of this Amendment which could now be
asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above. Borrower waives the provisions of California Civil Code section 1542, which states: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE
TIME OF EXECUTING THE RELEASE AND THAT IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>C<SMALL>OUNTERPARTS</SMALL></B><SMALL></SMALL>. This Amendment may be signed in any number of counterparts, and by different
parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument. All counterparts shall be deemed an original of this Amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment may be executed by facsimile, portable document format (.pdf) or similar technology
signature, and such signature shall constitute an original for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>I<SMALL>NCORPORATION</SMALL> B<SMALL>Y</SMALL>
R<SMALL>EFERENCE</SMALL>. </B>The provisions of Section&nbsp;11 of the Loan Agreement shall be deemed incorporated herein by reference, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>R<SMALL>EAFFIRMATION</SMALL></B><SMALL></SMALL>. By executing and delivering a counterpart hereof, (i)&nbsp;Borrower hereby
agrees that all Advances incurred by Borrower shall be secured by the Collateral pursuant to the applicable Loan Documents in accordance with the terms and provisions thereof and (ii)&nbsp;Borrower hereby (A)&nbsp;agrees that, notwithstanding the
effectiveness of this Amendment, after giving effect to this Amendment, the Loan Documents continue to be in full force and effect, (B)&nbsp;agrees that all of the Liens and security interests created and arising under the Loan Documents remain in
full force and effect on a continuous basis, and the perfected status and priority of each such Lien and security interest continues in full force and effect on a continuous basis, unimpaired, uninterrupted and undischarged, as collateral security
for its obligations, liabilities and indebtedness under the Loan Agreement to the extent provided in, and subject to the limitations and qualifications set forth in, such Loan Documents (as amended by this Amendment) and (C)&nbsp;affirms and
confirms all of its obligations, liabilities and indebtedness under the Loan Agreement and each other Loan Document, in each case after giving effect to this Amendment, including the pledge of and/or grant of a security interest in its assets as
Collateral pursuant to the Loan Documents to secure such Secured Obligations, all as provided in the Loan Documents, and acknowledges and agrees that such obligations, liabilities, guarantee, pledge and grant continue in full force and effect in
respect of, and to secure, such Secured Obligations under the Loan Agreement and the other Loan Documents, in each case, to the extent provided in, and subject to the limitations and qualifications set forth in, such Loan Documents (as amended by
this Amendment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS <B>WHEREOF, </B>the parties have duly authorized and caused this Amendment to be
executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BORROWERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MADRIGAL PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brian Lynch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brian Lynch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CANTICLE PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brian Lynch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brian Lynch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page -First Amendment to LSA} </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted in Palo Alto, California: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AGENT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES CAPITAL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES CAPITA L, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES PRIVATE CREDIT FUND I L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Hercules Adviser LLC, its I</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Hercules Adviser LLC, its Investment Adviser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Seth Meyer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page - First Amendment to LSA] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex A</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended Loan Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I><FONT STYLE="font-family:Times New Roman" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Execution
Version</U></FONT></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LOAN AND SECURITY AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LOAN AND SECURITY AGREEMENT
<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(as amended by that certain First Amendment to Loan and Security Agreement dated as of February&nbsp;3, 2023 (the
&#147;First Amendment&#148;)) </U></FONT><FONT STYLE="font-family:Times New Roman">is made and dated as of May&nbsp;9, 2022 and is entered into by and among MADRIGAL PHARMACEUTICALS, INC., a Delaware corporation (&#147;Madrigal&#148;), CANTICLE
PHARMACEUTICALS, INC., a Delaware corporation (&#147;Canticle&#148;), and each of their respective Subsidiaries from time to time party hereto as borrower (individually or collectively, as the context may require, &#147;Borrower&#148;), the several
banks and other financial institutions or entities from time to time parties to this Agreement (each, a &#147;Lender&#148; and collectively referred to as the &#147;Lenders&#148;) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity
as administrative agent and collateral agent for itself and the Lenders (in such capacity, &#147;Agent&#148;). </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Borrower has requested the Lenders make available to Borrower one or more Advances in an aggregate principal amount of up to Two Hundred
and Fifty Million Dollars ($250,000,000) (the &#147;Term Loans&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Lenders are willing to make such Advances on the terms
and conditions set forth in this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, Borrower, Agent and the Lenders agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1. <U>DEFINITIONS AND RULES OF CONSTRUCTION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Account Control Agreement(s)&#148; means any agreement entered into by and among Agent, Borrower and a third party bank or other
institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent&#146;s first priority security interest in the subject account or accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;ACH Authorization&#148; means the ACH Debit Authorization Agreement in substantially the form of Exhibit H, which account numbers shall
be redacted for security purposes if and when filed publicly by Borrower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Acquisition&#148; means any transaction or series of
related transactions for the purpose of or resulting, directly or indirectly, in (a)&nbsp;the acquisition of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit of operation of a Person,
(b)&nbsp;the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of
Borrower, or (c)&nbsp;the acquisition of, including the acquisition of the right to use, develop or sell (in each case, including through licensing), any product, product line or Intellectual Property of or from any other Person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Acquisition Deferred Payments&#148; means, with respect to an Acquisition, any
&#147;earnouts,&#148; holdbacks, performance based-milestones, royalties, purchase price adjustments, profit sharing arrangements, indemnifications, noncompetition agreements, incentive payments, and other similar payment obligations, and other
contingent obligations and agreements consisting of the adjustment of purchase price or similar adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Advance&#148; means a
Term Loan Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Advance Date&#148; means the funding date of any Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Advance Request&#148; means a request for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A, which
account numbers shall be redacted for security purposes if and when filed publicly by Borrower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Affiliate&#148; means (a)&nbsp;any
Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b)&nbsp;any Person directly or indirectly owning, controlling or holding with power to vote thirty percent (30%) or more of the
outstanding voting securities of another Person, or (c)&nbsp;any Person thirty percent (30%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities. As
used in the defined term &#147;Affiliate,&#148; the term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting
securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Agreement&#148; means this Loan and Security Agreement, as amended <FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">by the First</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Amendment and as may be further amended</U></FONT><FONT STYLE="font-family:Times New Roman">, restated, amended and restated,
supplemented or otherwise modified from time to time. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Amortization Date&#148; means initially, <FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>November</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">May </U></FONT><FONT
STYLE="font-family:Times New Roman">1,
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2024</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2025</U></FONT>
<FONT STYLE="font-family:Times New Roman">; provided however, that (a</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>)&nbsp;if the Clinical Milestone is achieved prior to November&nbsp;1, 2024, such date
shall be extended to May&nbsp;1, 2025, (b</STRIKE></FONT><FONT STYLE="font-family:Times New Roman">) if the Approval Milestone is achieved prior to May&nbsp;1, 2025, such date shall be extended to May&nbsp;1, 2026, and (</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>c</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">b</U></FONT><FONT
STYLE="font-family:Times New Roman">) if (i)&nbsp;the Revenue Milestone is achieved prior to May&nbsp;1, 2026 and (ii)&nbsp;Borrower remains in compliance with Section&nbsp;7.20, such date shall be extended to the earlier of (A)&nbsp;May&nbsp;3,
2027 and (B)&nbsp;the first day of the fiscal month immediately following the occurrence of any default under Section&nbsp;7.20 (but in no event earlier than forty-eight (48)&nbsp;months). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Anti-Corruption Laws&#148; means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its respective
Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other
jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Anti-Terrorism Laws&#148; means any laws, rules, regulations or orders relating to terrorism or money laundering,
including without limitation Executive Order No.&nbsp;13224 (effective September&nbsp;24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Approval Milestone&#148; means the satisfaction of each of the following events: (a)&nbsp;no default or Event of Default shall have
occurred and be continuing, <FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and </U></FONT><FONT STYLE="font-family:Times New Roman">(b</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>)&nbsp;the Clinical Milestone has been achieved, and (c</STRIKE></FONT><FONT STYLE="font-family:Times New Roman">)&nbsp;Borrower shall have delivered evidence satisfactory
to Agent (as determined by Agent in its reasonable discretion) that the FDA shall have approved the sale and marketing of one dose of Resmetirom in the United States of America (including the grant of accelerated approval under 21 U.S.C. &#167; 356)
for the treatment of patients with NASH with a label claim that is generally consistent with what Borrower sought in its New Drug Application. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Blocked Person&#148; means any Person: (a)&nbsp;listed in the annex to, or is
otherwise subject to the provisions of, Executive Order No.&nbsp;13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order
No.&nbsp;13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d)&nbsp;a Person that commits, threatens or conspires to commit or supports &#147;terrorism&#148; as
defined in Executive Order No.&nbsp;13224, or (e)&nbsp;a Person that is named a &#147;specially designated national&#148; or &#147;blocked person&#148; on the most current list published by OFAC or other similar list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Board&#148; means, with respect to any Person that is a corporation, its board of directors; with respect to any Person that is a
limited liability company, its board of managers, board of members or similar governing body; with respect to any other Person that is a legal entity, such Person&#146;s governing body in accordance with its Organizational Documents; and with
respect to each of the foregoing, any committee or subcommittee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Books&#148; means Borrower&#146;s or any of its
Subsidiaries&#146; books and records including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#146;s or its Subsidiaries&#146; assets or liabilities, the Collateral, business operations or financial condition, and
all computer programs or storage or any equipment containing such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Business Day&#148; means any day other than
Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Cash&#148;
means all cash, Cash Equivalents and liquid funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Cash Equivalents&#148; means investments listed under clause (ii)&nbsp;of the
definition of &#147;Permitted Investments&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; means any reorganization, recapitalization, consolidation
or merger (or similar transaction or series of related transactions) of Borrower, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower&#146;s outstanding
shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of
the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the
surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Charter&#148; means, with respect to any Person, such Person&#146;s incorporation, formation or equivalent
documents, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>&#147;Clinical Milestone&#148; means the satisfaction of
each of the following events: (a)&nbsp;no default or Event of Default shall have occurred and be continuing and (b)&nbsp;Borrower shall have announced and delivered supporting documentation satisfactory to Agent (as determined by Agent in its
reasonable discretion) that Borrower has achieved a protocol specified primary endpoint for at least one dose from the Phase 3 MAESTRO-NASH (NCT03900429) trial, which taken together with the safety data from the Phase 3 <FONT
STYLE="white-space:nowrap">MAESTRO-NAFLD-1</FONT> (NCT04197479) trial and the overall safety profile from both such trials, support the filing of a New Drug Application as the next immediate step in development (as determined by Borrower&#146;s
executive team and Board, subject to the Lenders&#146; reasonable verification).</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">3</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Closing Date&#148; means the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Code&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Common Stock&#148; means the Common Stock, $0.0001 par value per share, of Madrigal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Company IP&#148; means any and all of the following, as they exist in and throughout the United States of America: (a)&nbsp;Current
Company IP; (b)&nbsp;improvements, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, provisionals or any substitute applications, any Patent issued with respect to any of
the Current Company IP, any Patent right claiming the composition of matter of, or the method of making or using, the Products in the United States of America, any reissue, reexamination, renewal or Patent term extension or adjustment (including any
supplementary protection certificate) of any such Patent, and any confirmation Patent or registration Patent or patent of addition based on any such Patent; (c)&nbsp;trade secrets or trade secret rights, including any rights to unpatented
inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> <FONT STYLE="white-space:nowrap">show-how,</FONT> operating manuals, confidential or proprietary information, research in progress, algorithms, data, databases, data collections, designs,
processes, procedures, methods, protocols, materials, formulae, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples, in each case, as
specifically related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Products; (d)&nbsp;any and all IP Ancillary Rights specifically
relating to any of the foregoing; and (e)&nbsp;regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale,
distribution or sale of the Products and all data provided in any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Compliance Certificate&#148; means a
certificate in the form attached hereto as Exhibit E. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Contingent Obligation&#148; means, as applied to any Person, any direct or
indirect liability, contingent or otherwise, of that Person with respect to (i)&nbsp;any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, <FONT
STYLE="white-space:nowrap">co-made</FONT> or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii)&nbsp;any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii)&nbsp;all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or
other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term &#147;Contingent Obligation&#148; shall not include endorsements for
collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is
made or, if not stated or determinable, the amount that would be required to be shown as a liability on a balance sheet prepared in accordance with GAAP; provided, however, that such amount shall not in any event exceed the maximum amount of the
obligations under the guarantee or other support arrangement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">4</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Copyright License&#148; means any written agreement granting any right to use any
Copyright or Copyright registration, now owned or hereafter acquired by any Loan Party or in which any Loan Party now holds or hereafter acquires any interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Copyrights&#148; means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of America,
any State thereof, or of any other country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Deposit Accounts&#148; means any &#147;deposit accounts,&#148; as such term is defined
in the UCC, and includes any checking account, savings account, or certificate of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Domestic Subsidiary&#148; means any
Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or any other jurisdiction within the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Due Diligence Fee&#148; means Sixty Five Thousand Dollars ($65,000), which fee has been paid to the Lenders prior to the Closing Date,
and shall be deemed fully earned on such date regardless of the early termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Equity Interests&#148; means,
with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person but excluding, for the avoidance of doubt, securities offered in connection
with any Permitted Convertible Debt and any other Indebtedness that is convertible into or otherwise exchangeable for, Equity Interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;ERISA&#148; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Excluded Account&#148; means (a)&nbsp;any Deposit Account that is used solely as a payroll or payables account, the funds in which
consist solely of funds held in trust for any director, officer, employee or former employee of such Borrower or Subsidiary for (i)&nbsp;salary accruals or (ii)&nbsp;amounts held under any employee benefit, deferred compensation or incentive
compensation plan maintained by such Borrower or Subsidiary or funds representing earned or deferred compensation for the directors, employees and former employees of such Borrower or Subsidiary to be paid in the ordinary course of business;
<U>provided </U>that the aggregate amount across any payroll accounts under clause (i)&nbsp;above shall not exceed the amount needed for the then-next two (2)&nbsp;payroll cycles or in accordance with IRS requirements, (b)&nbsp;escrow accounts,
Deposit Accounts and trust accounts, in each case used exclusively to maintain cash collateral pursuant to Section&nbsp;7.5 and the definition of &#147;Permitted Liens&#148;, (c) any Deposit Account held by a Foreign Subsidiary or an Immaterial
Subsidiary, (d)&nbsp;any Deposit Account or account holding Investment Property with a balance of no more than $250,000, or $750,000 in the aggregate for all such accounts and (e)&nbsp;any other Deposit Account approved by the Agent in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;FDA&#148; means the U.S. Food and Drug Administration or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;FDA Good Manufacturing Practices&#148; means the applicable requirements, standards and expectations for drug manufacturing activities
set forth in the Food, Drug and Cosmetic Act (&#147;FDCA&#148;) and its implementing regulations (for example, for pharmaceuticals being used in Phase 2 or 3 studies, and commercial pharmaceuticals, 21 C.F.R. Parts 210 and 211) and relevant FDA
guidance documents (for example, for pharmaceuticals in Phase 1, FDA guidance entitled &#147;CGMP for Phase 1 Investigational Drugs&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">5</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;FDA Laws&#148; means all applicable statutes, rules, regulations, standards,
guidelines, policies and orders and Requirements of Law administered, implemented, enforced or issued by FDA or any comparable governmental authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Federal Health Care Program Laws&#148; means collectively, federal Medicare or federal or state Medicaid statutes, Sections 1128, 1128A,
1128B, 1128C or 1877 of the Social Security Act (42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7,</FONT> <FONT STYLE="white-space:nowrap">1320a-7a,</FONT> <FONT STYLE="white-space:nowrap">1320a-7b,</FONT> <FONT
STYLE="white-space:nowrap">1320a-7c,</FONT> <FONT STYLE="white-space:nowrap">1320a-7h</FONT> and 1395nn), the federal TRICARE statute (10 U.S.C. &#167; 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. &#167; 3729 et seq.), criminal false
claims statutes (e.g., 18 U.S.C. &#167;&#167; 287 and 1001), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. &#167; 3801 et seq.), HIPAA, or related regulations or other Requirements of Law that directly or indirectly govern the health care
industry, programs of governmental authorities related to healthcare, health care professionals or other health care participants, or relationships among health care providers, suppliers, distributors, manufacturers and patients, and the pricing,
sale and reimbursement of health care items or services including the collection and reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug
Rebate Program (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1396r-8)</FONT> and any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1395w-3a),</FONT> the Public
Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#147;First
Amendment&#148; has the meaning given to it in the preamble of this Agreement.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#147;First
Amendment Closing Date&#148; means February&nbsp;3, 2023.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Foreign
Subsidiary&#148; means a Subsidiary other than a Domestic Subsidiary and any Domestic Subsidiary if it has no material assets other than the Equity Interests of one or more Foreign Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;GAAP&#148; means generally accepted accounting principles in the United States of America, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Guarantor&#148; means any subsidiary of Borrower that enters into a Guaranty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Guaranty&#148; means a guaranty with respect to the Secured Obligations, in form and substance satisfactory to Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Immaterial Subsidiary&#148; means on any date, any Subsidiary of Borrower acquired or formed after the Closing Date that has less than
2.5% of the consolidated assets of Borrower and its Subsidiaries (or 5% of the consolidated assets of Borrowers and its Subsidiaries for all such Immaterial Subsidiaries) for the most recently ended period for which financial statements have been
delivered (or required to have been delivered) pursuant to <U>Sections 7.1(a), (b) or (c)</U><U></U>&nbsp;prior to such date and designated as an &#147;Immaterial Subsidiary&#148; by Borrower in a written notice delivered to Agent (including any
Compliance Certificate), provided that no Subsidiary of Borrower shall qualify as an &#147;Immaterial Subsidiary&#148; if such Subsidiary (a)&nbsp;holds material Intellectual Property, (b)&nbsp;is party to the Roche Agreement or (c)&nbsp;is party to
any other Material Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">6</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Indebtedness&#148; means indebtedness of any kind, including (a)&nbsp;all indebtedness
for borrowed money or the deferred purchase price of property or services (excluding trade credit and incentive or deferred compensation authorized or entered into in the ordinary course of business), including reimbursement and other obligations
with respect to surety bonds and letters of credit, (b)&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments, (c)&nbsp;all capital lease obligations, (d) equity securities of any Person subject to repurchase or
redemption other than at the sole option of such Person, (e) &#147;earnouts&#148;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature
arising out of purchase and sale contracts, in each case, only to the extent required to be reflected as a liability on a balance sheet prepared in accordance with GAAP, (f) [reserved], (g) <FONT STYLE="white-space:nowrap">non-contingent</FONT>
obligations to reimburse any bank or Person in respect of amounts paid under a letter of credit, banker&#146;s acceptance or similar instrument, and (h)&nbsp;all Contingent Obligations. For the avoidance of doubt, any Permitted Equity Derivatives
that do not give rise to any cash payment obligations shall not constitute Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Initial Facility Charge&#148; means Three
Hundred and Twenty-Five Thousand Dollars ($325,000), which is payable to the Lenders in accordance with Section&nbsp;4.1(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Insolvency Proceeding&#148; means any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Intellectual Property&#148; means all of each Loan Party&#146;s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions;
mask works; each Loan Party&#146;s applications therefor and reissues, extensions, or renewals thereof; and each Loan Party&#146;s goodwill associated with any of the foregoing, together with each Loan Party&#146;s rights to sue for past, present
and future infringement of Intellectual Property and the goodwill associated therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Investment&#148; means (a)&nbsp;any
beneficial ownership (including stock, partnership interests, limited liability company interests, or other securities) of or in any Person, (b)&nbsp;any loan, advance or capital contribution to any Person or (c)&nbsp;any Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;IP Ancillary Rights&#148; means, with respect to any Copyright, Trademark, Patent, software, trade secrets or trade secret rights,
including any rights to unpatented inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> <FONT STYLE="white-space:nowrap">show-how</FONT> and operating manuals, all income, royalties, proceeds and liabilities at any time due or payable or
asserted under or with respect to any of the foregoing or otherwise with respect thereto, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other
impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, software, trade secrets or trade secret rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;IRS&#148; means the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Joinder Agreements&#148; means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto
as Exhibit F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;License&#148; means any Copyright License, Patent License, Trademark License or other Intellectual Property license
of rights or interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">7</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Lien&#148; means any mortgage, deed of trust, pledge, hypothecation, assignment for
security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the
nature of a security interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Loan&#148; means the Advances made under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Loan Documents&#148; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the
Joinder Agreements, all UCC Financing Statements, the Warrants, any Pledge Agreement, any Guaranty, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to
time be amended, modified, supplemented or restated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Loan Party&#148; means Borrower and/or any Guarantor, as the context may
require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Market Capitalization&#148; means, as of any date of determination, the product of (a)&nbsp;the number of outstanding
shares of Common Stock publicly disclosed in the most recent filing of Madrigal with the Securities and Exchange Commission as outstanding as of such date of determination and (b)&nbsp;the most recent closing price of Madrigal&#146;s Common Stock
(as quoted on Bloomberg L.P.&#146;s page or any successor page thereto of Bloomberg L.P. or if such page is not available, any other commercially available source). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Material Adverse Effect&#148; means a material adverse effect upon: (i)&nbsp;the business, operations, properties, assets or financial
condition of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or the Lenders to enforce any of its
rights or remedies with respect to the Secured Obligations; or (iii)&nbsp;the Collateral or Agent&#146;s Liens on the Collateral or the priority of such Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Material Agreement&#148; means (i)&nbsp;the Roche Agreement and (ii)&nbsp;any other license, agreement or other contractual arrangement,
the termination of which could be reasonably expected to result in a Material Adverse Effect, individually or in the aggregate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Material Indebtedness&#148; means any indebtedness having an aggregate principal amount of [***] or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Material Regulatory Liabilities&#148; means (a)(i) any liabilities arising from the violation of Public Health Laws, Federal Health Care
Program Laws, and other applicable comparable Requirements of Law, or from any <FONT STYLE="white-space:nowrap">non-routing</FONT> terms, conditions of or requirements imposed relative to any Registrations (including costs of actions required under
applicable Requirements of Law, including FDA Laws and Federal Health Care Program Laws, or necessary to remedy any violation of any terms or conditions applicable to any Registrations), including, but not limited to, withdrawal of approval, recall,
revocation, suspension, import refusal and seizure of any Product, and (ii)&nbsp;any loss of recurring annual revenues as a result of any loss, suspension or limitation of any Registrations, which, in the case of each of clauses (i)&nbsp;and (ii),
could reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Maximum Term Loan Amount&#148; means Two Hundred and Fifty
Million Dollars ($250,000,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;NASH&#148; means <FONT STYLE="white-space:nowrap">Non-Alcoholic</FONT> SteatoHepatitis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">8</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;New Drug Application&#148; means a new drug application submitted by Borrower to the
FDA for authorization to market a product in the United States of America, as defined in the applicable laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#147;</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">New
 Drug Application Milestone</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#148;</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> means the satisfaction of each of the following</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">events
(a)</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&nbsp;no default or Event of Default shall have occurred and be continuing, and (b)</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&nbsp;Borrower shall</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">have delivered evidence satisfactory to Agent (as determined in its reasonable discretion) that the FDA</U></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">has accepted Borrower</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#146;</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">s
 New Drug Application for the commercializing of Resmetirom for the treatment</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt"> of patients with NASH in the
United States of America.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;NIH&#148; means the National Institutes of
Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;Non-Disclosure</FONT> Agreement&#148; means that certain Confidential Disclosure Agreement
by and between Borrower and Agent dated as of January&nbsp;5, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;OFAC&#148; means the U.S. Department of Treasury Office of
Foreign Assets Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;OFAC Lists&#148; means, collectively, the Specially Designated Nationals and Blocked Persons List
maintained by OFAC pursuant to Executive Order No.&nbsp;13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any
other applicable Executive Orders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Organizational Documents&#148; means with respect to any Person, such Person&#146;s Charter and
(a)&nbsp;if such Person is a corporation, its bylaws, (b)&nbsp;if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c)&nbsp;if such Person is a partnership, its partnership agreement (or
similar agreement), each of the foregoing with all current amendments or modifications thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Patent License&#148; means any
written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement any Loan Party now holds or hereafter acquires any interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Patents&#148; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all
registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Acquisition&#148; means any Acquisition (including by way of merger or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
arrangement), in each case located principally within the United States of America, which is conducted in accordance with the following requirements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) of a business or Person or product engaged in a line of business related to that of Borrower or its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) unless otherwise agreed by Agent in its sole discretion, if such Acquisition is structured as a stock acquisition, then
the Person so acquired shall either (A)&nbsp;become a wholly-owned Subsidiary of Borrower or of a Subsidiary and Borrower shall comply, or cause such Subsidiary to comply, with 7.13 hereof or (B)&nbsp;such Person shall be merged with and into a Loan
Party (with such Loan Party being the surviving entity); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">9</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if such Acquisition is structured as the acquisition or <FONT
STYLE="white-space:nowrap">in-licensing</FONT> of assets, such assets shall be acquired by a Loan Party, and shall be free and clear of Liens other than Permitted Liens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Borrower shall have delivered to the Lenders not less than seven (7)&nbsp;nor more than forty five (45)&nbsp;days prior to
the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information, copies of then-current drafts of all available material documents relating to such acquisition, and available historical financial
statements for such acquired entity, division or line of business, in each case in form and substance satisfactory to the Lenders and demonstrating compliance with the covenants set forth in Section&nbsp;7.20 hereof on a pro forma basis as if the
Acquisition occurred on the first day of the most recent measurement period; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) both immediately before and after such
Acquisition no Default or Event of Default shall have occurred and be continuing; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the sum of the purchase price
of such proposed new Acquisition, computed on the basis of total acquisition consideration paid or incurred, or to be paid or incurred, by Borrower with respect thereto (excluding for such purpose any unpaid Acquisition Deferred Payments; but
including the amount of Permitted Indebtedness assumed or to which such assets, businesses or business or ownership interest or shares, or any Person so acquired, is subject) <U>provided </U>that, the sum of the purchase price shall not be greater
than (1) [***] for any single Acquisition or group of related Acquisitions or (2) [***] for all such Acquisitions during the term of this Agreement; <U>provided </U>further that (x)&nbsp;that acquisition consideration funded by proceeds from the
sale and issuance of Borrower&#146;s Equity Interests in a transaction not resulting in a Change in Control, which sale and issuance is consummated prior to, but no more than three (3)&nbsp;months prior to the consummation of such Acquisition, shall
be disregarded in determining compliance with this clause (vi)&nbsp;and (y) for any Acquisition in which the consideration consists of Equity Interest of Borrower, in whole or in part, the value of such Equity Interests shall be disregarded in
determining compliance with this clause (vi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Convertible Debt&#148; means issuance by Borrower of convertible notes in
an aggregate principal amount of not more than Four Hundred Million Dollars ($400,000,000); provided that such convertible notes shall (a)&nbsp;not require any scheduled amortization or otherwise require payment of principal prior to, or have a
scheduled maturity date, earlier than, one hundred eighty (180)&nbsp;days after the Term Loan Maturity Date (other than in the case of a fundamental change, or such other similar term, as defined in the definitive documents governing such Permitted
Convertible Debt), (b) be unsecured or secured, (c)&nbsp;not be guaranteed by any Subsidiary of Borrower that is not a Loan Party, (d)&nbsp;if secured, contain usual and customary subordination terms for underwritten offerings of senior subordinated
convertible notes and (e)&nbsp;if secured, shall specifically designate this Agreement and all Secured Obligations as &#147;designated senior indebtedness&#148; or similar term so that the subordination terms referred to in clause (d)&nbsp;of this
definition specifically refer to such notes as being subordinated to the Secured Obligations pursuant to such subordination terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Equity Derivatives&#148; means any forward purchase, accelerated share purchase, call option, warrant transaction or other
equity derivative transactions entered into in connection with the Permitted Convertible Debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">10</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Indebtedness&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Indebtedness of Borrower in favor of the Lenders or Agent arising under this Agreement or any other Loan Document; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Indebtedness of up to $1,000,000 outstanding at any time secured by a Lien described in clause (vii)&nbsp;of the defined
term &#147;Permitted Liens,&#148; provided such Indebtedness does not exceed the cost of the Equipment financed with such Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) (a) Indebtedness to trade creditors incurred in the ordinary course of business and (b)&nbsp;Indebtedness incurred in the
ordinary course of business with corporate credit cards in an amount not to exceed $1,000,000 at any time outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)
Indebtedness that also constitutes a Permitted Investment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Subordinated Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) reimbursement obligations in connection with letters of credit that are secured by Cash and issued on behalf of Borrower
or a Subsidiary thereof in an amount not to exceed $750,000 at any time outstanding<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>,</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">;</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) other unsecured Indebtedness in an amount not to exceed $1,000,000 at any time outstanding<FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>,</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">;</U></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) intercompany Indebtedness as long as either (A)&nbsp;each of the
Subsidiary obligor and the Subsidiary obligee under such Indebtedness is a Subsidiary that has executed a Joinder Agreement or (B)&nbsp;such indebtedness constitutes a Permitted Investment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Permitted Convertible Debt; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) the financing of insurance premiums in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) surety and appeal bonds, performance bonds, customs bonds and other obligations of a like nature incurred in the ordinary
course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) to the extent constituting Indebtedness, Acquisition Deferred Payments incurred in connection
with Permitted Investments; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) Indebtedness with respect to any Permitted Royalty Transaction; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not
increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be, and subject to any limitations on aggregate amount of such Indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Investment&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments existing or pending on the Closing Date which are disclosed in Schedule 1B; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">11</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (a) marketable direct obligations issued or unconditionally guaranteed
by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least <FONT STYLE="white-space:nowrap">A-2</FONT> or
<FONT STYLE="white-space:nowrap">P-2</FONT> from either Standard&nbsp;&amp; Poor&#146;s Corporation or Moody&#146;s Investors Services, (b)&nbsp;commercial paper maturing no more than one year from the date of creation thereof and currently having a
rating of at least <FONT STYLE="white-space:nowrap">A-2</FONT> or <FONT STYLE="white-space:nowrap">P-2</FONT> from either Standard&nbsp;&amp; Poor&#146;s Corporation or Moody&#146;s Investors Service, (c)&nbsp;certificates of deposit issued by any
bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, and (d)&nbsp;money market accounts; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Investments pursuant to Borrower&#146;s investment policy that has been provided to Agent prior to the Closing Date or any
investment policy that has been approved in writing by Agent in its reasonable discretion; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Investments accepted in
connection with Permitted Transfers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Investments (including debt obligations)&nbsp;(A) received in connection with
the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent or doubtful obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business and (B)&nbsp;consisting of the
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and
suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vii)&nbsp;shall not apply to Investments of any Loan Party in any Subsidiary of a Loan Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Investments consisting of (A)&nbsp;loans not involving the net transfer on a substantially contemporaneous basis of cash
proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower&#146;s Board; (B)&nbsp;other loans to employees, officers
or directors in an amount not to exceed $500,000 per fiscal year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) Investments consisting of travel advances in the
ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) (A) Investments by a Loan Party in any other Loan Party and (B)&nbsp;Investments in
newly-formed Domestic Subsidiaries, provided that each such Domestic Subsidiary enters into a Joinder Agreement promptly after its formation and executes such other documents as shall be reasonably requested by Agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Investments in Foreign Subsidiaries that are not Borrowers or Guarantors that do not exceed $500,000 in the aggregate in
any fiscal year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) joint ventures or strategic alliances in the ordinary course of Borrower&#146;s business consisting
of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensing of technology, the development of technology or the providing of technical support, provided that cash Investments (if any) by Borrower or the applicable Subsidiary do not exceed
$500,000 in the aggregate in any fiscal year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) Investments of any Loan Party in or to other Loan Parties; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">12</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) Investments constituting Permitted Acquisitions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) Permitted Equity Derivatives; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) additional Investments that do not exceed $1,000,000 in the aggregate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Liens&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Liens in favor of Agent or the Lenders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not yet due or being contested in good
faith by appropriate proceedings diligently conducted; provided, that Borrower maintains adequate reserves therefor on Borrower&#146;s Books in accordance with GAAP (to the extent required thereby); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like
Persons arising in the ordinary course of Borrower&#146;s business and imposed without action of such parties; provided, that the payment thereof is not yet required; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default
hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) (A) deposits to secure the performance of obligations (including by way deposits to secure letters of
credit issued to secure the same) under commercial supply and/or manufacturing agreements arising in the ordinary course of Borrower&#146;s business and (B)&nbsp;the following deposits, to the extent made in the ordinary course of business: deposits
under worker&#146;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or
other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to
secure indemnity, performance or other similar bonds; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Liens on Equipment, software or other intellectual property or
other assets and the proceeds thereof constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii)&nbsp;of &#147;Permitted Indebtedness&#148;; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Liens incurred in connection with Subordinated Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in
any material respect with the business of the licensor, including licenses permitted by clause (ii)&nbsp;of &#147;Permitted Transfers&#148;; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are
promptly paid on or before the date they become due; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">13</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) Liens on insurance proceeds securing the payment of financed insurance
premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) statutory and common law rights of <FONT STYLE="white-space:nowrap">set-off</FONT> and other similar rights as to
deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) easements,
zoning restrictions, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way</FONT></FONT> and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not
materially impair the value or marketability of the related property; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) (A) Liens on Cash securing obligations
permitted under clauses (vii)&nbsp;and (iv)(b) of the defined term &#147;Permitted Indebtedness&#148; and (B)&nbsp;security deposits in connection with real property leases, the combination of (A)&nbsp;and (B) in an aggregate amount not to exceed
$1,250,000 at any time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) Liens securing obligations under a Permitted Royalty Transaction to the extent that such Lien
solely encumbers the royalty interest purchased pursuant to such Permitted Royalty Transaction or a pledge of the stock of a special purpose entity contemplated under the definition of &#147;Permitted Royalty Transaction&#148;; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type
described in clauses (i)&nbsp;through (x) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or
refinanced (as may have been reduced by any payment thereon) does not increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Royalty Transaction&#148; means any
royalty or revenue interest financing whereby Madrigal or any other Loan Party receives upfront Unrestricted Cash (including, not subject to any redemption, clawback, escrow or similar encumbrance or restriction) in exchange for rights to receive
future payments based on net sales or revenue, as applicable, of Resmetirom in an amount not to exceed, in the aggregate for all such Permitted Royalty Transactions, the Specified Percentage (as set forth in Schedule 1D) of worldwide net sales or
revenue, as applicable, in any calendar year; provided that such royalty or revenue interest financing shall be on terms and conditions, and with a purchaser, in each case consented to in writing by Agent and (a)&nbsp;if structured as Indebtedness,
not have a scheduled maturity date earlier than one hundred eighty (180)&nbsp;days after the Term Loan Maturity Date, (b)&nbsp;if secured, not be secured by any Lien or other security interest on any Intellectual Property unless subject to an
intercreditor agreement reasonably satisfactory to Agent, and (c)&nbsp;not result in a transfer of ownership of any Intellectual Property other than in accordance with such intercreditor agreement or as set forth below. Notwithstanding anything
herein to the contrary, subject to such consent in writing by Agent, a Permitted Royalty Transaction may be structured on a <FONT STYLE="white-space:nowrap">non-recourse</FONT> basis (other than customary securitization undertakings and/or a pledge
of special purpose entity stock) with a special purpose entity that is a wholly-owned Subsidiary of a Loan Party, and in such case Agent and Lenders shall enter into further amendments to the Loan Documents as are reasonably requested by the Company
to give effect to such Permitted Royalty Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">14</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Permitted Transfers&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) sales of Inventory in the ordinary course of business, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business on arm&#146;s
length terms, that could not result in a legal transfer of title of the licensed property and that may be exclusive in respects other than territory or may be exclusive or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> as to region or
territory but only as to discrete geographical areas outside of the United States of America in the ordinary course of business, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) dispositions of <FONT STYLE="white-space:nowrap">worn-out,</FONT> obsolete or surplus Equipment at fair market value in
the ordinary course of business, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) (A) transfers of assets to any Loan Party and (B)&nbsp;transfers of assets from
any Subsidiary that is not a Loan Party to another Subsidiary that is not a Loan Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) the unwinding, settlement or
termination of any obligations under or in respect of any Permitted Equity Derivatives; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) transfers of Cash in the
ordinary course of business, subject to the limitations set forth in the Loan Documents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) sales, settlement,
forgiveness or discounting, in the ordinary course of business, of past due or doubtful accounts in connection with the collection or compromise thereof or in connection with the bankruptcy or reorganization of suppliers or customers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) the lapse, abandonment or other disposition of Intellectual Property that is, in the reasonable good faith judgment of
Borrower or a Subsidiary, no longer economically practicable or commercially desirable to maintain or useful in the conduct of the business of Borrower and its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) transfers made in connection with the Permitted Royalty Transaction; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) other Transfers of assets having a fair market value of not more than $1,000,000 in the aggregate in any fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Person&#148; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association,
corporation, limited liability company, institution, other entity or government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Pledge Agreement&#148; means (i)&nbsp;the Pledge
Agreement dated as of the Closing Date between Borrower and Agent, as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified and (ii)&nbsp;any other pledge agreement entered into to secure the
Secured Obligations, as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Public Health Laws&#148; means all Requirements of Law relating to the procurement, development, clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> evaluation, product approval or licensure, manufacture, production, analysis, distribution, dispensing, importation, exportation, use, handling, quality, sale, labeling, promotion, clinical trial
registration or post market requirements of any drug, biologic or other product (including, without limitation, any ingredient or component of the foregoing products) subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
&#167; 301 et seq.) and the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), including without limitation the regulations promulgated by the FDA at Title 21 of the Code of Federal Regulations and all applicable regulations promulgated by
the NIH and codified at Title 42 of the Code of Federal Regulations, and guidance, compliance, guides, and other policies issued by the FDA, the NIH and other comparable governmental authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">15</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Products&#148; means all products, software, service offerings, technical data or
technology currently being designed, manufactured or sold by Borrower or any of its Subsidiaries or which Borrower or any of its Subsidiaries intends to sell, license, or distribute in the future including any products or service offerings under
development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower or such Subsidiary since formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Receivables&#148; means (i)&nbsp;all of Borrower&#146;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters
of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii)&nbsp;all customer lists, software, and business records related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Register&#148; has the meaning specified in Section&nbsp;11.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Registrations&#148; means authorizations, approvals, licenses, permits, certificates, registrations, listings, certificates, or
exemptions of or issued by any governmental authority (including marketing approvals, investigational new drug applications, product recertifications, drug manufacturing establishment registration and product listing, pricing and reimbursement
approvals, labeling approvals or their foreign equivalent) that are required for the research, development, manufacture, commercialization, distribution, marketing, storage, transportation, pricing, governmental authority reimbursement, use and sale
of Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Regulatory Action&#148; means an administrative or regulatory enforcement action, proceeding or investigation, warning
letter, untitled letter, Form 483 or similar inspectional observations, other notice of violation letter, recall, seizure, Section&nbsp;305 notice or other similar written communication, or consent decree, issued or required by the FDA or under the
Public Health Laws, the NIH or a comparable governmental authority in any other regulatory jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Required Lenders&#148;
means at any time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loans then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Requirements of Law&#148; means, with respect to any Person, collectively, the common law and all federal, state, provincial, local,
foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and
the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any governmental authority, in each case that are applicable to or binding upon such Person or any of its property or to which such
Person or any of its property is subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Resmetirom&#148; means Borower&#146;s resmetirom product candidate for NASH and <FONT
STYLE="white-space:nowrap">non-alcoholic</FONT> fatty liver disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Responsible Officer&#148; means any of the Chief Executive
Officer, General Counsel (or Chief Legal Officer) and Chief Financial Officer of Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">16</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Revenue Milestone&#148; means satisfaction of each of the following events:
(a)&nbsp;no default or Event of Default shall have occurred and be continuing, (b)&nbsp;the Approval Milestone has been achieved, and (c)&nbsp;Borrower shall have delivered evidence satisfactory to Agent (as determined by Agent in its sole
discretion) that after the Closing Date and prior to January 31, 2026, Borrower has achieved at least [***] in T3M Net Product Revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Roche Agreement&#148; means that certain Research, Development and Commercialization Agreement, dated as of December 18, 2008, by and
between Madrigal (as successor in interest to VIA Pharmaceuticals, Inc.), <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Inc. and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd, as amended, restated, amended and restated,
supplemented or otherwise modified from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Sanctioned Country&#148; means, at any time, a country or territory which is
the subject or target of any Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Sanctioned Person&#148; means, at any time, (a)&nbsp;any Person listed in any
Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member
state, (b)&nbsp;any Person operating, organized or resident in a Sanctioned Country or (c)&nbsp;any Person controlled by any such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Sanctions&#148; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by
(a)&nbsp;the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or (b)&nbsp;the United Nations Security Council, the European Union or Her
Majesty&#146;s Treasury of the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Secured Obligations&#148; means Borrower&#146;s obligations under this Agreement and
any Loan Document (other than the Warrants), including any obligation to pay any amount now owing or later arising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Subordinated
Indebtedness&#148; means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its sole discretion and subject to a subordination agreement in form and substance satisfactory to Agent in
its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Subsequent Financing&#148; means the closing of any Madrigal financing involving the sale and issuance of
Madrigal&#146;s Equity Interests that is broadly marketed to multiple investors and which becomes effective after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Subsidiary&#148; means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which
Borrower owns or controls 50% or more of the outstanding voting securities, directly or indirectly. If not otherwise specified, a Subsidiary shall mean a direct or indirect Subsidiary of Borrower, including each entity listed on Schedule 1 hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;T3M Net Product Revenue&#148; means the net product revenue of Borrower and its Subsidiaries, as determined in accordance with
GAAP, from the sale of Resmetirom (which, for the avoidance of doubt, may include royalty or profit sharing revenue recognized in accordance with GAAP, but which shall not include any upfront or milestone-based payments under business development or
licensing transactions) in the United States of America, measured on a trailing three-month basis as of the date of the most recently delivered monthly financial statements in accordance with Section&nbsp;7.1(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">17</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Taxes&#148; means all present or future taxes, levies, imposts, duties, deductions,
withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Term Commitment&#148; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrower in a
principal amount not to exceed the amount set forth under the heading &#147;Term Commitment&#148; opposite such Lender&#146;s name on Schedule 1.1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Term Loan Advance&#148; means each Tranche 1 Advance, Tranche
<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2a First Amendment
Closing Date</U></FONT><FONT STYLE="font-family:Times New Roman"> Advance, </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Tranche 2a Subsequent Advance,
Tranche 2b Advance, </U></FONT><FONT STYLE="font-family:Times New Roman">Tranche 3 Advance, Tranche 4 Advance and any other Term Loan funds advanced under this Agreement. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Term Loan Interest Rate&#148; means for any day a per annum rate of interest equal to the greater of either (i)&nbsp;the prime rate as
reported in The Wall Street Journal plus
<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>3.95</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2.45</U></FONT><FONT
STYLE="font-family:Times New Roman">%, and (ii)
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>7.45</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">8.25</U></FONT>
<FONT STYLE="font-family:Times New Roman">%. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Term Loan Maturity Date&#148; means May&nbsp;1, 2026; provided, however, if the
Approval Milestone is achieved, then May&nbsp;3, 2027; provided further, that if such day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Trademark License&#148; means any written agreement granting any right to use any Trademark or Trademark registration, now owned or
hereafter acquired by any Loan Party or in which any Loan Party now holds or hereafter acquires any interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Trademarks&#148;
means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the
United States of America, any State thereof or any other country or any political subdivision thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 1&#148; means the
Advances pursuant to Section&nbsp;2.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>
2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2a</U></FONT><FONT STYLE="font-family:Times New Roman">&#148; means the Advances pursuant to
Section&nbsp;2.2(b)</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(i) and 2.2(b)(ii)</U></FONT><FONT STYLE="font-family:Times New Roman">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">&#147;Tranche 2b&#148;
 means the Advances made pursuant to Section&nbsp;2.2(c).</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 2
Facility Charge&#148; means zero point five percent (0.50%) of each <FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">of the</U></FONT><FONT
STYLE="font-family:Times New Roman"> Tranche
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2a First
Amendment Closing Date Advance, the Tranche 2a Subsequent Advance and the Tranche 2b</U></FONT><FONT STYLE="font-family:Times New Roman"> Advance, which is payable to the Lenders in accordance with Section&nbsp;4.2(d). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 3&#148; means the Advances pursuant to
Section&nbsp;
2.2(<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>c</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">d</U></FONT><FONT
STYLE="font-family:Times New Roman">). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 3 Facility Charge&#148; means zero point five percent (0.50%) of each Tranche
3 Advance, which is payable to the Lenders in accordance with Section&nbsp;4.2(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 4&#148; means the Advances pursuant to
Section&nbsp;
2.2(<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>d</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">e</U></FONT><FONT
STYLE="font-family:Times New Roman">). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Tranche 4 Facility Charge&#148; means zero point five percent (0.50%) of each Tranche
4 Advance, which is payable to the Lenders in accordance with Section&nbsp;4.2(f). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">18</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;UCC&#148; means the Uniform Commercial Code as the same is, from time to time, in
effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent&#146;s Lien on any Collateral is governed by
the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term &#147;UCC&#148; shall mean the Uniform Commercial Code as in effect, from time to time, in such other
jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Unrestricted Cash&#148; means unrestricted Cash of Borrower maintained in Deposit Accounts or other accounts in Borrower&#146;s name
subject to an Account Control Agreement in favor of Agent, subject to any post-closing period provided under this Agreement to deliver Account Control Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Person&#148; means any Person that is a &#147;United States person&#148; as defined in Section&nbsp;7701(a)(30) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Warrant&#148; means any warrant entered into in connection with the Loan, as may be amended, restated or modified from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 The following terms are defined in the Sections or subsections referenced opposite such terms: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Agent</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assignee</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Borrower</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Claims</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Collateral</B></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Confidential
Information</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Confidentiality
Agreement</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current Company
IP</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">5.10(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>End of Term
Charge</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Event of
Default</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial
Statements</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indemnified
Person</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lenders</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preamble</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum
Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Participant
Register</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Test Date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">7.20(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prepayment
Charge</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Publicity
Materials</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Register</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Rights to
Payment</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Specified
Disputes</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">5.10(g)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Specified
Percentage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 1D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Third Party
IP</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">5.10(i)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tranche 1
Advance</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">2.2(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">19</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;padding-bottom:2pt; margin-bottom:-1pt; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tranche
<FONT COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2a First </U></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Amendment Closing
Date</U></FONT> Advance</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2(b<FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">)(i)</U></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Tranche 2a Subsequent </U></FONT><FONT
 COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Advance</U></FONT></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2.2(b)(ii)</U></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:11pt"><B>Tranche
<FONT COLOR="#ff0000"><STRIKE>3</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2b</U></FONT> Advance</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2(c)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:11pt"><B>Tranche
<FONT COLOR="#ff0000"><STRIKE>4</STRIKE></FONT><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">3</U></FONT> Advance</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2(d)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:11pt"><B><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Tranche 4 Advance</U></FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2.2(e)</U></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a
&#147;Section,&#148; &#147;subsection,&#148; &#147;Exhibit,&#148; &#147;Annex,&#148; or &#147;Schedule&#148; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically
provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP,
consistently applied; provided that, no effect shall be given to Accounting Standards Codification 842, Leases (or any other Accounting Standards Codification having similar result or effect) (and related interpretations) to the extent any lease (or
similar arrangement) would be required to be treated as a capital lease thereunder where such lease (or arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of such Accounting
Standards Codification. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. For all purposes under the
Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#146;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right,
obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b)&nbsp;if any new Person comes into existence, such new Person shall be deemed to have been
organized on the first date of its existence by the holders of its Equity Interests at such time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 2. <U>THE LOAN</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 [Reserved]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 Term Loan
Advances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Tranche 1 Advance. Subject to the terms and conditions of this Agreement, on the Closing Date, the Lenders
shall severally (and not jointly) make in an amount not to exceed their respective Term Commitments, and Borrower agrees to draw, a Term Loan Advance in an aggregate principal amount equal to Fifty Million Dollars ($50,000,000) (the &#147;Tranche 1
Advance&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(b)
</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Tranche 2a Advances. Subject to the terms and conditions
of this Agreement, (i) on the First Amendment Closing Date, the Lenders shall severally (and not jointly) make in an amount not to exceed their respective Term Commitments, and Borrower agrees to draw, a Term Loan Advance in an aggregate principal
amount equal to Thirty Five Million Dollars ($35,000,000) (the &#147;Tranche 2a First Amendment Closing Date Advance&#148;) and (ii)&nbsp;on or prior to June&nbsp;19, 2023, Borrower may request, and the Lenders shall severally (and not jointly)
make, an additional Term Loan Advance in an aggregate principal amount equal to Fifteen Million Dollars ($15,000,000) (the &#147;Tranche 2a Subsequent Advance&#148;).</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">20</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(c)
</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(b)</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> Tranche </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2b </U></FONT><FONT
STYLE="font-family:Times New Roman">Advance. Subject to the terms and conditions of this Agreement and the achievement of the </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>Clinical</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">New Drug Application</U></FONT><FONT STYLE="font-family:Times New Roman"> Milestone, on or prior to the earlier of </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>June</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">September</U></FONT><FONT
STYLE="font-family:Times New Roman"> 30, 2023 </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>or
ninety</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and
</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">the date that is ten</U></FONT><FONT STYLE="font-family:Times New Roman"> (</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>90</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">10</U></FONT><FONT
STYLE="font-family:Times New Roman">)&nbsp;days following the achievement of the </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>Clinical</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">New Drug Application </U></FONT><FONT STYLE="font-family:Times New Roman">Milestone, Borrower may request, and the Lenders
shall severally (and not jointly) make,
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>additional</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">a</U>
</FONT><FONT STYLE="font-family:Times New Roman"> Term Loan
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>Advances</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Advance
</U></FONT><FONT STYLE="font-family:Times New Roman"> in an aggregate principal amount </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>up to Fifty</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">equal to Fifteen</U></FONT><FONT STYLE="font-family:Times New Roman"> Million Dollars ($</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>50,000,000), in minimum draws of at least Ten Million Dollars ($10,000,000) (or if less than Ten Million Dollars ($10,000,000), the remaining amount of Term Loan Advances
available to be drawn pursuant to this Section&nbsp;2.2(b)) (each, a</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">15,000,000) (the</U></FONT><FONT
STYLE="font-family:Times New Roman"> &#147;Tranche
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2b</U></FONT><FONT
STYLE="font-family:Times New Roman"> Advance&#148;)</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>; provided that Borrower shall not be permitted to request more than two (2)&nbsp;Tranche 2 Advances in
total.</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(d)</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(c)</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> Tranche 3 Advance. Subject to the terms and conditions of this Agreement and the achievement of the Approval
Milestone, on or prior to the earlier of June&nbsp;30, 2024 or ninety (90)&nbsp;days following the achievement of the Approval Milestone, Borrower may request, and the Lenders shall severally (and not jointly) make, additional Term Loan Advances in
an aggregate principal amount up to Seventy-Five Million Dollars ($75,000,000), in minimum draws of at least Ten Million Dollars ($10,000,000) (or if less than Ten Million Dollars ($10,000,000), the remaining amount of Term Loan Advances available
to be drawn pursuant to this Section&nbsp;2.2(cd)) (each, a &#147;Tranche 3 Advance&#148;); provided that Borrower shall not be permitted to request more than two (2)&nbsp;Tranche 3 Advances in total. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(e)
</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(d)
Trance</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Tranche </U></FONT><FONT STYLE="font-family:Times New Roman">4 Advance. Subject to the terms and
conditions of this Agreement and conditioned on approval by the Lenders&#146; respective investment committees in their sole and unfettered discretion, prior to the Amortization Date, Borrower may request, and the Lenders shall severally (and not
jointly) make, additional Term Loan Advances in an aggregate principal amount of up to </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>Seventy-Five</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">Sixty</U></FONT><FONT STYLE="font-family:Times New Roman"> Million Dollars ($</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>75,000,000</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">60,000,000</U></FONT>
<FONT STYLE="font-family:Times New Roman">), in minimum draws of at least Ten Million Dollars ($10,000,000) (or if less than Ten Million Dollars ($10,000,000), the remaining amount of Term Loan Advances available to be drawn pursuant to this
Section&nbsp;
2.2(</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>d</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">e</U></FONT>
<FONT STYLE="font-family:Times New Roman">)) (each, a &#147;Tranche 4 Advance&#148;); provided that Borrower shall not be permitted to request more than two (2)&nbsp;Tranche 4 Advances in total. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate outstanding Term Loan Advances shall not exceed the Maximum Term Loan Amount. Each Term Loan Advance of each
Lender shall not exceed its respective Term Commitment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(f)</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(e)</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> Advance Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request
(at least one (1)&nbsp;Business Day before the Closing Date and at least five (5)&nbsp;Business Days before each Advance Date other than the Closing Date to Agent. The Lenders shall fund the Term Loan Advance in the manner requested by the Advance
Request provided that each of the conditions precedent to such Term Loan Advance set forth in Section&nbsp;4 is satisfied as of the requested Advance Date. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(g)
</U></FONT><FONT STYLE="font-family:Times New Roman">&nbsp;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(f)</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> Interest. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Term Loan Interest Rate. The principal balance of each Term Loan Advance shall bear interest thereon from such Advance Date
in an amount equal to the product of the outstanding Term Loan principal balance multiplied by the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan
Interest Rate will float and change on the day the prime rate changes from time to time. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">22</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(h)
</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>(g)</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> Payment. Borrower will pay interest on each
Term Loan Advance on the first Business Day of each month, beginning the month after the Advance Date. Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the day immediately preceding the Amortization Date, in
equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until the Secured Obligations (other than inchoate indemnity obligations) are
repaid. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction
(except as provided in Addendum 1) and regardless of any counterclaim or defense. If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day. Agent, for
the benefit of the Lenders, will initiate debit entries to Borrower&#146;s account as authorized on the ACH Authorization (i)&nbsp;on each payment date of all periodic obligations payable to the Lenders under each Term Loan Advance and
(ii)&nbsp;reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees and costs incurred by Agent or the Lenders in connection with Section&nbsp;11.12 of this Agreement; provided
that, with respect to clause (i)&nbsp;above, in the event that Agent informs Borrower that Agent will not initiate a debit entry to Borrower&#146;s account for a certain amount of the periodic obligations due on a specific payment date, Borrower
shall pay to Agent, for the ratable benefit of the Lenders, such amount of periodic obligations in full in immediately available funds on such payment date; provided, further, that, with respect to clause (i)&nbsp;above, if Agent informs Borrower
that Agent will not initiate a debit entry as described above later than the date that is three (3)&nbsp;Business Days prior to such payment date, Borrower shall pay to Agent, for the ratable benefit of the Lenders, such amount of periodic
obligations in full in immediately available funds on the date that is three (3)&nbsp;Business Days after the date on which Agent notifies Borrower thereof; provided, further, that, with respect to clause (ii) above, in the event that Agent informs
Borrower that Agent will not initiate a debit entry to Borrower&#146;s account for certain amounts of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees and costs incurred by Agent or the
Lenders, Borrower shall pay to Agent such amounts in full in immediately available funds within three (3)&nbsp;Business Days. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 Maximum Interest. Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties&#146;
intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be
deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#147;Maximum Rate&#148;). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to the Lenders an amount of interest in
excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of the
Secured Obligations consisting of the outstanding principal; second, after all principal is repaid, to the payment of the Lenders&#146; accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all
Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">23</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 Default Interest. In the event any payment is not paid on the scheduled
payment date (other than a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#146;s bank if Borrower had the funds to make the payment when due and makes the payment within three
(3)&nbsp;Business Days following Borrower&#146;s knowledge of such failure to pay), an amount equal to four percent (4%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of
Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section&nbsp;2.2(<FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>f</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">g</U></FONT><FONT
STYLE="font-family:Times New Roman">), plus four percent (4%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth
in
Section&nbsp;
2.2(</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>f</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">g</U></FONT>
<FONT STYLE="font-family:Times New Roman">) or this Section&nbsp;2.4, as applicable. </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 Prepayment. At its option
upon at least seven (7)&nbsp;Business Days prior written notice (which such notice may be conditioned upon the consummation of a transaction constituting a Change in Control, other transformative transaction or a refinancing of the Loans) to Agent,
Borrower may at any time prepay all or a portion of the outstanding Advances by paying the entire principal balance (or such portion thereof), all accrued and unpaid interest thereon, together with a prepayment charge equal to the following
percentage of the principal amount of the Advance being prepaid: with respect to each Advance, if the principal amount of such Advance is prepaid in any of the first twelve (12)&nbsp;months following the Closing Date, two percent (2.0%); after
twelve (12)&nbsp;months but on or prior to twenty four (24)&nbsp;months, one point five percent (1.5%); after twenty four (24)&nbsp;months but on or prior to thirty six (36)&nbsp;months, zero point five percent (0.5%); and thereafter, zero percent
(0%) (each, a &#147;Prepayment Charge&#148;). Borrower agrees that the Prepayment Charge is a reasonable calculation of the Lenders&#146; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an
early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon any prepayment hereunder; provided that, for the avoidance of doubt, no
Prepayment Charge shall be due if Borrower prepays all of the outstanding Advances in connection with the occurrence of a Change in Control. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if Agent and the
Lenders (in their sole and absolute discretion) or their respective Affiliates agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount
of any Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the
due date thereof shall be the immediately preceding Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 End of Term Charge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On the earliest to occur of (i)&nbsp;the Term Loan Maturity Date, (ii)&nbsp;the date that Borrower prepays in full the
outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement), or (iii)&nbsp;the date that the Secured Obligations become due and
payable (including by acceleration of the Secured Obligations during an Event of Default) pursuant to the terms of this Agreement, Borrower shall pay the Lenders a charge of five point three five percent (5.35%) of the aggregate original principal
amount of the Term Loan Advances made hereunder (including, for the avoidance of doubt, the principal amount of any partial prepayments of Term Loan Advances made pursuant to Section&nbsp;2.5) (the &#147;End of Term Charge&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">24</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the required payment date of such End of Term Charge,
the applicable pro rata portion of the End of Term Charge shall be deemed earned by the Lenders as of each date a Term Loan Advance is made. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business
Day, the due date thereof shall be the immediately preceding Business Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 Pro Rata Treatment. Each payment (including
prepayment) on account of any fee and any reduction of the Term Loans shall be made pro rata according to the Term Commitments of the relevant Lenders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 Taxes; Increased Costs. Borrower, Agent and the Lenders each hereby agree to the terms and conditions set forth on Addendum
1 attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 Treatment of Prepayment Charge and End of Term Charge. Borrower agrees that any Prepayment Charge
and any End of Term Charge payable shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently existing and existing as
of the Closing Date. The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu
of foreclosure, or by any other means. Each Loan Party expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the foregoing Prepayment
Charge and End of Term Charge in connection with any such acceleration. Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an
arm&#146;s length transaction between sophisticated business people, ably represented by counsel; (b)&nbsp;each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment
is made; (c)&nbsp;there has been a course of conduct between the Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not interest) in the
event of prepayment or acceleration; and (d)&nbsp;Borrower shall be estopped from claiming differently than as agreed to in this paragraph. Borrower expressly acknowledges that their agreement to pay each of the Prepayment Charge and the End of Term
Charge to the Lenders as herein described was on the Closing Date and continues to be a material inducement to the Lenders to provide the Term Loans. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 3. <U>SECURITY INTEREST</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 Grant of Security Interest. As security for the prompt and complete payment when due (whether on the payment dates or
otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower&#146;s right, title, and interest in and to the following property whether now owned or hereafter acquired (collectively, the
&#147;Collateral&#148;): (a) Receivables; (b)&nbsp;Equipment; (c) Fixtures; (d)&nbsp;General Intangibles (other than Intellectual Property); (e) Inventory; (f)&nbsp;Investment Property; (g)&nbsp;Deposit Accounts; (h)&nbsp;Cash; (i) Goods; and (j)
all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, or acquired by, Borrower and wherever located, and any of Borrower&#146;s property in the possession or under the control of Agent; and, to
the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing; <U>provided</U>, however, that the Collateral shall include
all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the &#147;Rights to Payment&#148;). Notwithstanding the
foregoing, if a judicial authority (including a U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">25</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is
necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent&#146;s
security interest in the Rights to Payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 Excluded Collateral. Notwithstanding the broad grant of the security
interest set forth in Section&nbsp;3.1, above, the Collateral shall not include (a)&nbsp;subject to the last sentence of Section&nbsp;3.1, any Intellectual Property, (b)&nbsp;licenses or contracts, including without limitation any licenses described
in clause (b) of the defined term &#147;Permitted Transfers,&#148; the terms of which prohibit the transfer, assignment or pledge thereof or require the consent of the licensor thereof or another party (but only to the extent such prohibition on
transfer, assignment or pledge is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC); provided further, that upon the termination of such prohibition or such consent being provided with respect
to any license or contract, such license or contract shall automatically be included in the Collateral, (c)&nbsp;more than 65% of the presently existing and hereafter arising issued and outstanding Equity Interests owned by Borrower or any other
Loan Party of any Foreign Subsidiary which Equity Interests entitle the holder thereof to vote for directors or any other matter, (d)&nbsp;any Excluded Accounts, (e)&nbsp;any property, right or asset held by any Loan Party to the extent that a grant
of a security interest therein is prohibited by applicable law, (f)&nbsp;the assets of any <FONT STYLE="white-space:nowrap">non-wholly</FONT> owned subsidiary pursuant to customary restrictions and conditions contained in agreements governing joint
ventures or strategic alliances that constitute Permitted Investments, provided that the applicable Loan Party has exercised its good faith best efforts to not agree to (or to remove) such customary restrictions and conditions, and
(g)&nbsp;interests in joint ventures that constitute Permitted Investments pursuant to customary restrictions and conditions contained in agreements governing such joint ventures. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 4. <U>CONDITIONS PRECEDENT TO LOAN</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Agent the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) duly executed copies of the Loan Documents (other than the Warrants, which shall be an original), Account Control
Agreements, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance
reasonably acceptable to Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) a legal opinion of Borrower&#146;s counsel in form and substance reasonably acceptable
to Agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) a copy of resolutions of Borrower&#146;s Board evidencing approval of (i)&nbsp;the Loan and other
transactions evidenced by the Loan Documents, and (ii)&nbsp;the Warrants and transactions evidenced thereby, certified by an officer of Borrower; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">26</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) certified copies of the Charter of Borrower, certified by the Secretary
of State of the applicable jurisdiction of organization and the other Organizational Documents,<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>, </STRIKE></FONT><FONT STYLE="font-family:Times New Roman">as amended
through the Closing Date, of Borrower, certified by an officer of Borrower; </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) a certificate of good standing for
Borrower from the applicable jurisdiction of organization and similar certificates from all other jurisdictions in which Borrower does business and where the failure to be qualified could have a Material Adverse Effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) a perfection certificate of Borrower, together with duly executed signatures thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) certified copies, dated as of a recent date, of searches for financing statements filed in the central filing office of the
State of Delaware; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Intellectual Property searches with respect to Borrower; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) payment of the Due Diligence Fee (which has been paid prior to the Closing Date), Initial Facility Charge and reimbursement
of Agent&#146;s and the Lenders&#146; current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) all certificates of insurance, endorsements, and copies of each insurance policy required pursuant to Section&nbsp;6.2; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) such other documents as Agent may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 All Advances. On each Advance Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Agent shall have received (i)&nbsp;an Advance Request for the relevant Advance as required by Section&nbsp;2.2(<FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>e</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">f</U></FONT><FONT
STYLE="font-family:Times New Roman">), duly executed by a Responsible Officer, and (ii)&nbsp;any other documents Agent may reasonably request. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as
of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its
part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE> with</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">With </U></FONT><FONT STYLE="font-family:Times New Roman">respect to any Tranche </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>2</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">2a First Amendment Closing
Date Advance, Tranche 2a Subsequent Advance or Tranche 2b</U></FONT><FONT STYLE="font-family:Times New Roman"> Advance, the Loan Parties shall have paid the
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">applicable portion of the </U></FONT><FONT STYLE="font-family:Times New Roman">Tranche 2 Facility Charge</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>;</STRIKE></FONT><FONT STYLE="font-family:Times New Roman">
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and with respect to the Tranche 2a Subsequent Advance, the Loan Parties shall have delivered to Agent duly
executed copies of Warrants with respect to such Tranche 2a Subsequent Advance, in substantially the form attached to the First Amendment as Annex F.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">27</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>with</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">With </U></FONT><FONT
STYLE="font-family:Times New Roman">respect to any Tranche 3 Advance, the Loan Parties shall have </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(i)
</U></FONT><FONT STYLE="font-family:Times New Roman">paid the Tranche 3 Facility Charge</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>;</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and (ii)&nbsp;delivered to Agent duly executed copies of Warrants with respect to Tranche 3, in substantially the form
attached to the First Amendment as Annex H.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>with</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">With </U></FONT><FONT
STYLE="font-family:Times New Roman">respect to any Tranche 4 Advance, the Loan Parties shall have </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(i)
</U></FONT><FONT STYLE="font-family:Times New Roman">paid the Tranche 4 Facility Charge</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>;</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">and (ii)&nbsp;delivered to Agent duly executed copies of Warrants with respect to Tranche 4, in substantially the form
attached to the First Amendment as Annex I.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Advance
Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in subsections (b)&nbsp;and (c) of this Section&nbsp;4.2 and as to the matters set forth in the Advance Request.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 No Default. As of the Closing Date and each Advance Date, (i)&nbsp;no fact or condition exists that could (or could,
with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii)&nbsp;no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 Post-Closing Deliveries. The Loan Parties shall deliver the documents or satisfy the conditions, as applicable, in
accordance with Schedule 4.4 hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 5. <U>REPRESENTATIONS AND WARRANTIES OF</U> <U>BORROWER</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower represents and warrants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 Organizational Status. Each Loan Party is a corporation or limited liability company, as applicable, duly organized,
legally existing and in good standing under the laws of its jurisdiction of organization, and is duly qualified as a foreign corporation, limited liability company or partnership, as the case may be, in all jurisdictions in which the nature of its
business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Each Loan Party&#146;s present name, former names (if any), locations, place of
formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit B, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after
the Closing Date in accordance with this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 Collateral. Each Loan Party owns the Collateral and the Current
Company IP (other than any <FONT STYLE="white-space:nowrap">in-licensed</FONT> Intellectual Property), free of all Liens, except for Permitted Liens. Each Loan Party has the power and authority to grant to Agent a Lien in the Collateral as security
for the Secured Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 Consents. Each Loan Party&#146;s execution, delivery and performance of this Agreement
and all other Loan Documents to which it is party, and Borrower&#146;s execution of the Warrants, (i)&nbsp;have been duly authorized by all necessary action in accordance with such Loan Party&#146;s Organizational Documents and applicable law,
(ii)&nbsp;will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens, (iii)&nbsp;do not violate (A)&nbsp;any provisions of such Loan Party&#146;s Organizational Documents, or (B)&nbsp;any law,
regulation, order, injunction, judgment, decree or writ to which Borrower is subject, and (iv)&nbsp;except as described on Schedule 5.3, do not violate any Material Agreement or require the consent or approval of any other Person which has not
already been obtained. The individual or individuals executing the Loan Documents on behalf of each Loan Party and the Warrants on behalf of Borrower are duly authorized to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">28</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 Material Adverse Effect. Since December&nbsp;31, 2021, no event that has
had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing, and no Loan Party is aware of any event or circumstance likely to occur that is reasonably expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 Actions Before Governmental Authorities. There are no actions, suits or proceedings at law or in equity or by or before any
governmental authority now pending or, to the knowledge of any Loan Party, threatened in writing against or affecting a Loan Party or its property, that is reasonably expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to
any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default under any (i)&nbsp;agreement or instrument evidencing
Material Indebtedness to which it is a party or by which it is bound, (ii)&nbsp;any Material Agreement or (iii)&nbsp;any other agreement to which default is reasonably expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Borrower nor any of its Subsidiaries is an &#147;investment company&#148; or a company &#147;controlled&#148; by an
&#147;investment company&#148; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the
Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a &#147;holding company&#148; or an
&#147;affiliate&#148; of a &#147;holding company&#148; or a &#147;subsidiary company&#148; of a &#147;holding company&#148; as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower&#146;s nor any of its
Subsidiaries&#146; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#146;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material
compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all governmental authorities that are necessary to
continue their respective businesses as currently conducted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) None of Borrower, any of its Subsidiaries, or, to
Borrower&#146;s knowledge, any of Borrower&#146;s or its Subsidiaries&#146; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i)&nbsp;in violation
of any Anti-Terrorism Law, (ii)&nbsp;engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or
(iii)&nbsp;is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this
Agreement, (x)&nbsp;conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y)&nbsp;deals in, or otherwise engages in any transaction relating to, any
property or interest in property blocked pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">29</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Executive Order No.&nbsp;13224, any similar executive order or other Anti-Terrorism Law. None of the funds to be provided under this Agreement will be used, directly or indirectly, (a)&nbsp;for
any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations or (b)&nbsp;for any payment to any governmental official or employee, political party, official of a political party,
candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 Information Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule
furnished (in each case, other than forecasts, projections and other forward looking statements and information), by or on behalf of any Loan Party to Agent in connection with any Loan Document or included therein or delivered pursuant thereto
contained, or, when taken as a whole, contains any material misstatement of fact or, when taken together with all other such information or documents, omitted or omits to state any material fact necessary to make the statements therein, in the light
of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections, forecasts or forward-looking statements
provided by any Loan Party to Agent, whether prior to or after the Closing Date, shall be (i)&nbsp;provided in good faith and based on the most current data and information available to such Loan Party, and (ii)&nbsp;the most current of such
projections provided to such Loan Party&#146;s Board (it being understood that such matters are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular
matters will be realized and that actual results may differ). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 Tax Matters. Except as described on Schedule 5.8 or in
the most recently delivered Compliance Certificate in accordance with Section&nbsp;7.1(d) (provided that such disclosure made in such Compliance Certificate shall not apply to a period covered by a prior Compliance Certificate and shall not cure any
default arising from any false or misleading misrepresentations and warranties when made or when deemed made), (a) Borrower and its Subsidiaries have filed all federal and state income Tax returns and other material Tax returns that they are
required to file, (b)&nbsp;Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are required to pay, except in the case of clause (a) and this clause (b), that
relate to Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP, and (c)&nbsp;to the best of Borrower&#146;s knowledge, no proposed or pending
Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 Intellectual Property Claims. Each Loan Party is the sole owner of, or otherwise has the right to use, the Intellectual
Property material to such Loan Party&#146;s business. Except as described on Schedule 5.9 and as may be updated by Borrower in a written notice (including any Compliance Certificate) provided from time to time after the Closing Date, (i)&nbsp;each
of the material Copyrights, Trademarks and Patents (other than patent applications) is valid and enforceable, (ii)&nbsp;no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and
(iii)&nbsp;except as set forth in the most recently delivered Compliance Certificate in accordance with Section&nbsp;7.1(d), no claim has been made in writing to any Loan Party that any material part of the Intellectual Property violates the rights
of any third party. Exhibit C (and as may be updated by Borrower in a written notice provided from time to time after the Closing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">30</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Date) is a true, correct and complete list of each of each Loan Party&#146;s registered Patents and filed Patent applications, registered Trademarks, registered Copyrights, and Material
Agreements under which such Loan Party licenses Intellectual Property from third parties (other than shrink-wrap software licenses, licenses that are commercially available to the public, open source licenses, licenses disclosed in writing to Agent
as required under this Agreement and immaterial Intellectual Property licensed to Borrower in the ordinary course of business), together with application or registration numbers, as applicable, owned by such Loan Party or any Subsidiary, in each
case as of the Closing Date. No Loan Party is in material breach of, nor has any Loan Party failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to each Loan Party&#146;s knowledge, no third
party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 Intellectual Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A true, correct and complete list of each pending, registered or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
Intellectual Property that, individually or taken together with any other such Intellectual Property, is material to the business of Borrower and its Subsidiaries, taken as a whole, relating to the research, development, manufacture, production,
use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Products, and is owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> by or exclusively licensed to Borrower or any of its
Subsidiaries (collectively, the &#147;Current Company IP&#148;), including its name/title, current owner or <FONT STYLE="white-space:nowrap">co-owners</FONT> (including ownership interest), registration, patent or application number, and
registration or application date, issued or filed in the United States of America, is set forth on Schedule 5.10(a) or in the most recently delivered Compliance Certificate in accordance with Section&nbsp;7.1(d) (provided that such disclosure made
in such Compliance Certificate shall not apply to a period covered by a prior Compliance Certificate and shall not cure any default arising from any false or misleading misrepresentations and warranties when made or when deemed made). Except as set
forth on Schedule 5.10(a), (i)&nbsp;(A) each item of owned Current Company IP is valid, subsisting and (other than with respect to Patent applications) enforceable and no such item of Current Company IP has lapsed, expired, been cancelled or
invalidated or become abandoned or unenforceable, and (B) no written notice has been received challenging the inventorship or ownership, or relating to any lapse, expiration, invalidation, abandonment or unenforceability, of any such item of Current
Company IP, and (ii)&nbsp;(A) each such item of Current Company IP which is exclusively licensed from another Person is valid, subsisting and enforceable and no such item of Current Company IP has lapsed, expired, been canceled or invalidated, or
become abandoned or unenforceable, and (B) no written notice has been received challenging the inventorship or ownership, or relating to any lapse, expiration, invalidation, abandonment or unenforceability, of any such item of Current Company IP. To
the knowledge of any Loan Party, there are no published Patents, Patent applications, articles or prior art references that would reasonably be expected to materially adversely affect the exploitation of the Products. Except as set forth on Schedule
5.10(a) or in the most recently delivered Compliance Certificate in accordance with Section&nbsp;7.1(d) (provided that such disclosure made in such Compliance Certificate shall not apply to a period covered by a prior Compliance Certificate and
shall not cure any default arising from any false or misleading misrepresentations and warranties when made or when deemed made), (x) each Person who has or has had any rights in or to owned Current Company IP or any trade secrets owned by Borrower
or any of its Subsidiaries, including each inventor named on the Patents within such owned Current Company IP filed by Borrower or any of its Subsidiaries has executed an agreement assigning his, her or its entire right, title and interest in and to
such owned Current Company IP and such trade secrets, and the inventions, improvements, discoveries, writings, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">31</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
works of authorship, information and other intellectual property embodied, described or claimed therein, to the stated owner thereof, and (y)&nbsp;no such Person has any contractual or other
obligation that would preclude or conflict with such assignment or the exploitation of the Products or entitle such Person to ongoing payments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) (i) Borrower or any of its Subsidiaries possesses valid title to the Current Company IP for which it is listed as the owner
or <FONT STYLE="white-space:nowrap">co-owner,</FONT> as applicable, on Schedule 5.10(a); and (ii)&nbsp;there are no Liens on any Current Company IP (other than Permitted Liens). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no material maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period
for any of the Current Company IP which is owned or exclusively licensed to Borrower or any of its Subsidiaries, nor have any applications or registrations therefore lapsed or become abandoned, been cancelled or expired. There are no material
maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Company IP which is <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed to Borrower or any of its Subsidiaries,
nor have any applications or registrations therefor lapsed or become abandoned, been canceled or expired. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There are no
unpaid fees or royalties under any Material Agreements that have become due, or are expected to become overdue. Each Material Agreement is in full force and effect and is legal, valid, binding and enforceable in accordance with its respective terms,
except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&#146; rights generally or by equitable principles relating to enforceability. Except as set forth on Schedule 5.10(d),
neither Borrower nor any of its Subsidiaries, as applicable, is in breach of or default in any manner that could reasonably be expected to materially affect the Products under any Material Agreement to which it is a party or may otherwise be bound,
and to the knowledge of each Loan Party no circumstances or grounds exist that would give rise to a claim of breach or right of rescission, termination, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> revision or amendment of any of the
Material Agreements, including the execution, delivery and performance of this Agreement and the other Loan Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
No payments by Borrower or any of its Subsidiaries are due to any other Person in respect of the Current Company IP, other than pursuant to the Material Agreements and those fees payable to patent offices in connection with the prosecution and
maintenance of the Current Company IP, any applicable taxes and associated attorney fees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither Borrower nor any of
its Subsidiaries has undertaken or omitted to undertake any acts, and to the knowledge of each Loan Party no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the enforceability or scope of (i)&nbsp;the Current
Company IP in any manner that could reasonably be expected to materially adversely affect the Products, or (ii)&nbsp;in the case of Current Company IP owned or <FONT STYLE="white-space:nowrap">co-owned</FONT> or exclusively or <FONT
STYLE="white-space:nowrap">non-exclusively</FONT> licensed by Borrower or any of its Subsidiaries, except as set forth on Schedule 5.10(f), Borrower&#146;s or Subsidiary&#146;s entitlement to own or license and exploit such Current Company IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Except as described on Schedule 5.9 or in the most recently delivered Compliance Certificate in accordance with
Section&nbsp;7.1(d), there is no requested, filed pending, decided or settled opposition, interference proceeding, reissue proceeding, reexamination proceeding, inter-partes review proceeding, post-grant review proceeding, cancellation proceeding,
injunction, litigation, paragraph IV patent certification or lawsuit under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">32</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Hatch-Waxman Act, hearing, investigation, complaint, arbitration, mediation, demand, International Trade Commission investigation, decree or any other dispute, disagreement, or claim, in each
case alleged in writing to Borrower or any of its Subsidiaries (collectively referred to hereinafter as &#147;Specified Disputes&#148;), nor to the knowledge of any Loan Party, has any such Specified Dispute been threatened in writing, in each case
challenging the legality, validity, enforceability or ownership of any Current Company IP, in each case that would have a material adverse effect on the Products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) In each case where an issued Patent within the Current Company IP is owned or
<FONT STYLE="white-space:nowrap">co-owned</FONT> by Borrower or any of its Subsidiaries by assignment, the assignment has been duly recorded with the U.S. Patent and Trademark Office. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth on Schedule 5.10(i) or in the most recently delivered Compliance Certificate in accordance with
Section&nbsp;7.1(d) (provided that such disclosure made in such Compliance Certificate shall not apply to a period covered by a prior Compliance Certificate and shall not cure any default arising from any false or misleading misrepresentations and
warranties when made or when deemed made), there are no pending or, to the knowledge of any Loan Party, threatened (in writing) claims against Borrower or any of its Subsidiaries alleging (i)&nbsp;that any research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Products in the United States of America infringes or violates (or in the past infringed or violated) the rights of any third
parties in or to any Intellectual Property (&#147;Third Party IP&#148;) or constitutes a misappropriation of (or in the past constituted a misappropriation of) any Third Party IP, or (ii)&nbsp;that any Current Company IP is invalid or unenforceable.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Except as set forth on Schedule 5.10(j), the manufacture, production, use, commercialization, marketing, importing,
storage, transport, offer for sale, distribution or sale of the Products does not, to the knowledge of any Loan Party, infringe or violate any issued or registered Third Party IP (including any issued Patent within the Third Party IP) or constitute
a misappropriation of any Third Party IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Except as set forth on Schedule 5.10(k), there are no settlements, covenants
not to sue, consents, judgments, orders or similar obligations which: (i)&nbsp;restrict the rights of Borrower or any of its Subsidiaries to use any Intellectual Property relating to the research, development, manufacture, production, use,
commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Products (in order to accommodate any Third Party IP or otherwise), or (ii)&nbsp;permit any third parties to use any Company IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Except as set forth on Schedule 5.10(l), to the knowledge of any Loan Party (i)&nbsp;there is no infringement or violation
by any Person of any of the Company IP or the rights therein, and (ii)&nbsp;there is no misappropriation by any Person of any Company IP or the subject matter thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Borrower and each of its Subsidiaries have taken all commercially reasonable measures customary in the biopharmaceutical
industry to protect the confidentiality and value of all trade secrets owned by Borrower or any of its Subsidiaries or used or held for use by Borrower or any of its Subsidiaries, in each case relating to the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">33</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) [Reserved]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Except as described on Schedule 5.10(o), each Loan Party has all material rights with respect to Intellectual Property
necessary or material in the operation or conduct of such Loan Party&#146;s business as currently conducted and proposed to be conducted by such Loan Party. Without limiting the generality of the foregoing, and in the case of Licenses, except for
restrictions that are unenforceable under Division 9 of the UCC, each Loan Party has the right, to the extent required to operate such Loan Party&#146;s business, to freely transfer, license or assign Intellectual Property owned by such Loan Party
and necessary or material in the operation or conduct of such Loan Party&#146;s business as currently conducted and proposed to be conducted by such Loan Party, without condition, restriction or payment of any kind (other than license payments in
the ordinary course of business) to any third party. Each Loan Party owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are
material to such Loan Party&#146;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Products that are material to such Loan Party&#146;s business, in each case, except
customary covenants in inbound license agreements and equipment leases where such Loan Party is the licensee or lessee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) No material software or other materials used by any Loan Party or any of their Subsidiaries (or used in any Products) are
subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) in a manner that would cause such software or other materials to have to
be (i)&nbsp;distributed to third parties at no charge or a minimal charge (royalty-free basis); (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer; or (iii)&nbsp;used in a manner
that requires disclosure or distribution in source code form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 Products. Except as set forth on Schedule 5.11, at the
time of any shipment of Products in the United States of America occurring prior to the Closing Date, the units thereof so shipped complied with their relevant specifications and were manufactured in all material respects in accordance with the
current FDA Good Manufacturing Practices. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 Financial Accounts. Exhibit D, as may be updated by Borrower in a written
notice provided to Agent after the Closing Date, is a true, correct and complete list of (a)&nbsp;all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b)&nbsp;all institutions at which
Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the
purpose of the account, and the complete account number therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 Employee Loans. Except for Permitted Investments,
no Loan Party has outstanding loans to any employee, officer or director of such Loan Party nor has any Loan Party guaranteed the payment of any loan made to an employee, officer or director of such Loan Party by a third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 Capitalization and Subsidiaries. The capitalization of each Subsidiary as of the Closing Date is set forth on Schedule
5.14 annexed hereto. No Loan Party owns any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by the Loan Parties in a written notice provided after the
Closing Date (including any Compliance Certificate), is a true, correct and complete list of each Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">34</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 6. <U>INSURANCE; INDEMNIFICATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance covering Borrower and
each of its Subsidiaries, on an occurrence form, against risks customarily insured against in Borrower&#146;s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising
injury, and contractual liability per the terms of the indemnification agreement found in Section&nbsp;6.3. Borrower must maintain a minimum of $1,000,000 of commercial general liability insurance for each occurrence. Borrower has and agrees to
maintain a minimum of $2,000,000 of directors&#146; and officers&#146; insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, but subject to the post-Closing period set forth in
Section&nbsp;4.4, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral,
provided that such insurance may be subject to standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this Section&nbsp;6.1 or fails to pay any premium thereon or fails to pay any other amount which Borrower is
obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing
interest at the then highest rate applicable to the Secured Obligations, and secured by the Collateral. Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a
reasonable time thereafter. No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#146;s waiver of any Event of Default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 Certificates. Borrower shall deliver to Agent certificates of insurance that evidence compliance with its insurance
obligations in Section&nbsp;6.1 (subject to Section&nbsp;4.4) and the obligations contained in this Section&nbsp;6.2. Borrower&#146;s insurance certificate shall reflect Agent (shown as &#147;Hercules Capital, Inc., as Agent&#148;, and its
successors and/or assigns) as an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#146;s approval, and a lenders loss payable for property insurance and
additional insured for any future liability insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#146;s loss payable endorsements for all
risk property damage insurance. All certificates of insurance will provide for a minimum of thirty (30)&nbsp;days&#146; advance written notice to Agent of cancellation (other than cancellation for <FONT STYLE="white-space:nowrap">non-payment</FONT>
of premiums, for which ten (10)&nbsp;days&#146; advance written notice shall be sufficient) or any other change adverse to Agent&#146;s interests. Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any
of Agent&#146;s rights, all of which are reserved. Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies
and shall promptly deliver to Agent updated insurance certificates with respect to such policies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 Indemnity. Each Loan
Party agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, <FONT STYLE="white-space:nowrap">in-house</FONT> attorneys, representatives and shareholders (each, an &#147;Indemnified Person&#148;) harmless
from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable and documented
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">35</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees and disbursements and other costs of investigation or defense (including those
incurred upon any appeal) (collectively, &#147;Liabilities&#148;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the
other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition
or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person&#146;s gross negligence or willful misconduct. This Section&nbsp;6.3 shall not apply with respect to Taxes other than any
Taxes that represent losses, claims, damages, etc. arising from any <FONT STYLE="white-space:nowrap">non-Tax</FONT> claim. In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or
punitive damages (including any loss of profits, business or anticipated savings). This Section&nbsp;6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 7. <U>COVENANTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrower agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 Financial Reports. Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the
&#147;Financial Statements&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) within thirty (30)&nbsp;days after the end of each month (other than the third
month of any calendar quarter), a management report containing a balance sheet and related statement of income, all certified by a Responsible Officer to the effect that they have been prepared in accordance with GAAP, except (i)&nbsp;for the
absence of footnotes, (ii)&nbsp;that they are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> or <FONT STYLE="white-space:nowrap">quarter-end</FONT> adjustments, and (iii)&nbsp;they do not contain certain <FONT
STYLE="white-space:nowrap">non-cash</FONT> items or other related adjustments that are customarily included in quarterly and annual financial statements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) within forty-five (45)&nbsp;days after the end of each calendar quarter, unaudited interim and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> financial statements as of the end of such calendar quarter (prepared on a consolidated basis), including balance sheet and related statements of income and cash
flows accompanied by a report detailing any material litigation by or against Borrower in the form attached as Exhibit K, certified by a Responsible Officer to the effect that they have been prepared in accordance with GAAP, except (i)&nbsp;for the
absence of footnotes, and (ii)&nbsp;that they are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) within ninety (90)&nbsp;days after the end of each fiscal year, unqualified (other than as to going concern qualification)
audited financial statements as of the end of such year (prepared on a consolidated basis), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding
fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent (it being understood that PricewaterhouseCoopers LLP or any other firm of national standing is acceptable to Agent),
accompanied by (i)&nbsp;any management report from such accountants and (ii)&nbsp;a report detailing any material litigation by or against Borrower in the form attached as Schedule 7.1(b); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">36</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Borrower will furnish to Agent concurrently with the delivery of
financial statements pursuant to subsections (a), (b) and (c)&nbsp;of this Section&nbsp;7.1, a Compliance Certificate in the form of Exhibit E; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or
reports that Borrower has made available to holders of its preferred stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental
authority that may be substituted therefor, or any national securities exchange; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) financial and business projections within sixty (60)&nbsp;days following the end of Borrower&#146;s fiscal year, as well as
budgets, operating plans (which shall include T3M Net Product Revenue projections of such fiscal year) and other financial information reasonably requested by Agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) prompt (and in any event within three (3)&nbsp;Business Days) notice if Borrower or any Subsidiary has knowledge that
Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a)&nbsp;is convicted on, (b)&nbsp;pleads <I>nolo contendere </I>to, (c)&nbsp;is indicted on, or (d) is arraigned and held over on charges involving money
laundering or predicate crimes to money laundering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) insurance renewal statements, annually or otherwise promptly upon
renewal of insurance policies required to be maintained in accordance with Section&nbsp;6.1; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) promptly upon the
preparation of any proposed, definitive investment policy, or upon the preparation of any update to any existing investment policy, Borrower will furnish to Agent a copy of such investment policy or such update to any existing investment policy.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Borrower shall not (without the consent of Agent, such consent not to be unreasonably withheld or delayed), make any change in its
(a)&nbsp;accounting policies or reporting practices, except as required by GAAP or pursuant to applicable securities laws or regulations of the Securities and Exchange Commission or (b)&nbsp;fiscal years or fiscal quarters. The fiscal year of
Borrower shall end on December 31. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The executed Compliance Certificate and all Financial Statements or other information required to be
delivered pursuant to clauses (a), (b), (c) and (d)&nbsp;above may be sent via <FONT STYLE="white-space:nowrap">e-mail</FONT> to [***] with a copy to [***], [***] and [***], provided, that if <FONT STYLE="white-space:nowrap">e-mail</FONT> is not
available or sending such Financial Statements via <FONT STYLE="white-space:nowrap">e-mail</FONT> is not possible, they shall be faxed to Agent at: [***], attention Account Manager: Madrigal Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, documents required to be delivered under Sections 7.1(a), (b), (c) or (f)&nbsp;above (to the extent any such
documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower makes such documents or materials publicly available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">37</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 Management Rights. Borrower shall permit any representative that Agent
or the Lenders authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal
business hours; <U>provided</U>, however, that so long as no Event of Default has occurred and is continuing, such examinations shall be limited to no more often than once per fiscal year. In addition, any such representative shall have the right to
meet with management and officers of Borrower to discuss such books of account and records at reasonable times and upon reasonable notice. In addition, Agent or the Lenders shall be entitled at reasonable times and intervals, and upon reasonable
notice, to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower&#146;s business operations. The parties intend
that the rights granted Agent and the Lenders shall constitute &#147;management rights&#148; within the meaning of 29 C.F.R. <FONT STYLE="white-space:nowrap">Section&nbsp;2510.3-101(d)(3)(ii),</FONT> but that any advice, recommendations or
participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders, nor be deemed an exercise by Agent or the Lenders of, control over Borrower&#146;s management or policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 Further Assurances. Borrower shall, and shall cause each other Loan Party to, from time to time execute, deliver and file,
alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements, promissory notes or other documents to perfect, give the highest priority to Agent&#146;s Lien on the Collateral (subject to
Permitted Liens) or otherwise evidence Agent&#146;s rights herein, in each case, as requested by Agent. Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that
may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby or pursuant to applicable Loan Documents. In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on
behalf of Borrower and to file such financing statements (including an indication that the financing statement covers &#147;all assets or all personal property&#148; of Borrower in accordance with
<FONT STYLE="white-space:nowrap">Section&nbsp;9-504</FONT> of the UCC), without the signature of Borrower either in Agent&#146;s name or in the name of Agent as agent and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Borrower. Borrower shall, and shall cause each other Loan Party to, reasonably protect and defend its title to the Collateral and Agent&#146;s Lien
thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4
Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, and shall not permit any Subsidiary to do so, other than Permitted Indebtedness, or prepay any Indebtedness or take any
actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a)&nbsp;the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion,
(b)&nbsp;purchase money Indebtedness pursuant to its then applicable payment schedule, (c) prepayment (i)&nbsp;by any Loan Party or Subsidiary of intercompany Indebtedness owed to Borrower, or (ii)&nbsp;by any Subsidiary that is not a Loan Party of
intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Loan Party, (d)&nbsp;Indebtedness to trade creditors in the ordinary course of business, (e)&nbsp;refinancings or replacements of Indebtedness described in clause
(xv)&nbsp;of the defined term &#147;Permitted Indebtedness&#148;, (f) Indebtedness owed under corporate credit cards to the extent constituting Permitted Indebtedness, or (g)&nbsp;as otherwise permitted hereunder or approved in writing by Agent.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">38</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 Collateral. Borrower shall, and shall cause each other Loan Party to, at
all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower&#146;s or any Loan Party&#146;s business or in which Borrower or any Loan Party now or hereafter holds any interest free and clear from any
Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process affecting the Collateral, the Intellectual Property, such other property or assets, or any Liens thereon, provided however, that the
Collateral and such other property or assets may be subject to Permitted Liens. Without limiting the next sentence, Borrower shall not, and shall cause each other Loan Party not to, agree with any Person other than Agent or the Lenders not to
encumber its property. Borrower shall not, and shall cause each other Loan Party not to, enter into or suffer to exist or become effective any agreement that prohibits or limits the ability of Borrower or any Loan Party to create, incur, assume or
suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other than (a)&nbsp;this Agreement and the other
Loan Documents, (b)&nbsp;any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby), (c)
customary restrictions on the assignment of leases, licenses and other agreements, (d)&nbsp;any agreements governing accounts described in clauses (i)&nbsp;and (ii) of the definition of Excluded Accounts and the assets contained therein and
(e)&nbsp;any agreements governing Permitted Royalty Transactions so long as such prohibitions and limitations are limited solely to clause (xv)&nbsp;of the defined term &#147;Permitted Liens&#148;. Borrower and each Loan Party shall cause each of
their Subsidiaries to reasonably protect and defend such Subsidiary&#146;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower and each Loan Party shall cause each of their Subsidiaries at
all times to keep such Subsidiary&#146;s property and assets free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any judicial proceeding affecting such Subsidiary&#146;s assets to the
extent such judicial proceeding is reasonably likely to result in damages, expenses or liabilities in excess of [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6
Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 Distributions. Borrower shall not, nor shall it permit any Subsidiary to, (a)&nbsp;repurchase or redeem any class of
shares, stock or other Equity Interest other than (i)&nbsp;repurchases of stock of Borrower from former employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such
securities in an aggregate amount not to exceed $500,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or could exist after giving effect to the repurchases, or (ii)&nbsp;the conversion of any of its convertible
securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, including the delivery of the conversion consideration in connection therewith in the form of common stock of Madrigal and cash
in lieu of fractional shares; (b)&nbsp;declare or pay any cash dividend or make a cash distribution on any class of stock or other Equity Interest, except that a Subsidiary of Borrower may pay dividends or make distributions to Borrower or a
Subsidiary of Borrower; (c)&nbsp;except for Permitted Investments, lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate; or (d)&nbsp;waive,
release or forgive any Indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 Transfers. Except for Permitted Transfers, Borrower shall not, and shall not permit any Subsidiary to, voluntarily or
involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets (including Cash). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">39</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 Mergers and Consolidations. Borrower shall not (a)&nbsp;merge or
consolidate, nor permit any of its Subsidiaries to merge or consolidate, with or into any other business organization, other than mergers or consolidations of (i)&nbsp;a Subsidiary which is not a Loan Party into another Subsidiary or into a Loan
Party, or (ii)&nbsp;a Loan Party into another Loan Party (provided that Borrower shall be the surviving entity in any transaction involving Borrower) or (b)&nbsp;except for Permitted Investments, acquire, or permit any of its Subsidiaries to
acquire, in each case including for the avoidance of doubt through a merger, purchase, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangement or any similar transaction, all or substantially all of the capital stock or property of another
Person; provided however, that Borrower shall be permitted to enter into Permitted Acquisitions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 Taxes. Borrower
shall, and shall cause each of its Subsidiaries to, pay when due all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or such Subsidiary or the Collateral or upon Borrower&#146;s (or such
Subsidiary&#146;s) ownership, possession, use, operation or disposition thereof or upon Borrower&#146;s (or such Subsidiary&#146;s) rents, receipts or earnings arising therefrom. Borrower shall, and shall cause each of its Subsidiaries to,
accurately file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed. Notwithstanding the foregoing, Borrower and its Subsidiaries may
contest, in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 Certain Changes. Neither Borrower nor any Subsidiary shall change its jurisdiction of organization, organizational form or
legal name without twenty (20)&nbsp;days&#146; prior written notice to Agent. Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither Borrower nor any Domestic Subsidiary shall relocate its chief executive office or its
principal place of business unless: (i)&nbsp;it has provided prior written notice to Agent; and (ii)&nbsp;such relocation shall be within the continental United States of America. Neither Borrower nor any Subsidiary shall relocate any item of
Collateral (other than (w)&nbsp;transfers of Inventory within the supply chain and to and from clinical sites, in each case, in the ordinary course of business, (x)&nbsp;distribution and sales of Inventory in the ordinary course of business,
(y)&nbsp;relocations of purchased Fibroscan Equipment to and from clinical sites or other Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z)&nbsp;relocations of Collateral from a location described on Exhibit B to
another location described on Exhibit B) unless (i)&nbsp;it has provided prompt written notice to Agent, (ii)&nbsp;such relocation is within the continental United States of America and, (iii)&nbsp;if such relocation is to a third party bailee, it
has delivered a bailee agreement in form and substance reasonably acceptable to Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 Deposit Accounts. Neither
Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except (i)&nbsp;with respect to which Agent has an Account Control Agreement and (ii)&nbsp;any Excluded Accounts, provided that no Deposit
Accounts held by a Foreign Subsidiary or an Immaterial Subsidiary shall have balance in excess of $250,000, or $750,000 in the aggregate for all such Excluded Accounts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.13 Joinder of Subsidiaries. Borrower shall notify Agent of each Subsidiary formed or acquired subsequent to the Closing Date
and, within twenty (20)&nbsp;days of formation or acquisition, shall cause any such Subsidiary which is not a Foreign Subsidiary to execute and deliver to Agent a Joinder Agreement or, if requested by Agent, a Guaranty and appropriate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">40</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
collateral security documents to secure the obligations pursuant to such Guaranty; provided, however, that such joinder shall not be required (i)&nbsp;of any Immaterial Subsidiary, (ii)&nbsp;of
any Domestic Subsidiary which is not wholly-owned directly or indirectly by Borrower or one or more Domestic Subsidiaries, or (iii)&nbsp;if Agent determines (in its sole discretion) that the benefit from the entry into such Joinder Agreement is
outweighed by the undue burden and expense to Borrower. For the avoidance of doubt, Borrower may, at its option, cause any Foreign Subsidiary to execute and deliver to Agent a Joinder Agreement or, if requested by Agent in connection with
Borrower&#146;s election of such option, a Guaranty and appropriate collateral security documents to secure obligations pursuant to such Guaranty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.14 [RESERVED] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.15 Notification of Event of Default. Borrower shall notify Agent promptly (and in any event within two (2)&nbsp;Business
Days) after becoming aware of the occurrence of any Event of Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.16 Regulatory and Product Notices. Borrower shall
within three (3)&nbsp;Business Days after the receipt or occurrence thereof notify Agent of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) any written notice from a
governmental authority received by Borrower or its Subsidiaries alleging potential or actual violations of any Public Health Law by Borrower or its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any written notice from a governmental authority that the FDA (or international equivalent) is limiting, suspending or
revoking any Registration (including, but not limited to, by the issuance of a clinical hold); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any written notice from
a governmental authority that Borrower or its Subsidiaries has become subject to any Regulatory Action; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the exclusion
or debarment from any governmental healthcare program or debarment or disqualification by FDA (or international equivalent) of Borrower or its Subsidiaries or its or their authorized officers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any notice from a governmental authority that Borrower or any Subsidiary, or any of their licensees or sublicensees
(including licensees or sublicensees under any Material Agreement), is being investigated or is the subject of any allegation of potential or actual violations of any Federal Health Care Program Laws; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any written notice from a governmental authority that any product of Borrower or its Subsidiaries has been seized,
withdrawn, recalled, detained, or subject to a suspension of manufacturing, or the commencement of any proceedings in the United States of America or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of
any Product are pending or threatened in writing against Borrower or its Subsidiaries; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) narrowing or limiting the
scope of marketing authorization or the labeling of the Products of Borrower and its Subsidiaries under any such Registration, it being understood that the Approval Milestone is contingent on a label claim that is generally consistent with or
generally as favorable as what Borrower sought for one dose of Resmetirom in its New Drug Application (as determined by Agent in its reasonable discretion). except, in each case of (a)&nbsp;through (g) above, where such action would not reasonably
be expected to have, either individually or in the aggregate, Material Regulatory Liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">41</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.17 Use of Proceeds. Borrower agrees that the proceeds of the Loans shall
be used solely to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes. The proceeds of the Loans will not be used in violation of Anti-Corruption Laws or applicable Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.18 Material Agreement. Borrower shall not, without the consent of Agent, terminate, or amend in a manner materially adverse
to the Lenders, the Roche Agreement. Borrower shall give prompt written notice to Agent of entering into a Material Agreement or terminating or amending in a manner materially adverse to the Lenders a Material Agreement. Notwithstanding the
foregoing, any notices required to be delivered under this Section&nbsp;7.18 (to the extent any such documents are included in materials otherwise filed with the Securities and Exchange Commission) may be delivered electronically and if so
delivered, shall be deemed to have been delivered on the date on which Borrower makes such documents or materials publicly available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.19 Compliance with Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrower shall maintain, and shall cause each of its Subsidiaries to maintain, compliance in all material respects with all
applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required governmental
authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#146;s business. Borrower shall not become an &#147;investment company&#148; or a company controlled by an
&#147;investment company&#148;, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation X, T and U of the Federal Reserve
Board of Governors). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries
permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its
Subsidiaries, permit any Affiliate to, directly or indirectly, (i)&nbsp;conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods
or services to or for the benefit of any Blocked Person, (ii)&nbsp;deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No.&nbsp;13224 or any similar executive order
or other Anti-Terrorism Law, or (iii)&nbsp;engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order
No.&nbsp;13224 or other Anti-Terrorism Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Borrower has implemented and shall maintain in effect policies and
procedures designed to ensure compliance by Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers
and employees and to the knowledge of Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">42</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Neither Borrower, nor any of its Subsidiaries nor any of their
respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or any of its Subsidiaries that shall act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned
Person. No Loan, use of proceeds or other transaction contemplated by this Agreement shall violate Anti-Corruption Laws or applicable Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.20 Financial Covenants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Minimum Cash. Beginning on January&nbsp;1, 2023, Borrower shall at all times maintain Unrestricted Cash in an amount not
less than $35,000,000; provided that, upon (i)&nbsp;achievement of the Approval Milestone and (ii)&nbsp;the effectiveness of the covenant set forth in Section&nbsp;7.20(b), Borrower shall at all times maintain Unrestricted Cash in an amount not less
than the greater of (A) $25,000,000 and (B) 20% of the aggregate outstanding principal amount of the Term Loans (it being understood that in no event shall the dollar amount in this clause (B)&nbsp;be greater than $35,000,000). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Performance Covenant. Beginning on the date upon which financial statements pursuant to Section&nbsp;7.1(a) are required to
be delivered for the period ending September&nbsp;30, 2024, tested on a monthly basis from and after such date, Borrower&#146;s T3M Net Product Revenue shall be [***]. Notwithstanding the foregoing, this Section&nbsp;7.20(b) shall be waived for any
particular month to the extent that Borrower maintains either (x)&nbsp;a Market Capitalization (measured on an average basis for the five (5)&nbsp;market trading days prior to the end of such month) of at least $1,200,000,000 or
(y)&nbsp;Unrestricted Cash in an amount not less than 75% of the aggregate outstanding principal amount of the Term Loans at all times during the maintenance period beginning on the first day of such month through and including the date that is five
(5)&nbsp;Business Days prior to the date on which Borrower has delivered the financial statements and the Compliance Certificate for such month in accordance with Sections 7.1(a), (b) and (d)&nbsp;to Agent. For the avoidance of doubt, if Borrower
fails to so maintain either the Market Capitalization or Unrestricted Cash in the amounts required pursuant to the preceding sentence, then Borrower shall be required to comply with the minimum net product revenue requirements of this
Section&nbsp;7.20(b) for such month). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.21 Intellectual Property. Borrower shall, and shall cause each other Loan Party
to, (i) reasonably protect, defend and maintain the validity and enforceability of the Company IP material to Borrowers&#146; business; (ii)&nbsp;promptly upon a Responsible Officer having actual knowledge thereof, advise Agent in writing of
material infringements of Company IP; and (iii)&nbsp;not allow any Company IP material to Borrowers&#146; business to be abandoned, forfeited or dedicated to the public (other than Permitted Transfers) without Agent&#146;s written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">43</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.22 Transactions with Affiliates. Borrower shall not, and shall not permit
any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than those
that might be obtained in an arm&#146;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary, other than (i)&nbsp;consulting payments (excluding board and committee fees and equity compensation as publicly
disclosed or approved by the Board) to members of Borrower&#146;s Board in an amount not to exceed $60,000 in any fiscal year and (ii)&nbsp;transactions between Borrower and its Subsidiaries. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 8. <U>RIGHT TO INVEST</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 Borrower shall give timely prior written notice to Agent of each Subsequent Financing and shall use commercially
reasonable efforts to permit the Lenders or their Affiliates, or the assignees or nominees of the Lenders or their Affiliates, to participate in such Subsequent Financings in an aggregate amount of up to Five Million Dollars ($5,000,000) (with
respect to all such Subsequent Financings) on substantially the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing (subject to compliance with applicable securities laws and regulations). This
Section&nbsp;8.1, and all rights and obligations granted hereunder, shall automatically terminate upon the earliest to occur of (a)&nbsp;termination of the security interest granted pursuant to Section&nbsp;3.1 of this Agreement, (b)&nbsp;such time
that the Lenders or their Affiliates, or the assignees or nominees of the Lenders or their Affiliates, have purchased Five Million Dollars ($5,000,000) of Madrigal&#146;s Equity Interests in the aggregate pursuant to the preceding sentence in prior
Subsequent Financings, and (c)&nbsp;Borrower has previously extended two (2) such offers to permit the Lenders or their Affiliates, or the assignees or nominees of the Lenders or their Affiliates, to participate in Subsequent Financings. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 9. <U>EVENTS OF DEFAULT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any one or more of the following events shall be an event of default (each, an &#147;Event of Default&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 Payments. A Loan Party fails to pay any amount due under this Agreement or any of the other Loan Documents on the
applicable due date; provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#146;s bank if Borrower had the funds to make
the payment when due and makes the payment within three (3)&nbsp;Business Days following Borrower&#146;s knowledge of such failure to pay; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 Covenants. A Loan Party breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement,
or any of the other Loan Documents or any other agreement among any Loan Party, Agent and the Lenders, and (a)&nbsp;with respect to a default under any covenant under this Agreement (other than under Sections 6 and 7), any other Loan Document, or
any other agreement among Borrower, Agent and the Lenders, such default continues for more than fifteen (15)&nbsp;days after the earlier of the date on which (i)&nbsp;Agent or the Lenders has given notice of such default to Borrower and
(ii)&nbsp;Borrower has actual knowledge of such default or (b)&nbsp;with respect to a default under any of Sections 6 and 7, the occurrence of such default; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 Material Adverse Effect. A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect;
provided that, solely for purposes of this Section&nbsp;9.3, the failure to achieve the <FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>Clinical</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">New Drug Application</U></FONT><FONT STYLE="font-family:Times New Roman"> Milestone or the Approval Milestone shall not in
and of itself constitute a Material Adverse Effect under this Section&nbsp;9.3; or </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">44</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 Representations. Any representation or warranty made by any Loan Party
in any Loan Document shall have been false or misleading in any material respect when made or when deemed made; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5
Insolvency. (a)&nbsp;Any Loan Party (i)&nbsp;shall make an assignment for the benefit of creditors; or (ii)&nbsp;shall be unable to pay its debts as they become due or be unable to pay or perform under the Loan Documents, or shall become insolvent;
or (iii)&nbsp;shall file a voluntary petition in bankruptcy; or (iv)&nbsp;shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under
any present or future statute, law or regulation pertinent to such circumstances; or (v)&nbsp;shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of any Loan Party or of all or any substantial part (i.e.,
<FONT STYLE="white-space:nowrap">33-1/3%</FONT> or more) of the assets or property of any Loan Party; or (vi)&nbsp;shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees;
or (b)&nbsp;any Loan Party or its directors or a majority of the holders of its Equity Interests shall take any action initiating any of the foregoing actions described in clauses (a)(i) through (a)(vi); or (c)&nbsp;either (i) forty-five consecutive
(45)&nbsp;days shall have expired after the commencement of an involuntary action against any Loan Party seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute,
law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of any Loan Party being stayed; or (ii)&nbsp;a stay of any such order or proceedings shall thereafter be set
aside and the action setting it aside shall not be timely appealed; or (iii)&nbsp;any Loan Party shall file any answer admitting or not contesting the material allegations of a petition filed against such Loan Party in any such proceedings; or
(iv)&nbsp;the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v)&nbsp;forty-five consecutive (45)&nbsp;days shall have expired after the appointment, without the
consent or acquiescence of any Loan Party, of any trustee, receiver or liquidator of such Loan Party or of all or any substantial part of the properties of such Loan Party without such appointment being vacated; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 Attachments; Judgments. Any portion of any Loan Party&#146;s assets is attached or seized, or a levy is filed against any
such assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least
$[***], or any Loan Party is enjoined or in any way prevented by court order from conducting any part of its business; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 Other Obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The occurrence of any default in the payment of any Indebtedness (other than amounts owing under the Loan Documents) under
any agreement or obligation of any Loan Party involving Indebtedness in excess of $[***]; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) There is, under any
agreement to which any Loan Party is a party with a third party or parties, any default resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the
aggregate in excess of $[***]; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">45</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 The occurrence of any default under (i)&nbsp;the Roche Agreement that
permits the counterparty thereto to terminate the Roche Agreement or (ii)&nbsp;any other Material Agreement that permits the counterparty thereto to terminate such Material Agreement or accelerate payments owed thereunder in excess of the amount set
forth on Schedule 9.8. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 10. <U>REMEDIES</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 General. Upon the occurrence and during the continuation of any one or more Events of Default, Agent may, and at the
direction of the Required Lenders shall, accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence and
continuation of an Event of Default of the type described in Section&nbsp;9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and
payable, in each case without any further notice or act). Borrower hereby irrevocably appoints Agent as its lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to: exercisable following the
occurrence and during the continuation of an Event of Default, (i)&nbsp;sign Borrower&#146;s name on any invoice or bill of lading for any account or drafts against account debtors or endorse Borrower&#146;s name on any checks, payment instruments,
or other forms of payment or security; (ii)&nbsp;demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or
defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent&#146;s or Borrower&#146;s name, as Agent may elect); (iii) make, settle, and adjust all claims under
Borrower&#146;s insurance policies; (iv)&nbsp;pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the
same; (v)&nbsp;transfer the Collateral into the name of Agent or a third party as the UCC permits; (vi) receive, open and dispose of mail addressed to Borrower and (vii)&nbsp;notify all account debtors to pay Agent directly. Borrower hereby appoints
Agent as its lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to sign Borrower&#146;s name on any documents necessary to perfect or continue the perfection of Agent&#146;s security interest in
the Collateral regardless of whether an Event of Default has occurred until all Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement)
have been satisfied in full and the Loan Documents (other than the Warrants) have been terminated. Agent&#146;s foregoing appointment as Borrower&#146;s attorney in fact, and all of Agent&#146;s rights and powers, coupled with an interest, are
irrevocable until all Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and the Loan Documents
(other than the Warrants) have been terminated. Upon the occurrence and during the continuation of an Event of Default, Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the Collateral
under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the
right to occupy, utilize, process and commingle the Collateral. All Agent&#146;s rights and remedies shall be cumulative and not exclusive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 Collection; Foreclosure. Upon the occurrence and during the continuance
of any Event of Default, Agent may, and at the direction of the Required Lenders shall, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then
condition or following any commercially reasonable preparation or processing, in such order as Agent may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or
private sale may occur upon ten (10)&nbsp;calendar days&#146; prior written notice to Borrower. Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to
Agent and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">First, to Agent and the Lenders in an amount sufficient to pay in full Agent&#146;s and the Lenders&#146; reasonable costs and
professionals&#146; and advisors&#146; fees and expenses as described in Section&nbsp;11.12; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Second, to the Lenders, ratably, in an amount
equal to the then unpaid amount of the Secured Obligations (including principal and interest, including, for the avoidance of doubt, any interest required to be paid pursuant to Section&nbsp;2.4), in such order and priority as Agent may choose in
its sole discretion; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Finally, after the full and final payment in Cash of all of the Secured Obligations (other than inchoate
obligations), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a
secured party under the UCC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 No Waiver. Agent shall be under no obligation to marshal any of the Collateral for the
benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 Cumulative Remedies. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and
remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers
and remedies of Agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 11. <U>MISCELLANEOUS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the
remainder of such provision or the remaining provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 Notice. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to
the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i)&nbsp;the day of transmission by electronic mail or hand delivery or delivery by an overnight
express service or overnight mail delivery service; or (ii)&nbsp;the third calendar day after deposit in the United States of America mails, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with proper first class postage prepaid, in each case addressed to the party to be notified
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Agent: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Legal
Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer and Bryan Jadot </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email:
[***] Telephone: [***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Lenders: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES CAPITAL, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES PRIVATE CREDIT FUND 1 L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Chief Legal Officer and Bryan Jadot </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">400 Hamilton Avenue, Suite 310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94301 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email:
[***]Telephone: [***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Borrower: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Madrigal Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Brian Lynch, General </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Counsel Four Tower Bridge </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">200
Barr Harbor Drive, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">West Conshohocken, PA 19428 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">email: [***] Telephone: [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">or to such other address as each party may designate for itself by like notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 Entire Agreement; Amendments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or confidentiality agreements, letters, negotiations or other
documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#146;s revised proposal letter dated March&nbsp;29, 2022 and the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT>
Agreement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither this Agreement, any other Loan Document (other than the Warrants, which are subject to the
amendment provisions set forth therein), nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section&nbsp;11.3(b). The Required Lenders and the Loan Parties party to the relevant
Loan Document may, or, with the written consent of the Required Lenders, Agent and the Loan Parties party to the relevant Loan Document may, from time to time, (i)&nbsp;enter into written amendments, supplements or modifications hereto and to the
other Loan Documents for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">48</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Loan Parties hereunder or thereunder or
(ii)&nbsp;waive, on such terms and conditions as the Required Lenders or Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its
consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (A)&nbsp;forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any
amortization payment in respect of any Term Loan, reduce the stated rate of any interest or fee payable hereunder or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby;
(B)&nbsp;eliminate or reduce the voting rights of any Lender under this Section&nbsp;11.3(b) without the written consent of such Lender; (C)&nbsp;reduce any percentage specified in the defined term &#147;Required Lenders&#148;, consent to the
assignment or transfer by the Loan Parties of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Loan Party from its obligations under the Loan
Documents, in each case without the written consent of all Lenders; or (D)&nbsp;amend, modify or waive any provision of Section&nbsp;11.18 or Addendum 3 without the written consent of Agent. Any such waiver and any such amendment, supplement or
modification shall apply equally to each Lender and shall be binding upon the applicable Loan Parties, the Lenders, Agent and all future holders of the Loans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In
the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 No Waiver. The powers conferred upon Agent and the Lenders by this
Agreement are solely to protect their rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to exercise any such powers. No omission or delay by Agent or the
Lenders at any time to enforce any right or remedy reserved to them, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or
the Lenders is entitled, nor shall it in any way affect the right of Agent or the Lenders to enforce such provisions thereafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 Survival. All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in
any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution and delivery of this Agreement. Sections 6.3, 11.9, 11.10, 11.11, 11.15 and 11.18 shall survive the termination of
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to
the benefit of and be binding on Borrower and its permitted assigns (if any). No Loan Party shall assign its obligations under this Agreement or any of the other Loan Documents without Agent&#146;s express prior written consent, and any such
attempted assignment shall be void and of no effect. Agent and the Lenders may assign, transfer, or endorse their rights and obligations hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights and
obligations shall inure to the benefit of, and become obligations of, Agent&#146;s and the Lenders&#146; successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign,
transfer or endorse its rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
hereunder or under the Loan Documents to any party that is a direct competitor of Borrower (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an
Affiliate of any Lender or Agent shall be allowed. Notwithstanding the foregoing, (x)&nbsp;in connection with any assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein
shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party and (y)&nbsp;in connection with a Lender&#146;s own financing or securitization transactions,
the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such
securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge
or assignment under this clause (y)&nbsp;shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment
agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require.
Agent, acting solely for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrower, shall maintain at one of its offices in the United States of America a register for the recordation of the names and addresses of the
Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#147;Register&#148;). The entries in the Register shall be conclusive absent
manifest error, and Borrower, Agent and the Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for
inspection by Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8
Participations. Each Lender that sells a participation shall, acting solely for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrower, maintain a register on which it enters the name and address of each
participant and the principal amounts (and stated interest) of each participant&#146;s interest in the Loans or other obligations under the Loan Documents (the &#147;Participant Register&#148;); provided that no Lender shall have any obligation to
disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#146;s interest in any commitments, loans, its other obligations under any Loan Document) to any Person
except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> of the United States
Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes
of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register. Borrower agrees that each participant shall be entitled
to the benefits of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements under Section&nbsp;7 of Addendum 1 attached hereto (it being understood that the documentation required
under Section&nbsp;7 of Addendum 1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section&nbsp;11.7; provided that such participant
shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater
payment results from a change in law that occurs after the participant acquired the applicable participation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 Governing Law. This Agreement and the other Loan Documents have been
negotiated and delivered to Agent and the Lenders in the State of California, and shall have been accepted by Agent and the Lenders in the State of California. Payment to Agent and the Lenders by Borrower of the Secured Obligations is due in the
State of California. This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws
of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the
reference requirement of Section&nbsp;11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California. By execution and
delivery of this Agreement, each party hereto generally and unconditionally: (a)&nbsp;consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b)&nbsp;waives any objection as to jurisdiction or venue in Santa Clara
County, State of California; (c)&nbsp;agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d)&nbsp;irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or
the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section&nbsp;11.2, and shall be
deemed effective and received as set forth in Section&nbsp;11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other
jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11 Mutual Waiver of Jury Trial / Judicial Reference. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an
experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER, AGENT AND
THE LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#147;CLAIMS&#148;) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS
OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and the Lenders; Claims that arise out of
or are in any way connected to the relationship among Borrower, Agent and the Lenders; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, or any
other Loan Document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the waiver of jury trial set forth in Section&nbsp;11.11(a) is ineffective or unenforceable,
the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section&nbsp;638, before a mutually acceptable referee or, if the parties cannot agree, a referee
selected by the Presiding Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in
Section&nbsp;11.10, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">51</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12 Professional Fees. Each Loan Party promises to pay Agent&#146;s and
the Lenders&#146; fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable and documented attorneys&#146; fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower
promises to pay any and all reasonable attorneys&#146; and other professionals&#146; fees and expenses incurred by Agent and the Lenders after the Closing Date in connection with or related to: (a)&nbsp;the Loan; (b)&nbsp;the administration,
collection, or enforcement of the Loan; (c)&nbsp;the amendment or modification of the Loan Documents; (d)&nbsp;any waiver, consent, release, or termination under the Loan Documents; (e)&nbsp;the protection, preservation, audit, field exam, sale,
lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f)&nbsp;any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the
Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including
representing Agent or the Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#146;s estate, and any appeal or review thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13 Confidentiality. Agent and the Lenders acknowledge that certain items of Collateral and information provided to Agent and
the Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (i)&nbsp;is marked as confidential by Borrower at the time of disclosure, or (ii)&nbsp;should reasonably be understood to
be confidential (the &#147;Confidential Information&#148;). Accordingly, Agent and the Lenders agree that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Agent&#146;s security interest in the
Collateral shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and the Lenders may disclose any such information: (a)&nbsp;to its
Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors if Agent or the Lenders in their reasonable discretion determine that
any such party should have access to such information in connection with or associated with the performance Agent or the Lenders&#146; responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such
Confidential Information either (i)&nbsp;agrees to be bound by the confidentiality provisions of this paragraph or (ii)&nbsp;is otherwise subject to confidentiality restrictions as protective as the terms hereof and that reasonably protect against
the disclosure and use of Confidential Information pursuant to similar terms; (b)&nbsp;if such information is generally available to the public or to the extent such information becomes publicly available other than as a result of a breach of this
Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a source other than Borrower and not in violation of any confidentiality obligations
known to Agent or such Lender; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or the Lenders and any rating agency; (d) if required or
appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#146;s or the Lenders&#146; counsel; (e)&nbsp;to comply with any legal requirement or law applicable to
Agent or the Lenders or demanded by any governmental authority; (f)&nbsp;to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any
Loan Document, including Agent&#146;s sale, lease, or other disposition of Collateral after default, or any action or proceeding relating to any Loan Document; (g)&nbsp;to any participant or assignee of Agent or the Lenders or any prospective
participant or assignee; provided, that such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">52</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
participant or assignee or prospective participant or assignee is subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (h)&nbsp;to
any investor or potential investor (and each of their respective Affiliates or clients) in Agent or the Lenders (or each of their respective Affiliates); provided that such investor, potential investor, Affiliate or client is subject to
confidentiality obligations with respect to the Confidential Information as is consistent with clause (a)&nbsp;(ii) above); (i) otherwise to the extent consisting of general portfolio information that does not identify Borrower; or
(j)&nbsp;otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan
Documents. Agent&#146;s and the Lenders&#146; obligations under this Section&nbsp;11.13 shall supersede all of their respective obligations under the <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14 Assignment of Rights. Borrower acknowledges and understands that Agent or the Lenders may, subject to Section&nbsp;11.7,
sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an &#147;Assignee&#148;). After such assignment the term &#147;Agent&#148; or &#147;Lender&#148; as used in the Loan Documents shall mean and
include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and the
Lenders shall retain all rights, powers and remedies hereby given. No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder. The Lenders agree that in the event of any transfer by it of any promissory
notes, it will endorse thereon a notation as to the portion of the principal of such promissory notes, which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15 Revival of Secured Obligations; Termination. Other than as set forth in Section&nbsp;11.6, this Agreement and the other
Loan Documents shall terminate on the payment in full in cash of the Secured Obligations (other than any obligations that expressly survive termination). Notwithstanding the preceding sentence, this Agreement and the Loan Documents shall remain in
full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is
appointed for all or any significant part of Borrower&#146;s assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders. The Loan Documents and the Secured Obligations and Collateral security shall continue to be
effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations (other than obligations that expressly survive termination) or any transfer of Collateral to Agent, or any part
thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders or by any obligee of the Secured Obligations, whether as a &#147;voidable preference,&#148;
&#147;fraudulent conveyance,&#148; or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned,
or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or the Lenders
in Cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16 Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in
any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">53</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17 No Third Party Beneficiaries. No provisions of the Loan Documents are
intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, the Lenders and Borrower unless specifically provided otherwise herein, and, except as
otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, the Lenders and the Loan Parties which are a party thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18 Agency. Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto. Borrower
acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19 Publicity. None of the
parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#146; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a)&nbsp;the other party&#146;s name
(including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties&#146; web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client
lists, public relations materials or on its web site (together, the &#147;Publicity Materials&#148;); (b) the names of officers of such other parties in the Publicity Materials; and (c)&nbsp;such other parties&#146; name, trademarks, servicemarks in
any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i)&nbsp;to the extent necessary to comply with the requests of any regulators, legal requirements
or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii)&nbsp;to comply with
Section&nbsp;11.13. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.20 Multiple Borrowers. Each Borrower hereby agrees to the terms and conditions set forth on
Addendum 4 attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.21 Electronic Execution of Certain Other Documents. The words &#147;execution,&#148;
&#147;execute,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments,
assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of records in electronic
form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law,
including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(SIGNATURES TO FOLLOW) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">Table of Annexes, Addenda, Exhibits and Schedules</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Addendum&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Taxes; Increased Costs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Addendum 2:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Reserved]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Addendum 3:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Agent and Lender Terms</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Addendum 4:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Multiple Borrower Terms</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit A:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Advance Request</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attachment to Advance Request</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit B:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name, Locations, and Other Information</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit C:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Patents, Trademarks, Copyrights and Licenses</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit D:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Deposit Accounts and Investment Accounts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit E:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Compliance Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit F:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joinder Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit G:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Reserved]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit H:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ACH Debit Authorization Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit I:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Reserved]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Exhibit&nbsp;J-1:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Exhibit&nbsp;J-2:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Exhibit&nbsp;J-3:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Exhibit&nbsp;J-4:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Commitments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Subsidiaries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Indebtedness</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1B</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Investments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1C</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Existing Permitted Liens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 1D</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Specified Percentage</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 4.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Post-Closing Deliveries</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consents, Etc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 5.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tax Matters</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 5.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property Claims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(a)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Current Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(d)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Matters Relating to Current Material Agreements</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(f)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Enforceability, Entitlement and Exploitation of Current Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(i)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Claims of Infringement on Third Party IP by Current Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(j)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Infringement on Third Party IP by Current Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(k)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Obligations Relating to Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(l)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Party Infringements of Company IP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;5.10(o)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 5.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Products</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 5.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Capitalization</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule&nbsp;7.20(b)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Performance Covenant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Schedule 9.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cross-Default</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Annex&nbsp;D-1,&nbsp;D-2,</FONT></FONT><BR>and <FONT STYLE="white-space:nowrap">D-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 1 Warrants</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Annex&nbsp;E-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 2a Warrants</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Annex F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 2a Subsequent Advance Warrants</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Annex G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 2b Warrants</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Annex H</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 3 Warrants</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Annex I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tranche 4 Warrants</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mdgl-20230203.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/10/2023 2:26:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:mdgl="http://www.madrigalpharma.com/20230203"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.madrigalpharma.com/20230203"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdgl-20230203_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdgl-20230203_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mdgl-20230203_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/10/2023 2:26:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mdgl-20230203_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/10/2023 2:26:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mdgl-20230203.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139697843973072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001157601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MADRIGAL PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3508648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Four Tower Bridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">200 Barr Harbor Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">West Conshohocken<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">824-2827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 Par Value Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDGL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d457771d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdgl-20230203.xsd" xlink:type="simple"/>
    <context id="duration_2023-02-03_to_2023-02-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157601</identifier>
        </entity>
        <period>
            <startDate>2023-02-03</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-02-03_to_2023-02-03">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-02-03_to_2023-02-03"
      id="Hidden_dei_EntityCentralIndexKey">0001157601</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-02-03_to_2023-02-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-02-03_to_2023-02-03">2023-02-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-02-03_to_2023-02-03">MADRIGAL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-02-03_to_2023-02-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-02-03_to_2023-02-03">001-33277</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-02-03_to_2023-02-03">04-3508648</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-02-03_to_2023-02-03">Four Tower Bridge</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-02-03_to_2023-02-03">200 Barr Harbor Drive</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-02-03_to_2023-02-03">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-02-03_to_2023-02-03">West Conshohocken</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-02-03_to_2023-02-03">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-02-03_to_2023-02-03">19428</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-02-03_to_2023-02-03">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-02-03_to_2023-02-03">824-2827</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-02-03_to_2023-02-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-02-03_to_2023-02-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-02-03_to_2023-02-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-02-03_to_2023-02-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-02-03_to_2023-02-03">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="duration_2023-02-03_to_2023-02-03">Common Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-02-03_to_2023-02-03">MDGL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-02-03_to_2023-02-03">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "&(258'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  AB$E6@YI2M.T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TU!,'1[6?&D(+B@> O)[&ZP^4,RTN[;V\;=+J(/X#$SOWSS
M#4RGH]0AX7,*$1-9S#>3&WR6.F[8D2A*@*R/Z%2NYX2?F_N0G*+YF0X0E?Y0
M!P3!^2TX)&44*5B 55R)K.^,ECJAHI#.>*-7?/Q,0X$9#3B@0T\9FKH!UB\3
MXVD:.K@"%AAA<OF[@&8EENJ?V-(!=DY.V:ZI<1SKL2VY>8<&WIX>7\JZE?69
ME-<X_\I6TBGBAETFO[;;^]T#ZP47;<5%Q>]V0DC>2"[>%]<??E=A%XS=VW]L
M?!'L._AU%_T74$L#!!0    ( "&(25:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$3;# ?*));5DN,ZC/WF>W?D/9'[O/S_ZX]MOR]G8?UB<D=G3^ (![9>@_5-
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  AB$E6'#AEZC\!   \ @
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M>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ (8A)5B0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  AB$E6@YI2M.T    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  A
MB$E6F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "&(2586FX&DD@0  /(1   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  A
MB$E6GZ ;\+$"  #B#   #0              @ '4#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( "&(25:7BKL<P    !,"   +              "  ; /
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "&(258<.&7J/P$  #P"   /
M          "  9D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  AB$E6
M)!Z;HJT   #X 0  &@              @ $%$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  AB$E699!YDAD!  #/ P  $P
M        @ 'J$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   T%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d457771d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d457771d8k.htm">d457771d8k.htm</File>
    <File>d457771dex101.htm</File>
    <File>d457771dex41.htm</File>
    <File>mdgl-20230203.xsd</File>
    <File>mdgl-20230203_lab.xml</File>
    <File>mdgl-20230203_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d457771d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d457771d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdgl-20230203_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdgl-20230203_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mdgl-20230203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mdgl",
   "nsuri": "http://www.madrigalpharma.com/20230203",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d457771d8k.htm",
      "contextRef": "duration_2023-02-03_to_2023-02-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d457771d8k.htm",
      "contextRef": "duration_2023-02-03_to_2023-02-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.madrigalpharma.com//20230203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-030281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-030281-xbrl.zip
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MGNH\FT68NB\6.]7V=F-OI[.W AJ?0MKW'DG8[VOW'R4.KY!^P(#%AS@A8']
MF"!MA\*9M9R2YA, !WZ(D]9EF\JVOHQ8O"R9^OYTZDCY&JB"FH^=^[7_8FJ<
MUBYK@QH[F<Y<?RZ"%R=)5J%FB4.J#_Y!%_*'=4D)Q(?YI-N-1_8E.WNOW9<T
MHO>RD>42?Z!GVX&04O\Y@]BNN;8O\,F/ G;EWX !^Q@X]KC %WWI^'IM++36
MQD*KT6 ?>1"PGWD  L*. ^<ZAXFM\KQ9&23MM2$91. 6,H#G071HOAP=^O#Q
M:P <Y:V]]E\Q6=GW/3GQ)[[U77CWI0!Y9E^#"PBU'"H?>>S [4)XGIR[U]QS
M>!&A7L"VQQF!!P7 &H$7/BS9_5]G=I^X]ZBYWVF5AQ:O/*98@K^*QA!F^F8!
M<)<SXRX3M\**0M 9\!A\";'YN@/1"E"6(6DW<U0I<'?6W--X%%V3I)#_\=->
MJ[E[( $/KIA-?$\PC\+>+8QPW @=)L:!<8!+@6O*-00JIAZTNQ=+5UH[NYOY
MZJ1[!_1G/E#L E=SSQA^K]6IMO9:Y8F0,FO1>BY/_Q,H4? J5%H\()T*7[D2
M'R#>B*G=-.!T5-+,Y=)L4M7>LN-/LYV\3#8WCOH387VGC4\^ XL'*@Z3'$/_
ME@V%Z]\@V? E$G<Y^U.Y /$C&SDN"JHC06I#X=E ]M 'RD\C-^2>\"/ISID$
MKI>C.<V@._A#P)>*S?2&;&I_)8)Q@*6\N7DW@NC(O\%^:*T=#/IEMY27=NX=
MO#UJ<!9'9$F4E@\'%\+%U:SGHD'4T=?[@T*;4::K?@V<$$B&>93(TX&R?+!/
M-?1]=\B!7"$P%V)Y?[?3.<BKLV4&=#&GP;(490\V5PNE?>"F*GP  M((8;-4
M5<-E!$S2:6UK#EVH(\#R@4ISE_4_7;)6NU&#ANLD'=[8=B6V'8 6M@#AWO@+
MJ##08^Y_,<\FR("A%3;R#+M4GS<[O-IL&96>\':F,,9P]M+16IU&38VXF?):
MWH3@,87@(A"HM[%\G(K^T/(&7T>C]3W.OY P+.5,P%K52J'-</PRC;^" -G5
M5F6X^;@BI,9\$Z)G$J)3*2,1O(G2"XM26U0[%>MQ14F/N;(H/7KX=>K9B!.(
MN.80'F,H!B-^9S<307O,"_$/1%.P*, K3CIFX\"_"2>(VAG&1%PR6XP@IJ7:
M,^62-K99OJXU*6=MLPI*^^X!N:6FL4-5:S.L6L-(?D7ZM(;5V%58K99V^: &
M.J15;OP4F+6'E>6N(P<4J6\<G1030>E.K4'O3KV:$3[3 'W5_YE42QK,A_S[
MM&@'\1C=P?"8$"R4'B>7.)B ; A76"'(AN>3UHFDH%: :YV>P-.K#F4>U)$R
MQ"W-Y<YQ\AL'ID8Y\P ^>!.(:T="/Y X[EGH8'/+PNHQ;(SG6&T>V%(E)G#\
M67D5?(5O&I%)RTDMBW!-R:?%>$ID%?Y$<"?LZ(D8V 'D\N3+#[!U_E;-^8Q[
M,2MD4DM66V G7K2DY I/D:L#&!8H)Y=+^5Q[@O=%XDMC+. HO(?#@-6/!O,I
MM*O(9RN2>@:D/<4&R[D^;T!<)K29>/%Z*K"6()  46(MLE[T*RSV69)'5!9P
M#@XG2?;:6W48.P):!J%O?=]B[QHU/#[/+GC _L/=2+ +<.P'D\(R\!?:/2Y#
MA993):'KG^LY_GSVZI=HJ&W\KON<8,HYX2B=IG3D"ARC\][@N/<_BB/8%W!1
M1<C.SOJ%R'F*(L2_W+4#:E]4[X[^_6_ 'X4>L9CF%#,^2BFAH0#:@1)R;_A<
MHH*'P?&NF%AA@1/I!]V?]NF_ [.@V6TF=U770-R]\_RX=TG\_6^Y[-S'KY?'
M)Y?5_M>SL][%X*1K/KSN[%RS69B>8_01&"F?=\H7N)R&8JH#DAI>4I(KQDD/
M]E+)M+O,J5KE"1X]P@USGW%F=K'8,29U'*HVZHT#06FU&ELG5[7S!%4\6-T>
MR)#%MQ1A;'CF Y5ZGFTR/_,$8E;NJI2!1_B!&!]Z8PYWO4#VJ\<*SQUO 6+5
MI5_L@F[]LD1$;""WV*EGU;8 ]>:<%DN=J& 5#'&Q.JG5..B;; ]\:QYL,@CV
MZ;"GC(; [@[,N<7Z$"\[%DCGXC0*G+OG,O/H,?1$.,\6X'FLLH.4D4"H^B8A
MD@+QHQ\$6.8K#9!;C/0090>)P1;IEUY@_#1>(G3!]T1A7DCA+8:'OVW K\;X
M/F&\E1E8<8CIDEH7IB_Y5*5BAJHD) 8BL[">;E0X$JPRQHH4(.% YB'WODN:
M0AW<21(V>-^8$T8J)>T'C&XPPM3'C <AP1 (6'<%76ZDE5D#;06D8<=4 Z9%
MKH4[9W2!4Z *7F!1Z<53QQ1%L._/(K B%R;M\YD3<C=A0_ 4YJX:/L\:IEMJ
M,,G4!(H=]?%CCEHZI.PPMZ>@2# E1LH$E#2>6=;@H[;!'!8]Q,P745L!S"HP
MFHPPNM7#;<74&*>07[M#R-7=!X\MY5=I-HGYQP+-S@%D6-)4FNQ4EE]4MEQ:
M@3-$AL-:IQK#T7S0#< @[IV=0:X$FV$&4!4RV8ZT7%^JS'M*(N-BQGX$' $=
M]9T-0,?[5%3!^#%WIQ)U2,(X;Y@<?\)9%F5Q2T=KCP /E789S@3(4%A@]4,M
M +@!]/S\L,Q/( T(6N\20*Z9E2#9'?,&%T,.?>3R6 XT.5.;3L5:B-V0F/T1
MR;! C2D1"B<\I.=#TM#@04G@/X@.8Q#@/6?7'(P_.G<S$F@OFBK0;(&,2;L\
M>(V<C;3#T0 $%&%DV(JSJ8B.SV<!X$AUY3*^% 3Y%)?]*W==B$L _)#]VX\"
M9/R9&TG6JG6VWQ-G51QGD^W56MOO44" ZA,:1T:N'H?#-SNRTC5[B^P?+Q54
MC02M!)AI;C=P 3#>S(>5 ]I&"/[8N<9F8C0"?6J,3L;':#9JK?>X%IBKT,*_
M.J[K37%;(,-N)>R#<:?C13 Z+%3O'! 3HM$=0[.QONOE76N[46NH90-,+N)>
M*SSFPIB@LM,V*6- K[ 13IRR'<-(\62L]&(5&H"MG AZEG14"M#L@'!E,.-M
M $,MI5 A(/8]VPR$C186;2S:E6[1BGV.FY1/  @!=0-,KO=M<$,9Z_)@>D(O
MX]?<<4EB@+O>-;<7T(-^$WNWL_BXQGHRK<E!TF T2]A;&<$'!\ !=\*FA^#0
M 1!M9D&0BRX=R"0@V9_1:F!<D&$L6U?*(EY5UH$T7;^8YHD-/<520\]3VRR)
MPD]Y0WZI;XL-8\^/V0'PZ+OVXIISD*&83_BU0BP?.BXZ#( N.^ WQ'H0^"$P
M &\>L;G1 /W_CG!!%(\IP]-6+MX]AAJ(&01W0_2W:*4-/5Z%Q *@!)>))*)=
M)!"IZ1*&2<8W[LRF8M5PX@0)IR[R93OF2YQN-P=\(*8@,1(680K=\WXL8H&L
M0$KYH_.?,"^$$'^D5)]A0'^(XD@:5$OFI^.>JMF^AL6-:$-23D7H!/XTZ\J;
M-CE68[A9Z:I=4+H[BJQ'0CN-ZPY!O=\ ]WXN4R776B:(ZXWHY^:JP0KPU(Q-
MUM'PLKB=X6:K,A@I<B=FPKBM2I87)3EC$\CZ:-$<@0W#.4I(V(F77J@CE(K(
M\9%QFK2BP2J,(G*E/7*P>IB]$N090A!!FN:5F:6/,0MF3%.B/D@EO-O+80F8
MSX]"VN)&6J58>9E_M(6:#6P^[9&3T.8&1YV35P0ITU.F_(A+W^7-8M& S84!
M%]WD5T<K A<7" X[GY-Q-33+VJ\X$E%2DEHF49/37;]VA*'$E(<J@K>U4Q%C
MH4E8V#%\/^4@AZE*">.0)+H5;WICT<SW"HPFDKI8-V34U""&ZXN!"R^C2\SB
M<206E&+L7JIS)#SK@N8LK,*(\;*KO@?HTI4>ND\*6VJQ&+T'?C2>+.)F6_O"
MA:,MX@M3",8EAW&81J^I4UGP,609MHPSG@RD.'^W=" >&XL [P0$!";>"=Y5
M)BC2!WVIH]82KQ0G1M,6DGFCBA@'KVE/]'F24K%\F(BC/U_$E-K,IB/KDH62
MD2P:EJSERK"#>T=AA?(8\?R@3/%($?6V&%U?Z,XI.P3A$0ZS</Q3Y5=TM'8#
M>@;)/>..';,+1>C%'/TJ=0L@V@C/KSR@FJE+;"(/4H8V]?**2/@)%$'/OD9>
MD.Q;6L-" +G%E$KN9.*"/(6,'EON]E)1%T&ELGGQ43%C>#"83;%=Y($0H,-W
MHZ"&H C#JBBPR('?WM_:[FPSB5NQ1.#TQBT%X1X>] TL"'*0^):*O'9V:\T6
M1>74<U/%0J%&(BI>!"XCC[A6%<%@*7$"CI-?<LJ83KF="R(2I!K71E-$)LZI
MRL_RF.^->L]Z38FI5N*XD Q[=B;]EG4=$HJKT[^X@(1214; 4M231+V46Z9)
M2-Z:019H$.E;#N6M".V%GL8H(G[-Q:<LAW/Q9\1=3)HTWK.05J93+T9A*,\1
MUX!ZC1N9H5P0:C0UU19H2E4LB.YI"SRO=C-C)!,0^CXFM\<",UF.GUC)\FV/
M F;#D0M<L )D$(# E=FHF-@Y'4_%^$W+60O$K+VVF.G5QW)&<3'%#G2[[2@"
ME2H*05T(K5",LF"3QE:BF/)A"E:! :1E^8&=M79E5%AG,;K"L;QV)R=?;*%V
M9_DU_(]<^6SVL5L&>/P!E&0?GC:D_WLWX]>BP ^L*6-/-DZ+%*A,[9-I(25Y
M(Q7)*LW-Q]62E58JUWWMN]%4:.\&,X-:.I4@8MAB5$!&!YDL/SAO B<!:$-5
M^:12'LYT*FQ$@8M^/?(HNXG/!'LC1__@$1MAZH7H,M;N4E%@4N#P9HU\NV33
MJ:+!3-H9;^S$:)P+7.CFP4*H$&<_"BBUC& K$&LE.CT?:?3=+-H-LH7KP%1T
M8X A&D_GVR%"\DR(JE*$RN$G[RO)\V1)U%F11)TR$KW,3FDLU(FSQX=@PA3!
M8Q>6Z0VJ5%(PLZ4DR03C80@/<2MY$%_(4.QK9ME1QV(RFD[CH,/$J=SZ,W+T
M*0PZD*%D!TTQ<%"<2X@+'HHB0;-*%6SFE"*RE,IK4"6M(9 C,_K/^/ I];=@
MUY'14\K3K,"*0*:GB!*\3@/@4MZ%VA14K(40H(C@U@9FKPF=,GV_C5;-$&?K
M6 ?C]T"*S(MEJW\)#EOP#&]2_F"ZG@ K(Y#2@<AXBLW.UM[^_CK6:]4HS:2R
M=$ 8[YP6) 03?5:0&#S0Z>LL)P"!<FQ&RE!G@LP";7;M<!Q!IH) "A_Q4!*G
M/<^";8.7(24JT[%/FI:TQ4R7R2P(=RH;7YPYRGK,L0K"K4Y.V]BZ<,#V"0N
M*RI) +X8"I5L$J'",4H<&J7X?GT8VE%5.X%0>P5QZ8'AN'@ ^L6TG&:J*+90
MDF=2;R5KD:P'X=,MZYG"H,UX?5@OD-W*,&HED_J>8;6&WDO -%88<LP1,5UG
MA(?4;B?.T @]MEF[Q")%Y[V''O=^*RAM'( #U/YA"TK[6!2B32QGQR F8*P^
MQ5G5KZG+EBBEGWI@[EI:7A/T=32J?N0NZDR3RQM,L*"DAR(PCC<(.4MN>7N<
M^M4'ZSC'BW^N%/4)4IUA!;%VBP+A<MJJ2M>AY#7#8B541@]1L24=5J;1D9W>
M9/:)9;9=:[1^6)G]YJ4.W@ZXJSRA$_"6PGFJZN_'E* DM;:&S" YG]\'.A=.
M:.Y@,&ZM!VHRKM<5WIACE0?YN[35H/P$^]J1/CBYE"X!5W"V6,E6[B=E0Q=T
MHBGS:+8G\UX45DA1I$I[?'I;3F_#@I<ZG26)"7,<GIXDWA=TS)SH[E3X9J45
MG^E>N#:"MJ#Q/HCMQHX^^0U*/7+5J,?*,R+3\:;DGEC)[?_()UT2'X3N;E9Q
ML:IC5@[P*U!O%7LS!N<.9FZMR<R'^M#:>I<;/ ['*S[<W\M=;J 2W":9K<^6
M!>:0F:T(8;ZM<AM!^Z[;"/8[F=L(D@F?])AP7@H*[Q)(7[K1J37_N>Z1U=*#
MJX7G4CE3OU5N=[9W=W>;MKCM-&N3<(HW]9?$E&J")+!4W^GLC?JXN &H QG<
M!50?A_H5")S^,/6]L:DK4:>CU+?RLTOQ"*FZ-WQB3K$4M-0?1GC5*T!+,LY+
MCXJGB)FGI;FU%]\4H#KU&@^WH)+\L-%ZYM^@6)'?FHT78+)F0W/9/<YS;14<
MU2H["WCWR"4[U<.Y2G\@4RX]K5=ZS$Z_-PGK>YX$4WLZ>(0"/3C\FST;5GZ"
MZXVYB;D[3\K:M '/+G GB<[V<#KP@'56>+X1N**"M>.VK7<O=8[\U,/CZ>RW
MCY=G=*QJ,VV+C*=QUR]3KFOS_R(.;&L%__6?K\T9S2?%]$Z-WIR1\6UR.OFJ
M*F6'0GC,UR<&TO=?44BZTVA"^%-I-C8KSO5B&+0T8S:H_A*7O96XN3]F:4C[
MK33DH:4ACQ5GF=4,3C^?]ZZ^79X,GCV#DO[==ZK=%+3E%Q?4+N07BJZ(3/L:
MN@ T>ZN?';ES9O%(T@$0QYQPU-M'$C"A-OHPAAN*"7='QF6A+(5NH+(6>.()
MAP/"3?P %FG?E<2XOPUX@9 O<Z%=88B7Y?A.'*&M$_3=_2-P:XUXQT#;CP_:
M:XA'[UCWNE<D/??(B1O:7IK 6C6^7/+[4:LXT"BB=WG0]#[O0C]5VQ=RS0U-
M\>Q!=R'DTH<S?R26(W_QX[S[=#"O=Y_>DENKUC29=5G'WV4$ ?IWC9W-/6OR
M[+?I_074$O$(WN3VA%RR2*4W"JU-(;I>\0E)-!">XP?L/UBC=1$(J0XA8\;F
ML_ H(=3W(T\*MRC\_T$CL,X=$=AA?>C;<W@R":?NT?\#4$L#!!0    ( "&(
M259 6?-;X L! **N!0 1    9#0U-S<W,61E>#$P,2YH=&WLO6ESV]B5/_R>
M5?P.J)YD2DK!:FOQTG;'5;1$M361)94D=T^>J;P 25!"&P08@)#,KOI_]^>L
M=P%!2I9ED^UP:I)8)'AQEW//?G[GYW>7[X_?_/RNVSEXTV[]?'ET>=Q]T_W?
M)]M/M[9__I'_A,]_E >"G]^>'OPS>/O+_NGQZ?G??_CMW=%E]X<W0;L%#^W'
MV20NWOQ\</1K<''YS^/NWW^X30:3ZU<OMYXEV0]!E"97V=]_2./AY <:ZTP?
M&T7%59(]F>3C5T_'D]>!_-W+)Y-\Q!\-\VSRI$S^B%]MV[^'T2A)IZ\NDU%<
M!B?Q;7">CR)X4^?XZ)>3O_]0)%?7\*J?W[[I?KI.>LDDP&4%/__X]LW//Y[A
MNIIFL+WSB%/HTY[0'/:[YY>=HY-@__3D\.B@>W)YU#D.CDX.3\_?=RZ/3D_@
MW\'ENZ.+H/N_[X[>'EW^=]8KQZ_?=2Z"M]WN27#Z_NCRLGL0=$X.@O/NV7%G
M'_[X[>CR7?#?_[6]]^+U__WM;W_[%_[SY6OXP7[GPT4W.+H,8+R3T\L 7M$]
MQQ?"S]NMWTX_'!_ 4S"7]V==..6C7[O'_PS>=<[?'WZ 21T&9Q_>'A_MPV<'
M1Q?[QZ<7W8,MLV_-!_>HVZ8G=P0G%_>K29)GP:]Q4>+__OSCT3*.[_#H_.(R
MZ+SOGAS ?R[OV(W')&-G$I>G>!F7\.+CT\X)D=Y%=__#^='E/X/.+^?=KK<3
MGWL@D_C3Y$F2#> MK_;^^GE3?'-YG90!'LO/%^\[Q\=O\'1^_I'_'73D0STL
M\X5\?GEJ/CF6CV!],S\_.3 ?7<A'LGK]O-W29W4W[*M@5S8F.$N^GS#7SBC.
M!O"?"7['5W4S@ <&T20>!%$9Y,/@,.X5551,@]TPV'FZLQM$V0"?H:. IY)L
MD@>]*7T<C?+L"J[VP?G1+W"US_#^ EOX<'FTWSF^"(&A[&^%010<Q&ET&Q5Q
MT,^+<5Y$=)TVS+3>1P.X;U'JS"H,]CO H/:/NW-';;?N&'8_RB9)/XW=Q6[
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M=]DAR,<,CJL?4T)(=!5A4B>Z_I+9/"@\/O)AARK!T/^/\L*,D:1XFS#3%!-
MDE$RX9EA$FE1C2?]*4JJ,D]!?O0ITS,OKJ(L^4-24-+DWU4RD#]&>'!PL-7(
M9+(%)8R91D601K<DKD H<%+F>)PFXG2D@ ",,Z$UC8LDZR?C5,6G)*CD&,MA
M+QU\T(<=3.!=)>M;X@5>D9O)+LB.B5"1=!:-&H^*I2>*YS@KX]*<(C[KA8&
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M,AT0!U+6WOO="=)05IR33OCO"O5]R:'R,^L$F*-V>AN+\L4%)79?26DX3%P
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MW=7*VW;K5\05R#.O&?31FV^=8WM\VCFANLZ+[OZ'\Z/+?P8=[5W_[:MW+K%
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MQQ*!Q!>_EKMCR_,\X?E?QG! ,)E1P_'#?+WC]XX>CY3"TNZA3,QH9+)F,8Y
M5P=M;@P0+C@=R1N\B8-3'!DDVI8PG=V=G;U@P_:GOD#X$BOL4,[M/'VZ+3E&
M'RXZP5D'6/;I)9X.?X@+(9XD:,=H2(Y$&];;_Q:CF82'TY_R+S4$3[_6M)U8
ML*M/#SO[R_-RS0C8&0.ZWG;;;<UBV1YQK?*5]>, )U.F!YO4O1$GZH%\9L/?
M[9:P2S8T>K%"S9)_9?E2DO-E'F!*H0;TU=0)1THUJ':8J]2+$7)39+#H-P]6
M0GYX4Y?1C0TR36\=0S1Y,:4&JNP Q8S008Q>&W+O]*;6,<K\W#2%133M(D::
MV[3-C@X/.NY[N6>V)&.54:I]C(J/L7KQ<3,&$DD]C\L1?$%ME)N8.'8)' &+
MZ4=NU@$^9[&?^_TXC1G>WW3L9IF^LQU\V+K8@JL,-^CYB]?![K/GFXSX39XJ
MA$HWD038'0HYD$ISTKEXQ_^*@$/TXE1;<.&R08^Z8C ]]GEBA()Z#^'SV#++
M <9'#Y/92SRZ@Z*Z0ATZE5B+;X7_">& 5\'[LO-E_J,UG/$CBJ^W:=[_B!%1
M<K?.J!W\L2.4TJ2<6"]S1'4KV@0.6Q,:3U8-+]SK#1+>H6)0','X@-E7SOIE
M/4B!0E7:O'.O.M,#-/02"H01+)Q]\,#)MULSL^\[LQ<^0^D[,"-I;YD0%CW%
MJ]3;-X@C#8+8F<39572%GXK>ZJ974*0 !,",^@@S&&A$P]L"#.50#\K)-36>
M8/T1F>(XD5Y-_ CGNHRQ24XIX0&C4FKV-ARW1AF2NY1&#K/$C9."K< FD .3
M)(XF"4?W!C'WUHFI/20U;).WPW#\<$\(>.P2L)@8HQS[59 A.:&SYS!>>6WU
M1IMS8XP%>&YIVN3;/"H&=V4ES)!U5$MUGV#Y  R$DM*T:'U]KY':+3($8MNX
M<TK:.CQ;&YBC-]@_TWX4<YC5">Q?89\^,AM[^6#:/ <OV&77Q$TXJ>I@*CX*
MRZ4P=] ?NZD3#4[XM+B*,O%<PWBF P'G<>-CMNF"]BHSRKDTAV9FPE=C$L>2
M"6;_EL8VRS(@W^;Y1]]D=&L^<*L\JQ^DOU.+PH_ %N92!P+T IM8.A8\=;+
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M:ARG_5RM9D9AM<F!#DR;&H7A2)@-TH-98)FIBUN)M2F%8@[9_G"$)L?9952
MY3?,W !YU9 QYC;7=:%+BM@<'):5P!KB$7> <*T+SL' U)L@'WMP6YKSMA%O
MBB30MJ2:+?#@%J.SI,64ISDVI.#-[QVJ8+T"%>1]P[N1(2AA#+)!VP!4?H=0
M>@'Z^;27VTSU;)ZE1A11(?FD7E]2Q$,49R+GOZS&!'9YN!G\'Z;S%#?QX%_P
M]]7FW9ZM+,^>V.(_T_?(W1 B!+D/M#7:R]WV5W0*=?0 **U'?%8SI7\AC6$!
MX]CVXLR,)A(7;/MKA\H;JX!*S%F8G\+HYR:*X7H  O\F0LY2(H8!>KD)5(Z\
M.$&!.8>2PDFI,TW$9-.&4,D5& 67W2XK3_6(VYX%AU&?"6N?_+\>][^\!DVG
MW7J'-80"A75Y"^^</IF7)+R[XV<)DRXUU48N;GIP ZUZ.49[H",GF\NSM- B
MN:'JO3/TGL?(_&?LY+'Y"GDSVB-2&>@P39N&[CL(L%$(MHOI3PG[Q4\I;[=Z
M]FN*J)CII(B1[2CH)5H$IL*/7B39@O924:#"@=/ _#S%KW ='09XV/D9 RC(
M,H&@X_@CRT$?X=+AP4X.LM[7 HR,>+C$TVPP#V9"Y]K>Q!;=*!.R92VO@TM4
M/["6'O[-.!KP#ZDK@G_Y2!JLGB@B!B*[1N7'X#:G7\]YF0NRPIE3G)TZ4(@2
M[_0DCD48):56+G =[ISQK_)\<)NDY+3#&/)$@5N:ZO3#&NS;G#$M%@C,C_-Y
MHI+ZR5,.*6?\#RN4FPC!@5+;!+Z:>\QK[*IIMK1*G,[RF*>F$<Y-:88;3+>0
MO DVW=XQK1M2_$TR?GB/5/_2O6=&92,L&<DM=6H+O.;&*9P?W%AI6XWZCNB%
MI+ HSH./LI[76@T[W>67=ZUG<3KNAO0T=SFT5SDTH#ME/IS<4FSY7I X;C>J
M>9@XP3>"Q''#H@VH.&R=87%!&!3Y-$HGB4&JB=4LL7#EJ+Q3TP;T5 ^JV,FX
M)XT?W72%A73.BSG@3SX[\0LV_%]PCJ@GVV#*/F<A7M?'P"/A6T:W0NIBN6@:
MO\=\.*=]AO6$P2@I*?$6# P18H,DK?A?-TF>FF16$<D)W+^D(+9E*L0BMH4]
M:!QOUGF/<JNM'REQV9VQ=;E\-#+4_!6(=7G7]/SBGB!X$B=?VDS_)T^(FHV+
MS_>&4-)JY'DD0VI@@8EO$]&0&?D3_I@9#.E$(@O<<7@NL Q>+X,L<[@L*3>O
M6'JFG%HITOYMB%4_LJ*J6=RG_!B8ET.]/'EA1=W:U?HEKM87:U?KRKA:L2)F
MYD9A@_(K0N$:8&D12DVLX@$11NU+PN!Z.L;;TU=CRQA]C.HBZM_4E&*Z!:%@
M-5:C7H&Z'B(MW4Q1N8Q)L''.E^_8U=K\FSRM$+00UH(BF:&T"2>'O5YH\&K?
M$AQ!A+$#$.4:PV,3DQ%(0\8FQ$B;]"D0OR'F]B.Z/FM,31E([+QDMVV[Q<XX
MAG6>6?S2."<HV#,BK\/Z-D:M0#2K6V E<&K)H#/=A6HS=V<8:CXA0M=A2)S\
MT6#5$ 5)$EMG_UW0$8>[$"Q]+,5.TC/#$;(A'^6L]&5EZL/^?G#(D5F@NPL3
MF>5A?R//PT3Q2.G"N!/&3S5)P!*1](\Q!2E&:GN%RQ;JO"%E0$,97N\%M*"P
MRI'L5!3FV.PM4LC[$0+U3+T4D':+_H$025K9B\A0B.L>.CF-?/>0IG'D9=*U
M-?QG.C;A[OXH*KA)+C'+IZWY-,$=P( !N;N7M9#WA(48['M-669 \[1]MT'"
M<! 'S$U \$/\UAC_^'E683>Q6LL5T_"$D"0L@#)W=NMCS[BDE(Y$B=,%CK,6
M' ![Q5.ND:?8;4#A704<P]<PR"2MQVG_$MD:W,;U!5Z/A/I<^I(A8H)V.B7K
M,;/K:[<0,/_?53YA9(>W:9[C]EP%QUMG6_J+L=/ RB:9TJ=B&E)*@?=;TA&'
MVISDBAK/HZ\]NHF2E &]7,07K6C#E"Y] ANG%OUX>9YFFU<P +,6)%N7\L1J
M^4PVTTZ>DFRR:DPM+A/GG#1L&3I]Q4(5P%S?9_J3F807*I0?F#K>Q=D[W ^"
M E/8)R9^K<7L'%[12)6;.99CL@V9.NQ'F,M4&^(""H%GX#]\<67@H)T7=Q2O
MT@TY8(<\KDI2WP0WX3#F1J&5$_=,&M-UN[MO&[SAES0/I7 JAM;^COYS4B1
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M[QM<>FND"J4L"K\GMQGHR[EQ^@^#++[*)PG1JM/;EQ*8E(T2>"I#+#!C-FE
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M10YV!=PM!,8</;HB^:#=A>U%6<Y6=+OU1YXQ=CNW1>%TFSLW]\X'>'/A )X
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M);E78+;*ZW)V/^@JSYU1M,&; P8P_R5L@9\<O9.PF7(L?24L[^Y7\LY>5<F
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MU,Q;LJE$!?<.#PI?G.(\<!KME@Y*?<ZNZ"PW@]N\2@>XP"+^=Y44W$,0_IR
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M>!F>/=Z]O3SH6G;;W0%Q4N9@><'@\KR\HM3.@R3?*,F[2G:;M3:2?"N/;]M
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M/QX%8&Z7W&KHS>5\/7-1MW[%W!W><ITW&553ZLT?F!_\HA;W-;K&,4M%)KX
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M7K?Q$;VO9 +#.OL2[1T];;WQGVE5]K[RL;R2H7F22-3O\Y? 0H-5: .1O2#
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M9>N9H1X!/=A(&]2))CL&=+6)$YWC4&L/TT[\Z S>5/,+;220=/QLLH;DJJW
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M\/(# #G\.@._9.SCD4/)E<)B(9/ B4FQ6I:ZY#L'(64:,YMOW!)?][62LG,
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MILA;3I?IZ5^8Q_&$J_1<NK7$W/P!U> ?ZV+&?_IC/3]GQ.8<RQ(HR8P2U1\
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MOP.K;U:BBTG<Q\[@83*./)6]8]56,$VV!!@D0I8+^]<2_NV)TM^[$X:=)K8
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M%[N$9UX$H0>.1E/E/7\HX=)9@I&7I(K^>XWL5=4D9HAF(A6/O(8:^"/I ,Y
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MIN#* W$**,\M"I9JS:HU1DM0J-!^D]%"MJAW#@:##/XHA6/@HK;..MYK>OJ
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MA?ZU^0Q:!M\%M9Y9-NBK1'04E?I?M-1^4[/G8ZV99AP!I2LA9/^(CI"00D@
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M0+7^Q4+=WH,7X!A+KOX.E>Q):@]%(/]\>!EDX+Y.Z=9TM?N<Q*^?.8J4?)<
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MD3$NWL'\-O&V]I1#S[Z S2!Z*GR>2R9P )?/,\PD>\GHQI2C]J-+="FLBX:
M\2+5$A"F85IQ7#>_76U^@Q.\[W=V9+NO89N!M5=JZMC&MQ7]85)$,*H!EIRR
M]\LGY1]7=U#,T C#T?O>D.RKW LFTRB9!>0VX4RM)-U>9%!1)%J.B'KKUH <
M)<H9N[F!,V5WJEQYD/CI")]U*._(E%U7_YIMJ7[T"Y##*>P?O+/(P7H34<UW
M2:J<-JA@SE=),L)%1W_4C)QVU5<_7;_&FV>_QD,=]DLD5D(%\"/CN@.:$6<%
M)9G ,7!L:W(%VIX)UVU&M._Z+:?*(\O6-_H5=!V\F[9K>PU+_HU[NQYVO":Z
M4#A3I,XMK]0F:W"* 86XOHALP?IQPNG8;DT[NN!U1A >5&:1DS W:G4I5,2!
M@$7ZV",Q^8$3N4#]BS,\VQAS\E7L=\?K\[#A7;@<*BG*M0XV-S#VBI,U'B8*
M%)0B&S5>)_0%PP*[O%7<M.PK%E?Z>+$.IL5'G:2"W;2][Y44%?@J-B6(#7>$
M9?4#>'&" ;8ADBO&Z/2,,9G).2=V"LKRS#ET_+$CG,*,,&-<47W.@M&VD^IJ
MJ1Z!WK/RD<&8SGM\MPK@X@L:^,5U<@NO2?FS'#J.5.@]7OQ8T&DP0)K=899[
M6P?;_$(W&LE+3!)Y.E7H*TO*T''!0%&A!9/82 RZB#\"V0?SBG>\LFK/)UOM
MGB;5)<I]#6%)J3\+>DDMTBMED8L6R'>C@_IS9U&D:-[*"YPS#T%"KR-1ZTQ6
M0$F6#69@MLMP=&*.E%BGN3J&_\:S&N^LTL1=#)%TJ1FO8B^-FF>&3IHCB"HX
MW9F5F5?=XG5$AH?$7T^"*SB\O*-M*FU8%J)3B:1+XW%$??.2\S09^BEOGLZ)
MA"6+:%!6R%*2!\9ABMJUMJ!L/TD/5U;=J$@<Y"^<M9&.GSHRGX(9YF2FQ9"C
MQ[E*&?.OB+*!P8M2L'QQ5.IG9HW&L4/E.Q4@-51H V'H#-K0_1X/.NGU2:I'
MF9:.C:^D!"XD\"^P?]3!SV'8I#.8<A L@T=(G-1H+*IFR7ZQ6 <&@863 TR!
MQQT'"C97PG4LNV_>N,-IV'FJX5@07/S1C<3$P7("6S@J1?X;E=<'H+&&*IM&
M9J5V![?#R<'E$<P;$.7.WLB0=":+^/'T4JG#+Q_5ST"CA/ $HPS1Q[?EY_;U
M.@;W;1K O+9QJ7U*\@6VZB53T!Z9<ZAY,R\!M1%H#O8U&_MH*\W*F1!2V&1M
MOQC$.*XPM2)L@E+!1&IB:TPNML4<^;?F]!LZ6847;&XL9 :,(D.'E2L!904K
M'(%M3;2?S4',5LPDN">_"C&M)*!8OF5"E\LM4R [TJS*R?GE$W5+#@#84&!#
MZH2@F9R!G=7PIIA6 (+_>C9%MJ'XC4EW&X49J@WEI]J,0.PCWBR+#H0 ='*]
M)G-M&I0I :0H)5P7*+\CV(YTYCREP=2#:P?2-DRX9CX-<+<42!-FYLSA$0[W
MFL.R2,Q*?'0@]Q'TUV0J"ZZ#HM/(IP,SPL>$@X(?I$5)SJ;0T_4MO'WV+3Q"
M!M\;SN#KMGOM[B>&<ST_$N3=-6AGA_.RWRK9 N@$A;]R>@(A65F^.#Q[R 53
M4H+@^&$Z7(@J0)U^6X$-S)/-#;'+-.-W&61@U?749L<ZV%TF-_?'^Q.LO7[+
M>WUV[AUUF_15\T2!+"."<:O;N=C!P_5C1WB6@'SC2D_?^%M!11VFX=259]7K
MC!N(':\F7WAN=0SZ?X"'1F%0*#F"6#[E)U=S_";^5U*&T?.F,A*9X<-H]8L'
M?A9J ;/0G[%68OB9B&%S ZB!LW01E)D@$H_/3P[;W1\_N+ZM=HR20!Q77&E7
M8VY*&924(<MYU,7O"M\ $2>H ,XQ?(W1[%10SU?4UKA3O_"Q%>1IWAT%P/UE
M#3RZ7W,P0G*X&C4&?Q' 0<P-0/0L A@;C5),J-5U9W@Q 0G;NV.O>VWB'A@'
MZ)3>W)#G<95GQ:6DQM(@A$4[>7MI_=:5.'NJM8D2.F6'ADP'D3L9[T09,";M
MFM&B! M$W> :+>O-X?^5R:MY^+?+7I]1Y]>5M=^O*5(4#\:J^=!N7(&5[3IL
M30K-.0BV/S3ZS^4)912?!ZG=NG=:0J<284X#(V=]MT:;+1QFU?75,RCS&&J0
MPEESZG3!R!X7D:A=F>.OG?@CM'SFA#CD.I.=/Z<\N['8SF4-\VN(N;92.XND
MISW.<ZBN%FLE1<UO&F J@_(3%,,AG'L$<3'82,RRD&CA$P(,&5Q"1F9AC0=M
MR40 PK&X0^J,&M55Y!5B"YLTXD& Z@8&/?!4A'59NM?^R/)#NY9_'<Y(Y:4[
M7D=R# H#$#/%!4A#JO8R<+9;M=%PT+U4.+S&L5"-CF^7*$-")&*WNUC80DM9
MQ:M!5K-53VUI]%P?@E(I,XZ"4D$' R57UU^T"&7Y+QZ$C3%D+=,<W=&:MN6B
MX,F'J:XX$[\##X3#:UFN@A4@'C/T#8)<LQ&-E)C6<1\%+QY+?KS&271F:Q7V
MUY]\4_PF^3[*@<JI)\L/A8(/XYG[0,B2\9+ RZ[\O&Y5V:=6L^JKA*WLJ%4&
M2Q/Y:<0NH9D0/XX8'7/V2CSAA(V?GYTJCR=*49;6G*-Z 5I_A$*Q5KXS3:N2
M@'0GZ*CJ@!2SA0G&06H<'%PIHJHB5P\0-Q8F 6QNZ/H^P2!FR(K[SH)UDIJP
M7&/1"P3VU7K#UH B7DY1*87>TX!=X<3MMANEL.\P0&<1:28*_D6+'W8]53M;
M5%#E9;P2&!C9(LD>8\-Z299$."'[73I82Q+T"G;B"F6V&Q6NU2JF_DP)H 6T
MHB3LPEPZ3T/KHERPA30VFK'JP^^V.7!UR?->?B_J/EI%FI-?3XM+L&TV]-E=
M1@+[+RL?![J"E7Q(JFQ-T;GV)6UQXF2IK$W+?Y4 S8USPK)J@X,U*AT^C]Y&
M.9,+5F/%V5225H@^%N,L&>0B[7ZIN'(4)4J:5STI;LD2*EVSO$9*26)]@LDZ
MMXKG"<'(S9V9 TRS6KZ,!W9"&)E5,B/%O"LY*.&(=))RFQQU@FJISDT(<5)R
M4 #&-CEPG2,KKK?,V,KK=N?3.H]&,GZ;C&H!BJ%^ 'G:3'W#O$*@CIWH- >)
M 6<GB55/01Y2W?\=!&*#* KASA1H4Y):*(PU[N25!&.-3"B90JA;.Q***$DL
M!-UA:ZA!,M!KZJ-UJXX6NVD&M-R(E:ON :H=4@#W.T:YX_68:Y9=>VK[M-7R
MG1GL*^]]+2F:C,EEV'NNOG.?$=]1^ZD==WW-A@,3AFUXS+@JS,2%QA5H'[3[
MI>ZZ(;!U]P6^\P1 KX1CMZV9F:DSJ*F:JV%/97>A"T)6?[A-]?'FAHZT$R9M
M2/D95B,MA7)1LIU)J..M%HZ,\2KAF\T\7*9M\2G;5ZE!;\(E]_,N!0RLR'MB
MY&8-'7 050:G*2)$M,&Q/Y116^C4=WI_1>.\(S%L55$0R6J:!X%H7;;R5)F3
M?PLGQ41\@%2?I^)]3'1ENE$MN<JNK:?J$?CEV2/P4,!HFQMUX 5WXAYTUUPS
M%J6N!FB_TW'4?).Q0;<(B\BW.!;9K1P:7^7:NQTRI_X/'Z@3W4F.D.PJ!^2Q
M[2;H5Q[,IH*SX3QOVR2'L8M>Y=#BHZP:08,DYDC1D30*RI7&OH(:"$?FX .U
M_Z90VII*1KK!,,)$NK'E!N<>OY+FK.'C[%CH*NJ+N&I<=&\[1B3>B,',QE=%
MWX,[HH95S4I= 4:A!'MP;9T(BD[Y:ZB(*^422SC%7.I;0+(K5+4$WT+,38W1
MS4)/PL@T0;>,0@3:+Z4(.=#F)IF99D4B)Z+^@[6%*59$JM[1PS#^J9B\\E8\
MTAB%*KW>S^;'=40%XYA1*>1<%^B $VT>S"M'/H.2)VN%U5RDR:]$!@V7"'0W
M+OIQ?<4!/7=0+1<SV#Y3G25G0A;"IG<,6942SAI6YKOA@Z1\^/8*->J,0.,'
M2!/AB[PCHV"(2=.JN=M*471-5*L5,53>"4)&O=-IA%!A[PZ!U#E]5WG%=TYK
M4:;/"LNY#KH<,5W29 Z)B.+1<A*$PTV94VXZM^/(C#$AGGQB@3B5ORL;XL&3
M$$#?)J;,4ZV-U];W G*M/./W\D=<2^K/<T-S5(#%PKPCQE%:)+V2X]W6')0=
M8+0&DWZ6U2+'$\O4<Z5*=Y/#W>#Y^JJ\W@;HFBFP[IGRALSU$,WGU3)N _VE
M*^.-%F:L3CEOJ%4F=.2D*9Z-!Y GV(UFZ:FT-W#!\.:N"ZF_-IPK7);0^.\X
MLBKNSKRA66&6>>-: @WQ@TX0'"%.5]5*BU,74 &4+SM(2$:3NHAMX)V2 KB%
M1#DU:RYU;7=TI,)BKROT+E:I0JK9D)50,B\KJ(3SX+2'J$T3DA.WI"Z'30W#
M_8VYI-_B+ EI8$EQ=8V(UJ4>/[7>)QMZ'RU$/H/C\)NL)!-SB8V0OFJSDL3E
M_ LXBQFKRN]^@IZ)7Y\]$P^F3P2D3QC$W:9)/U):Q;Y7V^:/S]$(5?HT$.Z@
M&2'($/M<T"&K*KO*E1?J=JWLG319<S59=5N4_H/\F/M0DG>#7"=4/J4'8?JK
MK?!04POH]H?4QJZ\!)=(7AMFG#V@ZPF9!X'>0+@5<B;=QVV_YY8LU774W=T(
M; ,+'CA>IQP=54]V*1-@5J_8B.N#&98V5^W,^/=VO6E>RO$LI7J]=TM!W:L1
MXWE&B$]QCFT<@0+()TLB.@IAE4Q'O-M0H;J7F-=[P_O+WB\C"X(;51%76L4K
M%>MU6;XD88N/2D&RD<E/ZK$@0>LO)8J',?6<*^>11JI-@O0N*+R!?%U@(58:
M]SM5R'6!M5QG?:KEZC54V4"GW?.:9X=>Z_Q3^PP^]Q16>^O\]*)YMHXZ DF"
M[E*=EI9RY;[/G,_W'>;J'-!?\688/PHBEC-.^0TPY%$TLRK',!N80NJ2(3('
MCW9^CF>#PZO,"!7ZR"#0K^+G-BCF-I-(/D)L+(,3C9/X);F>*#.FH?H=<N"6
M#_$8L<R% ^3^-_1216& W82&L)A7Y&;;W CB(2C#*8Y+.[E Y2@(O<O/LP2Q
M2&J 2K265;\?%4"+$E*^Y6MR"M+1.E<P!,R<N1Q;8H'C -W94;DZFVE$\01,
MO2#MT+_QP\C*L2AGG9@>6-<I:6\X'SA/BE3:AQ^;72^;@<4W@6%A\ OV/J5(
M=CS2*/?PCVEH51)R;WJ^1%#,!C,S3!L*TBGG7@!JMJ(WAF:M O>\RW.F/I:Z
M=ST8H! [!2174 ?&)Y>0XY1F5 %8FQ>TT$/6+46DNZ.#AUD[YR4T9W%_+#T8
M!$8@8TDF>@^8[C<WG%9EED? 3DZ+9Q;\A8PUM%&U= &XDJD6(D;(S=(F@9T2
M38.M8T3KX+0<(#@L J_)1;+YS/!6#CV1'6-/M+3%%1-)M68(4H0$4YM)2DTY
M.UL_97/#0ALWR>_.:L/VU4+55-SF^5RYT"BQ=P>FCQL0 ZTB\TPQ8L%U%X%.
M<9&61%*L8@T?U\LLP;[)U]#5BC=A@@1NWR3<9'-#,0:,&SA\X;W!L-0/PF!V
M"I.(61N#RZ@=+R$HH4H)3# M$ D^#:X$#)7.:DHYBZ9 @"+X[]E5\KK\$BTN
M:MYH3&YA Z@*@X&)P78?@Y@^1AL4<#SQ "3. B-U$["<KWS"F.2G,M!&(EH_
M8LY,I%Y">CQ*"C2G%2&NQ<SY99# B]S5M\:#=T;!E1\U6*YR-I*HF@8QSMW+
M!MC+E)^D'80EP4Z0.*C3&U=()EQ-W1A&6)T@G$7!R0V R@=^_#4MIOD0:P^Q
M*S0L*_X;>&IZY<?A_XKC>YSZ!1!HP-.Y"6;X>EH_]&&%Q<0L&Z&0^(QP(T=&
MQJ$F-T28#JR088I3F@Z6V<"FIK@\W(V%)F/ Q-S9E,\YEDX:82U/4IUF(CY[
MR'GSV1-V+;Q[=BT\< BMI:QS)+DFUH/!T13?PEEB[.J4B\48_Z:ARF@ICY"-
MMZ2!?DH+&X5SJ=!)YG^5:XW745AX5;J3&MG0"J0^5@Y']95PI'%=X9E%^M>:
MQ7S)4!N@T(*U8:0J+H<M,JM2EA*N;!%:UP!'#K'R%8[#R%DV%Q&G:T3$80G^
MB"(8\%YY@.W46 *)U! &S7=FVNPP(%PR-3*UC7*&"L!@'27/$D/KL"77TY-A
MFFRJ!B0L/5:(+<U7,6Q;TGHF^LO(SMO<^%Y#;T<9>@27NGR,:GN9UK7:;(7_
MT9-CC-LRKA"5W1DZ4*>'"E!J8;)0CA(@ ' G!*Z5$Y%AE2B5ZZO,):T9DN?;
MC?Z :J;50A>5M8%MNZIH#H[I-T5Y/V48N"I&2PP$H53-LG:J[+ZA/PV1'625
M3%&ZV*AQ-?<J2^_'DW>@<&-A\AZU?_5UO*72^\['Q"=_.*NU4 RHEZ2M""-:
M#ISPB@PUCJ':)E[%4;#8H"5>0GX_1^G,S:0$<XO#L(Z?>B'FEXR=KWZK1B8H
M8 ;$C$;G7/L&D[CWMHU=3 JU[3_=W, ,-Y-\50<WM@QE;@UHPV.1UNZY5XB
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MA @Q)9+!+-Y FEN)!CR!QXD;-H7AZ#"UX;>\C]=21J+B /1@7[!O@:B2"3#
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MDAZU[J$=)47J]9-;$ D':8BU:.L>T1Y(A@/00D \I /0P@]3T&B5;, ?USW
MSZA](\K9=7*=#+^B17C1]';?O=G[=>UC6Y$7K^)1O--[*8$>C BTZ,3#RV8$
M&@H4MS9I$UBV=47-%:CZ.X=C,$8K. J_!N)Z6$-(XYHSK^"8@LVL\=O?>TT5
ML-8AI2H4ZN;&$=ET^EIDF00$CQ?T5#*^!3(_HKC:43!("S^=,>]_W0#RWGO=
ML*&/R)O 8S)PEER4H$J]K+H=Y3R4Q%D7"\\-=G%I/F8_!*- W!CD\!0S-DSE
MO?E,0$'#1$'_^&C18K0;K<8@P*!B%%!=:D.E:$L5EG+]C%18CN'U5.]#TQ!
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M"3W Y,X/O\"7Q_W3DP__#U!+ P04    "  AB$E64)=0;D,#  !>"P  $0
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MK11*B2NX%(JK0G )GWO&O\&5*A(XEQ*F'F:)ID5SAV7267VP96Z+)5;\[1L
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MYL4\E8M'_@%02P$"% ,4    "  AB$E6@5@ N/D9   LF   #@
M    @ $     9#0U-S<W,60X:RYH=&U02P$"% ,4    "  AB$E60%GS6^ +
M 0"BK@4 $0              @ $E&@  9#0U-S<W,61E>#$P,2YH=&U02P$"
M% ,4    "  AB$E6$F+)RE%$   W9@$ $               @ $T)@$ 9#0U
M-S<W,61E>#0Q+FAT;5!+ 0(4 Q0    ( "&(2590EU!N0P,  %X+   1
M          "  ;-J 0!M9&=L+3(P,C,P,C S+GAS9%!+ 0(4 Q0    ( "&(
M258#6G:0EP8  +A)   5              "  25N 0!M9&=L+3(P,C,P,C S
M7VQA8BYX;6Q02P$"% ,4    "  AB$E6?WW\3]0$   .+@  %0
M    @ 'O= $ ;61G;"TR,#(S,#(P,U]P<F4N>&UL4$L%!@     &  8 ?@$
' /9Y 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
